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CHAPTER 1 - INTRODUCTION 
Our genome inherits all essential information to ensure the proper functioning and 
survival of the organism. Due to its chemical nature, the DNA interacts with many 
factors originating from inside and outside the cell, which often leads to the damaging 
of the DNA. In the introduction, I will outline the various existing kinds of DNA lesions 
and their origins. The highly specialized DNA damage response and the specialized 
pathways that are responsible for the repair of these damages are illustrated 
afterwards. I will then go further into detail about the repair of DNA damage by 
Homologous Recombination (HR). The focus of my PhD involves the function of the 
breast cancer susceptibility gene 2 (BRCA2) that not only plays a role in this particular 
pathway but also in other cellular processes like mitosis, cytokinesis and meiosis. 
Hence, I will then give a detailed overview of the various roles of BRCA2 to familiarize 
the reader with the current knowledge in the field. Even though there has been a lot of 
progress in the last 20 years of research on BRCA2, still many conundrums remain to 
be solved. Some of these open questions were central to this thesis and are outlined in 
the project description.  
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1. MAINTAINING GENOME INTEGRITY AFTER DNA DAMAGE 
1.1 THE DNA DAMAGE RESPONSE 
Chromosomal instability gives rise to most cancers. Aberrations in chromosome 
number and structures originate from unrepaired DNA damage throughout the cell 
cycle favoring tumor development. Our cells are constantly exposed to endogenous 
and exogenous DNA damage by a plethora of hazardous agents and processes. Each 
cell receives up to ten thousand lesions in the DNA per day 1. Our cells have evolved 
multiple mechanisms to accurately respond to each kind of DNA insult with a particular 
repair pathway. Endogenous damage originates from oxidative stress, spontaneous 
base modifications, replication errors and oxygen radicals resulting from normal 
metabolic pathways. Exogenous sources include the UV component of radiation and 
sunlight, chemical and genotoxic compounds and intercalating agents that alter the 
DNA structure 2 (Figure 1). As a consequence of DNA damage, the cell cycle is 
transiently arrested and the DNA metabolism including transcription and replication 
processes is inhibited until the damage is repaired. Often the cell is forced to induce 
apoptosis as a result of non-repairable or excessive damage that entails accumulation 
of mutations and genome instability (Figure 1). To prevent these events, the cells count 
on highly organized surveillance mechanisms and fine-tuned repair pathways. Inherited 
disorders involving defects in factors of any of these pathways predispose to 
malignancy 2. For example, Ataxia telangiectasia (A-T) is a rare neurodegenerative 
disease caused by a mutation in the gene coding for ATM kinase and results in 
hypersensitivity to radiation, as cells are not able to activate the DNA damage 
response 3. 
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1.2 SENSING AND SIGNALING DNA DAMAGE 
The DNA damage response (DDR) is a signaling transduction cascade that is activated 
by the cell upon DNA damage for the initiation of, among others, DNA damage repair 
processes, cell cycle arrest or apoptosis (see Figure 2). The complex network involves 
a plethora of different protein players such as sensors, mediators, transducers and 
effectors 1. After the DNA damage has occurred, the lesion is detected by sensor 
proteins that are specialized for each kind of damage: Small lesions in the DNA and 
replication stress result in the formation of stretches of ssDNA that subsequently recruit 
the ssDNA binding protein RPA. The persistence of RPA on the ssDNA recruits the 
sensor complex ATR-ATRIP for the stabilization of the structure, the arrest of the cell 
cycle and activation of the repair process 4. DNA double strand breaks (DSBs) are 
recognized by the sensor complex Mre11-RAD50-Nbs1 (MRN) that subsequently 
processes the DNA ends 5’-3’ by its nuclease activity and recruits other repair proteins 
5. Blunt ended DSBs are detected by the Ku protein, which recruits DNA-PK, a kinase 
that activates end-processing enzymes 1.  
Figure 1: A) Common DNA damaging agents (top) and resulting lesions in the DNA 
(middle). Each kind of lesion is repaired by a specialized repair process (bottom). B) 
Consequences of DNA damage in the cell: Transient cell cycle arrest at checkpoint 
(top) and inhibition of DNA metabolism (middle). Permanent changes in the DNA like 
mutations or chromosome aberrations can lead to cancer, ageing and diseases 
(bottom). Adapted from Hoeijmakers, 20012.  
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The information is transmitted from the sensor to the transducer that in turn, activates 
mediator proteins and downstream kinases 6. Besides DNA-PK that senses DSBs 
through Ku and directly activates DNA repair, two main DNA damage response 
signaling pathways have been described: Ataxia Telangiectasia Mutated (ATM)-
dependent and Ataxia Telangiectasia and RAD3-related (ATR)-dependent signaling 7. 
Like DNA-PK, ATM and ATR are PI3K-like protein kinases that phosphorylate mostly 
serine and threonine residues. ATM signaling cascade is activated by DSBs while ATR 
responds to replication stress and other small DNA lesions 8,9. ATM/ATR signaling 
activates the downstream kinases CHK1 and CHK2 that in turn induce the activity of 
Figure 2: The DNA damage response is induced by damage sensors upon DNA 
damage or replication stress. Sensors activate the ATM/ATR kinases for the regulation 
of mediator proteins or downstream kinases that control effector proteins. Effectors are 
responsible for the control of processes such as cell cycle control, DNA repair or 
apoptosis. Adapted from Sulli et al., 2012 247. 
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effectors like CDC25 (cell division cycle 25) or p53. The effectors are responsible for 
arresting the cell cycle at G1/S, intra-S and G2-M cell cycle checkpoints to ensure 
sufficient time to repair the DNA 1. CDC25 is a phosphatase that removes inhibitory 
phosphate residues from target cyclin-dependent kinases (CDKs), controlling in this 
way the entry and progression through the cell cycle. p53 is a central player in the 
transcriptional regulation of the cell cycle, apoptosis and senescence in response to 
DNA damage 8. At the same time, ATM and ATR activate mediator proteins for the 
DNA repair such as BRCA1 or 53BP1 via post-translational modifications. More than 
700 proteins regulated by ATM and ATR have been identified 10. 
Because the DNA is packaged into chromatin, chromatin-remodeling factors are 
important to give access to the sites of DNA damage. Phosphorylation of the variant 
histone γ-H2AX by ATM or ATR allows accumulation of the chromatin master regulator 
MDC1 at DNA damage sites acting as a platform for DNA repair proteins. The repair 
proteins recruited by MDC1 accumulate in discrete foci at DNA repair sites and are a 
sign of active repair 10,11 (Figure 2).  
Taken together, a multitude of factors are controlled through the DNA damage 
response to further mediate DNA replication, repair, cell cycle or apoptosis. In the 
following sections I will illustrate the different DNA repair pathways that are activated 
by the signaling cascade.  
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1.3 DNA REPAIR PATHWAYS 
Several specialized pathways exist for the repair of particular lesions. However, some 
of these lesions are repaired by a combination of pathways (Figure 3). In this section I 
will shortly present the different repair pathways described. Afterwards, I will go into 
further detail for the recombinational repair of DSBs (HR) and the repair of stalled 
replication forks as the protein of interest of my thesis, BRCA2, is directly involved in 
these pathways. Note that the protein names mentioned belong to the 
human/mammalian systems.  
  
Figure 3: DNA damage repair mechanisms in response to various types of DNA 
lesions (top) originating from exogenous and endogenous sources (in blue boxes). 
Base modifications can be repaired by direct reversal by MGMT or ABH enzymes or by 
base excision repair (BER). Base modifications such as deamination or replication 
errors are corrected via the mismatch repair (MMR). Bulky DNA adducts can be 
removed by nucleotide excision repair (NER). For the elimination of inter-strand 
crosslinks (ICL), translesion synthesis (TLS), NER, fanconi anemia pathway (FA) and 
homologous recombination (HR) are used. Protein-DNA crosslinks are repaired by a 
combination of PDB repair, TDP enzyme, NER, NHEJ and HR. Double-strand breaks 
(DSBs) are removed via HR or NHEJ; single-strand breaks (SSBs) by a SSB or DSB 
repair pathway. Unrepaired DNA lesions are mutagenic or toxic for the cells. Adapted 
from Roos et al., (2015)248. 
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1.3.1 DIRECT REPAIR, BASE EXCISION REPAIR, NUCLEOTIDE EXCISION 
REPAIR AND MISMATCH REPAIR 
Alkylating agents are a group of chemicals that are ubiquitously present in our 
environment. External alkylating agents can originate as nutritional byproducts, from 
tobacco smoke or pollutants. In the cells, they can arise from oxidative and biochemical 
reactions. Some cytotoxic agents are deployed as anti-cancer drugs since the 
beginning of therapy. Mono-or bifunctional alkylating agents react with the Nitrogen (N) 
or Oxygen (O) of DNA bases leading to simple or complex alkylated base lesions 
depending on the agent. Alkylating adducts in the DNA are usually N7-methyl guanine 
(7meG), N3-methyladenine (3meA) and O6-methylguanine (O6meG) that can give rise 
to mismatches during replication, depurination or replication arrest. Contingent on the 
kind of lesion, they can be repaired by several different repair processes 12 (Figure 3, 
left). By catalyzing the reversal of alkylated bases, simple modifications can be 
removed by direct DNA repair (DDR) with the help of O6-methylguanine DNA 
methyltransferase (MGMT) or members of the α-ketoglutarate-dependent dioxygenase 
family (ALKBH). Cancers with decreased MGMT expression are a suitable target for 
alkylating drugs 13. If not repaired before replication starts, O6-methylguanine (O6meG) 
will be reversed by the mismatch repair (MMR) system after the first genome 
duplication or by nucleotide excision repair 12 (Figure 4D). 
Base Excision Repair (BER) is the major pathway to remove deaminated, oxidized or 
alkylated bases and to repair single-strand breaks (SSBs) resulting from endogenous 
ROS or exogenous sources such as ionizing radiation or alkylating agents 14. As 
indicated by its name, the damaged bases are excised and the gap is filled with the 
correct bases to avoid mismatching and incorporation of an incorrect base during 
replication15. Abasic sites like uracil and hypoxanthine are caused by spontaneous 
hydrolytic deamination. Reactive oxygen species (ROS) oxidize DNA bases like 
guanine, leading to 8-oxoguanine, prone to mismatch with adenine. Also, some N-
alkylations of DNA bases require the repair by BER, as well as UV-light induced 
thymidine dimers that can be excised by BER glycosylase, although the preferred 
mechanism is NER16.  
The excision of the damaged base is performed by mono- or bi-functional DNA 
glycosylases, a class of enzymes that catalyze the cleavage of the glycosidic bond 
connecting the DNA base with the backbone, leaving an apurinic or apyrmidinic (AP) 
site. Each of these glycosylases recognize a small subset of corrupted bases that are 
cleaved off from the sugar-phosphate backbone 2. When single strand breaks are 
repaired by BER, PARP1 binds to the broken site and recruits polynucleotide kinase 
14 
 
(PNK) to create 5'-phosphate/3'-hydroxyl termini for BER. The APEI endonuclease 
nicks the strand at the abasic site. In the dominant ‘short patch’ repair pathway, the 5’ 
sugarless residue is removed by DNA polymerase β and the correct nucleotide is filled 
in, followed by XRCC1-DNA ligase3-sealing of the nick (Figure 4b). The ‘long patch’ 
pathway uses DNA Polδ/ε and PCNA to displace the 3’ strand by 2-10 nucleotides, the 
old strand is then cut by FEN1 endonuclease and the nick is sealed by DNA 
ligase116,17.  
Mice defective in any of the genes coding for DNA glycosylases have often no or minor 
defects. In contrast, the deletion of the genes coding for the enzymes downstream the 
glycosylases display severe phenotypes or are not viable 15.  
While base excision repair is responsible for minor base damages, Nucleotide 
Excision Repair (NER) removes a wide variety of bulky DNA lesions that distort the 
DNA structure:  
UV light causes photolesions such as cyclobutane–pyrimidine dimers (CPDs) and 6–4 
pyrimidine photoproducts (6–4PPs). Chemicals developing from endogenous or 
exogenous sources cause bulky adducts, while interstrand cross-links are induced by 
platinum drugs. For the removal of these lesions, two mechanisms exist that differ in 
the way the damage is recognized: Global Genome NER (GG-NER) and Transcription-
Coupled NER (TC-NER) 18 (Figure 4C). 
During GG-NER, the entire genome including also transcriptionally inactive genes is 
screened for irregularities in the DNA structure. The XPC-hHR23B complex recognizes 
helix distortions. The XPE/UVDDB complex assists in the recognition of mild lesions 
such as cyclobutane pyrimidine dimers. Binding of Xeroderma Pigmentosum 
complementation group C (XPC) to the lesions recruits the multifunctional transcription 
factor TFIIH. Transcription-coupled NER commences when the RNA polymerase II 
encounters a DNA lesion during transcription. Many protein factors are involved in TC-
NER, among these the CSA–CSB proteins ubiquitylate RNA Pol II to target it for 
degradation and render the DNA lesion accessible for repair 19,20. After the damage 
recognition, the stalled transcription apparatus recruits TFIIH and both GG-NER and 
TC-NER are channeled into a common repair pathway. The DNA damage is cut out by 
XPG 3′ and XPF–ERCC1 5′ nucleases and stabilized by XPG, XPA and RPA, 
surveilled by the TFIIH complex. The final gap-filling step of the lesions is achieved by 
the replication factors PCNA, replication factor C (RFC), DNA Pol δ, DNA Pol ε or DNA 
Pol κ and ligated by LigaseI or XRCCI-LigaseIII 18,19 (Figure 4C). 
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Many diseases are connected to defective NER; most of them predispose to an 
elevated cancer risk but also neurodegenerative disorders, highlighting the importance 
of this repair pathway. 
Defective GG-NER repair forces the cell to use TLS, an error-prone pathway to over-
replicate lesions (explained in replication stress chapter 1.3.2). The accumulation of 
mutations originating from TLS explains the high cancer incidence in Xeroderma 
Pigmentosum (XP) patients. They suffer from dry skin, abnormal pigmentation, 
photosensitivity and a 1000 fold risk to develop skin cancer induced by UV lesions. 
This is due to deficiencies in one or several XP genes coding for important NER 
factors. Cockayne-syndrome patients have a defective TC-NER and display a 
Figure 4: Mechanisms of BER, NER and MMR. B) A set of glycosylases (AAG) recognizes 
different kinds of damaged bases that are flipped out and cleaved off. Abasic sites are 
recognized by APE1 to nick the DNA. In short-patch BER, Polβ fills the nick and removes 
the 5‘ residue. DNA ligase3/XRCC1 complex seals the gap. C) In GG-NER, disrupted base 
pairs are detected by XPC-hHR23B complex, whereas TC-NER is activated when the RNA 
Pol II is stalled and replaced by CSB/CSA before recruitment of the TFIIH complex. The 
helicases of the complex unwind the DNA and XPF- ERCC1 cuts out the damaged piece so 
the replication machinery can fill the gap. D) In MMR, damage is recognized by MutS/MutL 
that nicks the DNA and recruits the EXO1 nuclease for strand resection. The ssDNA stretch 
is subsequently filled by polymerases and ligated. Adapted from Fu et al., 201212.  
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moderate risk to develop skin cancer but show severe neurological disorders. In mouse 
models, defective NER has been connected with both cancer development and 
neurodegeneration, whereas in humans it was observed that mutations in GG-NER 
genes predispose to cancer and defective TC-NER to neurological disorders 18–20. The 
DNA mismatch repair (MMR) is a mechanism to correct erroneous incorporated 
(mismatched) bases during replication and also mismatches arising from base 
alkylations such as O6meG that mispair with thymidine in replication 12. During normal 
replication, polymerases are highly precise and possess a proofreading mechanism to 
excise wrongly incorporated bases. However, when the replication is blocked, 
translesion synthesis polymerases that are more prone to insert wrong bases over-
replicate the lesions. In eukaryotes, the enzyme MutSα recognizes the mismatch in the 
discontinuous strand, which is then nicked by the MutLα endonuclease. 
The EXO1 exonuclease removes the segment including the mismatch while the 
exposed ssDNA strand is stabilized by RPA. With the help of PCNA, DNA polymerase 
δ synthesizes the missing piece and DNA ligase I re-ligates the 5’ and 3’ ends (Figure 
4d) 21–23. Defects in the MMR system increase spontaneous mutations up to 1000 fold 
causing base substitutions and recombination between sequences that are not exact 
homologous. A defective mismatch repair often gives rise to hereditary nonpolyposis 
colon cancer (HNCC) as well as sporadic tumors in different tissues 24.  
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1.3.2 DNA DAMAGE-ASSOCIATED REPLICATION STRESS  
The genome has to be duplicated accurately during replication to avoid genomic 
instability. The DNA is especially vulnerable during S phase because DNA lesions and 
other obstacles such as telomere ends, the transcription machinery or DNA secondary 
structures can interfere with the progression of the replisome leading to stalled 
replication forks. The resulting replication stress triggers the S-phase checkpoint to 
put the cell cycle on hold until the problem is solved.  
The blockage of replication forks leads to the uncoupling of the strand synthesis and 
the continuous activity of the MCM helicase, leaving long stretches of ssDNA behind 
that are subsequently covered by RPA to protect them from degradation by nucleases. 
The ssDNA-RPA complex is the signal to activate ATR-ATRIP kinases that 
phosphorylate downstream components for the stabilization of the fork, activation of 
fork repair and restart, the arrest of cell cycle progression but also the activation of 
dormant origins nearby 25,26 (Figure 5). 
Replication stress due to unrepaired DSBs extant from G1 phase or one-sided DSBs 
introduced at DNA nicks or abasic sites activates ATM or ATR after resection by 
endonucleases 26,27. If the lesion cannot be repaired and replication is not resumed, the 
replication fork is considered as collapsed, the stalled fork structure is probably 
degraded but the replisome remains chromatin-associated 28.  
The recovery of the fork can occur via several pathways (Figure 6): When the damage 
resides at the leading strand, the lagging strand synthesis can continue and a 
Translesion synthesis (TLS) polymerase over-replicates the damage on the leading 
Figure 5: Events at stalled replication forks: When the replication machinery 
encounters a DNA lesion (red star), DNA synthesis can resume downstream, 
generating a ssDNA-RPA stretch that is recognized by ATR/ATRIP. ATR then initiates 
a signaling cascade primarily mediated by the effector kinase CHK1. The signaling 
promotes fork stabilization, repair and restart, while preventing progression through the 
cell cycle, late origin firing and recombination until the damage is removed and 
replication can resume. Adapted from Zeman & Cimprich, 20144. 
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strand, leaving it to be repaired at a later time point by the post replication repair (PRR) 
29 (Figure 6, left). 
TLS polymerases are recruited by the monoubiquitination of PCNA on Lys164 by 
Rad6Rad18 once the replication fork stalls. In contrast to the replication polymerases, 
TLS polymerases display low fidelity and low speed but can accommodate base 
adducts into their active site, allowing the replication to continue. The TLS polymerase 
bypasses the lesion after polymerase switching and either the same or a different 
polymerase extends the strand before the polymerase is once more swapped to a 
high-fidelity DNA polymerase to continue replication 26,30. Loss of the TLS polymerase 
Pol η triggers the development of a type of Xeroderma Pigmentosum leading to cancer 
susceptibility 4.  
Homologous recombination (HR) is required to repair one-sided DSBs originating from 
stalled replication forks or from ssDNA nicks or gaps (Fork incision, Figure 6, bottom). 
End resection of the ssDNA is followed by strand invasion into the homologous sister 
chromatid by RAD51 nucleoprotein filament, DNA pairing and resolution of a Holliday 
junction 25,31. For an extensive description of the HR pathway and its factors involved, 
please refer to the homologous recombination section (1.4). 
In addition, the high-fidelity polymerase might reprime replication downstream the 
lesion, leaving a “daughter strand” ssDNA gap. This gap can either be filled by TLS 
polymerases or also repaired by HR (template switching, daughter strand gap repair). 
This error-free bypass of the lesion occurs via template switch where the newly 
synthesized sister chromatid is used as a template 26,29,32 (Figure 6, bottom). 
Which factors influence the choice between TLS and template switching as a 
mechanism for damage avoidance is not clear yet. While the repair by HR is more 
accurate and less error-prone, the formation of DSBs also endangers the DNA as it 
can give rise to dangerous lesions if misregulated. It was suggested that TLS is the 
preferred pathway during recombination as PCNA polyubiquitiylation has been less 
observed than monoubiquitylation33.  
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Fork regression is induced by polyubiquitilation of PCNA Lys163 by the 
Rad5/Ubc13/Mms2 ubiquitin ligase complex leading to a rearrangement of the fork 
promoted by RecQ helicases 34 (Figure 6, right). The fork can be reversed to push back 
the damage into the duplex region making it accessible for DNA repair by unwinding 
the leading and lagging strand. The replication fork is regressed by using the newly 
synthesized daughter strand of the undamaged sister chromatid as DNA template. This 
so-called “chicken foot” structure is similar to that of a Holliday junction and can be 
cleaved by the endonuclease MUS81, resulting in a single-ended DSB that is repaired 
by HR. Alternatively, the reversed fork is restarted behind the lesion via branch 
migration by helicases like RAD54 25,29. 
Stalled replication forks are protected by RAD51 that forms a nucleoprotein filament at 
newly replicated forks that are stuck or reversed, preventing the newly synthesized 
ssDNA from degradation by the endonuclease MRE11. BRCA2 stabilizes this RAD51 
nucleoprotein filament by interaction with its C-terminal RAD51 binding domain. Once 
the obstacle is removed, the replication machinery can progress to complete genome 
Figure 6: The DNA damage response (DDR) for the recovery of stalled replication 
forks and cell cycle arrest. The pathway choice is regulated by PCNA modifications. 
The stalling leads to downstream reinitiation of the polymerase, leaving a daughter 
strand gap that can be filled by translesion synthesis (left) or homologous 
recombination via template switching to avoid the damage (gap repair). Incision of the 
fork leads to a one-sided DSB that can be repaired by HR (bottom). The fork can also 
regress and the opposite strand is used as a template for replication until the lesion is 
repaired or bypassed by branch migration (right). Adapted from Heyer et al., 2010 32.  
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duplication. The BRCA2-RAD51 interaction is then disrupted by CDK1/2 
phosphorylation which allows entry into mitosis 35.  
Although the exact mechanisms and pathway choices for the removal of replication 
stress have not been completely elucidated yet, it is evident that replication stress is a 
primary driver of genetic instability and early onset tumorigenesis, for example in 
colorectal cancer 36. Unrepaired, non-fully replicated DNA leads to intertwined 
chromosomal segments (anaphase bridges) or chromosomal breaks that impair the 
proper segregation of the chromosomes in mitosis. Aberrant structures like lagging and 
acentric chromosomes or chromatid pieces get embedded in their own nuclear envelop 
which are transferred to daughter cells as extranuclear bodies (micronuclei), giving rise 
to genetic loss. To allow proper repair of chromosomal lesions these structures 
together with DNA repair proteins can be sequestered in 53BP1 inclusion bodies and 
transferred into G1 phase 25,37.   
1.3.3 INTERSTRAND CROSS-LINK REPAIR  
Interstrand cross-links (ICL) are caused by toxic agents used in cancer therapy such as 
cisplatin or mitomycin C but can also occur during metabolic reactions in the cell. They 
pose a toxic barrier for replication and transcription as they hinder the unwinding of the 
DNA by helicases 28. ICL induce the linkage of bases of the opposite strands that are 
impossible to remove without specialized repair mechanisms. Unresolved interstrand 
cross-links lead to chromosome rearrangements, breakage and cell death 38. 
Sensitivity to ICLs is also characteristic of the pediatric cancer predisposition syndrome 
called Fanconi anemia, which is marked by bone marrow failure, developmental 
defects, and a high incidence of cancer 39. 
The pathway to repair ICLs depends on the mode of lesion recognition. In non-
replicating cells, ICLs are repaired by NER. The lesion is first recognized by XPC-
HR23B-centrin complex or when the transcription complex encounters the lesion. XPF-
ERCC1 and XPG endonucleases cut on either side of the ICL (unhooking) and the 
resulting gap is filled by TLS polymerases. This initiates the second cycle of repair by 
NER, the excision of the flipped-out overhang by XPF-ERCC1 and gap filling by DNA 
polymerases and Ligase 3 40. The recombination-dependent ICL repair pathway (FA 
pathway) acts in S or G2 phase, when the lesion is recognized upon stalling of the 
replication fork. This complex repair pathway includes NER, HR and TLS. Many 
proteins participate in this process; shortly, FANCM recognizes the ICL and associates 
with the FA core complex (group I) constituted of seven of the FA proteins. 
Subsequently, FANC1 and FANCD2 (group II) are ubiquitylated to recruit other 
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recombination proteins required for the repair process: RAD51, RAD52, RAD54, 
BRCA1, as well as the FANCN (PALB2), FANCJ (BRIP1) and BRCA2 (FANCD1) 
(group III) for stabilization of the complex. At the same time, FANCD2 and FANCI 
factors bind endonucleases for the removal of the cross-link, TLS synthesis and repair 
of the lesion by HR 40,41.  
1.3.4 DNA-PROTEIN CROSS-LINK REPAIR 
The interaction between proteins and DNA is required for all forms of cellular 
processes. When these DNA-protein interactions are trapped by cross-linking of the 
protein with the DNA, they become highly toxic DNA adducts (DNA protein cross-links; 
DPCs) which need to be removed. Enzymatic DNA-protein cross-links arise when 
enzymes such as topoisomerase, glycosylase or polymerase transiently bind to the 
DNA and their release is inhibited by structural changes in the DNA or small molecules. 
Non-enzymatic DPCs can result from random protein-DNA interactions that are cross-
linked by potent endogenous or exogenous agents such as formaldehyde, 
acetaldehyde or irradiation. These bulky DNA adducts inhibit the progression of 
transcriptional or replication machinery and if left unrepaired, cause sister chromatid 
exchange, micronuclei and gross chromosomal rearrangements 42. Due to the high 
diversity of possible DPCs, several repair pathways are implicated in their repair. 
Tyrosyl-DNA phospho-diesterase 1 (TPD1) and tyrosyl-DNA phospho-diesterase 1 
(TDP2) remove topoisomerase I and II adducts, respectively, by cleaving the tyrosine 
bond between the enzyme and the DNA 43. MRE11 and CTB-interacting protein (CtIP) 
can remove DCPs at DSBs. Small DPCs can be repaired by the NER pathway. Stalling 
of the replisome can recruit the DPC protease that proteolyses the DPC and releases 
the stalled helicase but not the polymerase, leaving an ssDNA gap to be filled by TLS 
polymerases. In the absence of DCP protease, the fork stalls and is cleaved resulting 
in a single-ended DSB to be repaired by HR. Alternatively, the fork can converge with 
an incoming fork to unwind the DNA past the DPC or repair it by an ICL repair-like 
mechanism. When only the polymerase is stalled at the DPC, it is either removed by 
proteases and the ssDNA gap is filled by TLS or repaired by template switching as 
discussed for stalled replication fork repair above. Taken together, DPC proteases 
have been only recently shown to be a crucial measure for protection of the genome 
and are a potential target for cancer therapy 44.  
 
22 
 
1.3.6 DNA SINGLE-STRAND BREAK REPAIR  
Single-strand breaks (SSB) occur frequently in the genome, most commonly through 
the oxidative attack of reactive oxygen species (ROS) on DNA bases or sugar 
residues, resulting in the loss of one nucleotide and damaged 5’ or 3’ termini 45. SSB 
can also be produced during BER when abasic sites and oxidized or damaged bases 
are removed. It was also shown that abortive topoisomerase I functioning result in 
SSBs as well as ribonucleotides erroneously integrated into the DNA 46. In S-phase, 
replication stress is induced when the fork stalls at SSBs, usually leading to the 
formation of one-ended DSBs that are repaired by HR. Even though SSBs can either 
arise from different sources, the enzymes responsible for the repair have similar 
mechanisms: Detection of the SSB, DNA end processing, gap filling and ligation 45.  
When the sugar residue is damaged, SSBs are recognized by Poly-ADP ribose 
polymerase 1 (PARP-1), an enzyme that catalyzes the transfer of Poly (ADP-ribose) 
chains to itself and to other proteins activating the SSB repair pathway. Indirect SSBs 
that occur during BER do not require PARP1 for detection as they are directly 
channeled to DNA end processing when APE1/lyase remains bound to the abasic site. 
SSBs emerging in ribonucleotide excision repair or resulting from abortive 
topoisomerase I cleavage activity are assumed to also be recognized by PARP1. 
The DNA end-processing complex to resect damaged 5’ or 3’ ends is either recruited 
by APE1 and Polβ or via PARP1 and XRCC1. It involves many repair enzymes 
including APE1, Polβ, PNKP, APTX, and TDP1. Once the damaged 3’ or 5’ end is 
restored, the gap can be filled by short-patch (one nucleotide) or long-patch (several 
nucleotides) repair. The polymerases that are implicated in gap filling are Polβ, δ and ε. 
In long-patch repair, FEN1 removes the 5’ nucleotides. Ligase 1 and 3, stabilized by 
XRCCI and PCNA, respectively, are the gap filling enzymes to complete SSB repair 45–
49. Given that SSB are the most common DNA damage (up to 10.000 lesions per 
day/cell), it is not surprising that defects in SSB repair proteins such as XRCC1 and 
Polβ are connected to cancer. Ataxia-oculomotor apraxia 1 and Spinocerebellar ataxia 
with axonal neuropathy 1 are inherited neurological disorders with mutations in genes 
involved in the SSB repair pathway 46.  
1.3.7 DNA DOUBLE-STRAND BREAK REPAIR  
DNA double-strand breaks (DSBs) are among the most toxic and mutagenic lesions 
and if not repaired, lead to chromosome loss or fragmentation, gross chromosomal 
rearrangements and genetic instability. In addition, in higher organisms, the HR 
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pathway is also necessary in meiosis I.50. A DSB is considered as a breakage of the 
phosphor-sugar backbones of two DNA strands at the exact same position or in close 
proximity leading to the dissociation of the double helix 51.  
The sources for the breakage of the DNA double-strand are diverse: exogenous 
sources like ionizing radiation (IR), radiomimetic drugs such as alkylating agents and 
crosslinking agents, or topoisomerase inhibitors used for cancer therapy. 
Endogenous agents causing DSBs include metabolically created reactive oxygen 
species (ROS), stalled replication forks or when telomeres become critically shortened 
52,53. 
Besides the classical two-ended DSBs arising during the cell cycle by direct fracture of 
the DNA (Figure 7A), other forms of DSBs are produced during replication. When the 
replication fork stalls at unrepaired SSBs, they can be transformed into one-ended 
DSBs to be repaired by HR (Figure 7B). Likewise, daughter strand gaps can arise 
when the DNA synthesis is resumed after a lesion in the context of the replication fork 
(Figure 7C) 50. To maintain genome stability, the DSBs have to be faithfully repaired for 
which the cells have evolved highly specialized mechanisms; the DNA repair pathway 
involved will depend on the phase of the cell cycle.  
So far, four pathways for the repair of DSBs have been described: classical non-
homologous end-joining (c-NHEJ), homologous recombination (HR), single-strand 
annealing (SSA) as well as a recently discovered pathway called mirochomology-
mediated end joining (MMEJ) or alternative end-joining (a-NHEJ) 54. 
As described in Chapter 1.2, after the recognition of a DSB, the DNA damage 
response is activated via the ATM/ATR signaling cascade by phosphorylation of 
downstream mediators and effector kinases to regulate cellular processes including 
Figure 7: Origins of DNA substrates for the recombinational repair. A) Direct 
DSBs arise from fractures of the dsDNA. B) One-sided DSBs can be created 
when the replication machinery stalls at DNA lesions. C) A DNA lesion can be 
bypassed by the replication machinery and the daughter strand gap will be 
repaired by postreplicative recombinational repair. Adapted from Helleday et al. 
200750.  
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DNA repair, cell cycle progression and apoptosis.  
Classical non-homologous end-joining (c-NHEJ) can operate throughout the cell 
cycle as it does not require a homologous template or further DNA end resection for 
initation of the repair. DNA end resection is normally restricted to S/G2 phases and 
controlled by CDKs. During G1 and M phase, c-NHEJ is the primary pathway of choice 
55,56.  
The c-NHEJ process starts when a blunt DSB end is recognized by the Ku70/80 
heterodimer (KU) that binds to the DNA termini and recruits the catalytic subunits of 
DNA-PK. Phosphorylation by DNA-PK assembles enzymes such as XLF-XRCC4 
scaffold proteins for the stabilization of DNA ligase 4 to ligate the DSB ends. This 
results in a loss of nucleotides and can be mutagenic. If the 5’-3’-termini cannot be 
aligned directly, the endonuclease Artemis is recruited to process the ends and allow 
ligation 54,57 (Figure 8A). When Ku recognition of the DSB is inhibited in S/G2 phase, 
the DSB is first bound by the MRE11–RAD50–NBS1 complex (MRN complex), 
recruiting ATM to phosphorylate downstream targets. In contrast to NHEJ, the other 
DSB repair pathways rely on the resection of the 3’ end as well as the assembly of the 
BRCA1-PALB2-BRCA2 complex. The ubiquitylation of PALB2 by G1 factors inhibits 
the complex assembly with BRCA1 while deubiquitilyation in S-phase allows the repair 
by HR 58.  
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Alternative end-joining (a-NHEJ) or microhomology mediated end joining (MMEJ) 
was thought to be a back-up pathway to repair DSBs when the canonical NHEJ 
pathway was not available. Since recently, a-NHEJ is known to be active in cells 
proficient of c-NHEJ which points to differential activation of these pathways depending 
on the cell cycle state 54. 
Ku protein has a higher propensity for the association with DSBs than PARP-1 and 
thus determines the pathway choice between c-NHEJ and a-NHEJ. Moreover, in G2/S 
phase, the decision for HR or a-NHEJ depends on the resection state. Extensive 
resection by EXOI/BLM DNA2 complex favours HR whereas short resection by 
CtlP/MRE11 channels into the a-NHEJ pathway 59. It is assumed that PARP1 is 
responsible for the detection of the DSB whose ends are subsequently bound by the 
MRN complex. MRE11 and CtlP are then required for the 5’ and 3’ resection, 
respectively.  
In a-NHEJ, the DNA ends are joined together thanks to the presence of 
microhomologies. This pathway is highly mutagenic, leading to large 
deletions/insertions or chromosome translocations 54. For the successful end-joining, 
microhomologies of 1 nt are already sufficient to anneal with the complementary 
strand. If the annealed product is stable, the overhangs are directly cut by 
endonucleases. Otherwise flanking single-stranded regions require fill-in synthesis 
which is probably achieved by the TLS polymerase theta (Pol θ). The resulting flap 
Figure 8: DSB repair pathways. End resection of the DSB occurs primary in G1/S 
phase and determines pathway choice. A) Blunt DSBs can be repaired via NHEJ in 
G2/M phase when no homologous template is present. 3’ end resection of the DSB 
channels into HR, SSA or Alt-EJ. Here the pathway is chosen dependent on the 
resection state. B) Extensive resection initiates HR that blocks the SSA way (C). Short 
resection induces the Alt-EJ pathway (D). Adapted from Ceccaldi et al., 201655.  
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overhangs have to be removed by endonucleases and the ends are ligated using the 
XRCC1/Ligase III complex 54,55,57,59.  
Extensive resection by helicases coupled to nucleases generates long stretches of 
ssDNA that can be annealed by single-strand annealing (SSA) 60 (Figure 8C). The 
DSB ends are resected until homologous regions on both sides of the breaks are 
exposed. RAD52 promotes the annealing of the complementary ssDNA/RPA 
complexes. The non-homologous overhangs are removed by XPF/ERCC1, leading to 
deletion of long stretches of DNA that can cause genomic instability like translocations 
or chromosome fusions 32,61,62. SSA is a RAD51-independent pathway and is blocked 
by the proteins involved in HR when the two pathways compete for the resected DNA 
ends 63.  
Homologous recombination (HR) is considered as one of the most reliable ways for 
DNA repair and executes also other biological roles. HR 1) is critical for DNA double-
strand break repair arising from exogenous and endogenous sources 2) rescues 
stalled replication forks by repairing ssDNA breaks, gaps and one-sided DSBs. 3) 
provides telomere maintenance and 4) is essential for meiotic recombination by 
generating cross overs 64 (Figure 9). The notion that HR is important for the repair of 
DSBs comes from studies with Rad51 deficient mice that exhibited embryonic lethality 
65. Here I will separately discuss the roles of HR in its different biological functions and 
go into further detail about the mechanisms of HR for DSB for which BRCA2 is needed. 
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1.4 REPAIR OF DNA DOUBLE-STRAND BREAKS BY HR 
The defining step of homologous recombination is the invasion of the damaged strand 
into a homologous template, either the sister chromatid or homologous chromosome to 
prime DNA synthesis 66. As mentioned in S/G2 phase, HR is the pathway of choice for 
the repair of DSBs over c-NHEJ. After recognition of the break, the ATM kinase 
activates a signal cascade that initiates DSB repair and regulates the cell cycle. The 
committing step into HR (pre-synapsis) is the resection of the DSB at the 5’ end to 
produce 3’ ssDNA overhangs by the MRN complex (MRE11/RAD50/NBS1) and CtlP. 
MRN recruits BLM helicase-DNA1 helicase/nuclease or EXO1 exonuclease-BLM 
complexes to extensively resect the DNA 67. The ssDNA binding protein RPA binds to 
the exposed stretches of ssDNA, thus preventing secondary structures and unwanted 
resection. Subsequently, ATR phosphorylates its targets for activation of DNA repair 
such as BRCA1 or 53BP1 66,67. RPA-coated ssDNA poses a kinetic barrier that has to 
be overcome by the central recombinase RAD51 to access the DNA and start the HR 
process 61. HR mediator proteins including BRCA2 and the RAD51 paralogs are 
needed to ensure RAD51 binding to and filament formation on the ssDNA. Cells 
deficient of the central mediator protein BRCA2 are highly sensitive to DNA damage, 
reflecting its importance in HR 68. Shortly, BRCA2 binds RAD51 via its BRC repeats to 
facilitate binding and nucleation on the ssDNA 69–72. For an extensive description of 
BRCA2 function, please refer to Chapter 1.7. In humans there exist five RAD51 
paralogs with sequence similarity, but without recombination activities that form two 
complexes: RAD51B/RAD51C/RAD51D/XRCC2 and RAD51C/XRCC3. Their exact role 
in HR is not known but it is assumed that the complexes exist to stabilize the RAD51 
Figure 9: Homologous recombination is required in A) repair of DNA double-strand 
breaks during G2/S phase in mitotic cells when a template is available B) the rescue of 
stalled replication forks at DNA breaks C) meiotic recombination of programmed DSBs to 
ensure segregation of the chromosome homologues D) the maintenance of telomere 
ends to avoid telomere shortening. Adapted from Sung & Klein, 2006 64.  
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filament formation in response to DNA damage. Mice deficient in one of the RAD51 
paralogs are also embryonically lethal. However, cells depleted of the paralogs are less 
sensitive to DNA damage than cells deficient of BRCA2. Hence, RAD51 paralogs 
together with BRCA2 stabilize the RAD51 filament formation by blocking RAD51 
association with dsDNA and allowing it to nucleate on the ssDNA 61,73–75. 
During synapsis, the second stage of HR, the RAD51 filament starts homology search 
and once it is found, invades the homologous template strand, either the sister 
chromatid or a homologous chromosome 76–78. RAD51 associates with the motor 
protein RAD54 that functions to translocate RAD51 along the filament, remodel the 
chromatin and to open of the duplex DNA using its ATPase activity. Invasion of 
RAD51-ssDNA nucleoprotein filaments into the dsDNA results in the formation of a 
heteroduplex displacement loop (D-loop). In post-synapsis, DNA synthesis is primed 
from the 3’end of the invading strand and extended with PCNA by TLS DNA 
polymerases (Figure 10) 32,76–79. The dissolution of the extended D-loop can be 
achieved by three different pathways: double Holliday Junction (dHJ) subpathway, 
synthesis-dependent strand annealing (SDSA) or break-induced replication (BIR) 
(Figure 10). 
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In the double Holliday Junction (dHJ) pathway, the invading strand of the D-loop 
captures with and connects the end of the non-invading strand to form a double 
Holliday Junction intermediate. This branched structure migrates in the direction of 
DNA synthesis for which the invaded sister chromatid is used as a template. After DNA 
synthesis, the dHJ can either be dissolved by BLM-helicase TOPOIIIα-RMI/2 
topoisomerase complex resulting in a non-crossover structure. Resolution by the 
endonucleases GEN1, MUS81-EME1 or SLX1-SLX4 leaves a crossover leading to 
gene conversion that can facilitate genomic instability 32,50,80,81 (Figure 10C). 
SDSA resolves the D-loop by the helicase BLM and the newly synthesized ssDNA 
strand anneals with the complementary ssDNA strand resulting in non-crossover with 
the homologous strand (Figure 10D). Non-crossovers avoid the hazard of genomic 
Figure 10: DNA double-strand break repair pathways. The DSBs are resected resulting 
in a 3’ ssDNA overhang. A) NHEJ can ligate the blunt ends B) SSA anneals flanking 
homologous regions, resulting in a loss of DSB ends. Homologous recombination can 
occur via C) double-Holliday Junction pathway, where the invading strand captures then 
second end on the opposite site to stabilize the D-loop. It is then dissolved by helicases 
and topoisomerases resulting in non-crossovers (NCO) or resolved by endonucleases 
which can result in cross-overs (CO) or non-crossovers (NCO). D) In synthesis-
dependent strand annealing (SDSA), the newly synthesized strand dissociates and is 
ligated. E) break-induced repair (BIR) is required for the repair of one-ended DSBs (e.g. 
in replication). A new replication fork is established at the D-loop for DNA synthesis. The 
new strand is then used as a template for lagging strand synthesis, resulting in loss-of-
heterozygosity. Adapted from Metha & Haber, 2014 81. 
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rearrangements induced by dHJ or BIR, making SDSA the preferred subpathway 
63,81,82.  
When the second end is absent, one-ended DSBs resulting from stalled replication 
forks during replication or at telomeres are also repaired by a HR pathway, Break-
Induced Replication (BIR). Here, the D-loop structure is resolved by nucleases and a 
replication fork is re-established that can migrate semi-conservatively, duplicating the 
missing arm and may ultimately result in loss-of-heterozygosity (LOH) 83–85 (Figure 
10E).  
The evolution of these highly specialized mechanisms can be explained by the 
catastrophic consequences for the stability of the genome when DSB break repair is 
defective. First, unrepaired DSBs are toxic lesions for the cell. Second, the accurate 
rejoining of the two ends of a DSB and the reinsertion of the one-ended strand in the 
replication process, respectively, are of upmost importance to avoid chromosome 
breaks, chromatid translocations, deletions, inversions or amplifications that ultimately 
provoke tumorigenesis 86. In contrast, in meiosis, DSBs created by the endonuclease 
Spo11 activates genetic recombination between homologous chromosomes serve to 
generate genetic diversity which will be explained in detail in chapter 1.1050.  
1.5 TELOMERE MAINTENANCE 
At telomeres ends, the reverse transcriptase telomerase adds TTAGGG repeats to 
compensate for the loss of genetic material due to the inability of the replication 
machinery to progress to the ends of the DNA on the lagging strand. These repeats 
tend to form G-quadruplexes, which block replication fork progression. The G-
quadruplexes are unwound by the RecQ helicases WRN and BLM. Defects in these 
proteins are reflected by the cancer-prone disorders Werner’s and Bloom’s syndrome 
87. It is suggested that BRCA2 loads RAD51 to the telomeres for the formation of a T-
loop (telomere loop) structure for protective telomere end capping 88. In addition, 
BRCA2 protects the stalled replication fork at telomere ends from degradation by 
MRE11 in a way independent from DSB repair as it was shown before at replication 
forks outside the telomeres 35,89. 
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1.6 MEIOTIC RECOMBINATION 
Meiosis is a specialized process in the germ line to produce haploid gametes. The 
homologous chromatids are duplicated by replication, followed by the exchange of 
genetic material during recombination. Two segregation phases, Meiosis I and Meiosis 
II separate homologous chromosomes and then the sister chromatids to obtain a 
haploid set of chromosomes in the gametes 90. Recombination was initially studied in 
Meiosis I where it is responsible for the exchange of maternal and paternal 
homologous chromosomes to generate diversity by crossovers. In addition, HR is 
important for the physical connection of the homologues, termed chiasmata, which 
ensure the proper orientation at the meiotic spindle before segregation to the opposite 
poles 91. Meiotic recombination is initiated by the induction of a DSB by the 
topoisomerase-like protein Spo11 (Figure 11). Then, Spo11 is removed and 
exonucleases (MRN, CtlP, EXOI) generate the 3’ ssDNA tail that will serve as HR 
substrate 90. The central recombination protein in meiosis is DMC1, but the 
recombination proceeds as described in the HR section 83,90,92–94. DMC1 mutants show 
almost complete absence of meiotic recombination which is also the case for RAD51 
mutants, suggesting that both recombinases are needed for meiotic recombination 
events in non-overlapping functions 91,95. Although it was known that DMC1 interacts 
with BRCA2, the exact contribution of BRCA2 in meiotic recombination was unclear. 
During my PhD, I collaborated in a project to address this question (see Chapter 4). I 
will go into further detail about the current knowledge about the role of BRCA2 in 
meiotic recombination in Chapter 1.10.  
After completion of recombination and exchange of genetic material, cells undergo two 
meiotic divisions. First, the two homologous chromosomes segregate from each other 
in Meiosis I. Subsequently, the sister chromatids are pulled to the opposite spindle 
poles during Meiosis II, resulting in four genetically non-identical haploid gametes 96. 
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1.7 BRCA2, A VERSATILE PROTEIN  
Figure 11: Mechanism of meiotic 
recombination. A DSB is created 
by Spo11. This allows resection of 
the 5’ end by nucleases. The 
recombination protein DMC1 bind 
to the 3’ ssDNA overhangs 
generated, perform strand 
invasion, homology search and 
strand exchange in the template 
strand to prime DNA synthesis. 
RAD51 is thought to play an 
accessory role in this context95. 
The outcome of strand exchange 
will depend on e the pathway, dHJ 
or SDSA. In the dHJ pathway, the 
invading strand captures the 
second end of the invaded strand 
to form a dHJ that is resolved 
leading to crossover products. In 
the SDSA pathway, the invading 
strand is displaced after DNA 
synthesis and anneals to the other 
end of the DSB, yielding a 
noncrossover. Adapted from Lam 
& Keeney, 201590. 
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BRCA2 (breast cancer 2) was discovered as a breast cancer susceptibility gene when 
individuals with heterozygous germline mutations in BRCA2 were shown to have an 
elevated risk to develop breast, ovarian or pancreatic cancer. Mutations in BRCA1 or 
BRCA2 account for 15% of the genetic variants predisposing to breast cancer 97. The 
first hints to BRCA2 function came from Brca2 knock-out mice showing embryonic 
lethality as well as radiation and MMC hypersensitivity 68. The analysis of chromosome 
spreads on these mice cells displayed a chromosomal abnormalities like chromatid 
breaks and translocations, implicating a defective DSB repair and involvement of 
BRCA2 in this pathway 98. Shortly after, BRCA2 was found to interact with RAD51, 
linking the two proteins in the same pathway of DNA repair, Homologous 
Recombination (HR) 99.  
As a caretaker of genomic maintenance, BRCA2 is involved in mechanisms to ensure 
faithful genome duplication during replication (S phase), the repair of DNA damage 
before entering mitosis (S/G2) as well as the proper segregation of the chromosomes 
and cytokinesis in M phase 100 (Figure 12). Moreover, BRCA2 is also involved in 
meiotic recombination and telomere maintenance (1.5; 1.6). In the following chapters, I 
Figure 12: BRCA2 functions at various stages during cell cycle progression via 
via its numerous domains (numbers below correspond to the amino acid 
residues involved). Adapted from Lee, 2014 100.  
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will explain how BRCA2 fulfills its versatile roles. 
1.7.1 STRUCTURE, FUNCTIONAL DOMAINS, INTERACTION PARTNERS AND 
MODIFICATIONS OF BRCA2  
The tumor suppressor protein BRCA2 is a large multi-domain protein consisting of 
3,418 amino acids (390 kDa) that constitute 26 Exons of different sizes 101. It has no 
sequence similarity to any other protein described and only little sequence 
conservation in evolution, making it difficult to predict the functions of the domains by in 
silico tools 102. In addition, many regions of BRCA2 are predicted to be intrinsically 
disordered and do not show any folding patterns, this is especially the case for the N-
terminal domain. The enormous difficulties to purify the full-length protein in sufficient 
quantities have hampered the investigation of BRCA2 by biochemical characterization 
for years. However, since the first successful purifications of BRCA2 in 2010 70–72, it is 
possible to further study its individual domain functions and interaction partners in the 
context of the full-length protein. In my PhD project, I used the purification protocol 
developed in our lab to perform biochemical in vitro assays with full-length BRCA2 as 
well as with BRCA2 fragments. Indeed, as described in Chapter 1.14, the main project 
of my thesis aimed at identifying and characterizing new functional domains in the N-
terminus of BRCA2.  
Here, I will briefly discuss the current knowledge of BRCA2 functional domains and 
interaction partners. A more detailed description of the functions in the different 
pathways for the domains and interactions of BRCA2 described here can be found in 
the related chapters.  
The N-terminus comprises the first 1000 amino acids of BRCA2 and there is very little 
information about its function (Figure 13). Applying BRCA2 aa 1-1000 to FoldIndex 
software 103 reveals that half of the N-terminus is predicted to be intrinsically 
disordered. The prediction of its function based on sequence or domain conservation is 
Figure 13: BRCA2 structure displaying its functional domains (in color) and its 
interaction partners (below) as well as posttranslational modifications (P). Details are 
described in the text.  
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hence much more challenging 104 (Figure 14). Most of the known functions of the N-
terminal region come from studies with its interacting partners.  
PALB2 (Partner and Localizer of BRCA2) (PALB2) was identified in 
immunoprecipitation studies and shown to form a complex with BRCA1 and BRCA2 
required for their localization to the nucleus. This PALB/BRCA2/BRCA1 complex 
stabilizes BRCA2 to exerts its HR function 105,106. The interaction site with BRCA2 was 
mapped to the first 40 amino acids of the N-terminus, where missense mutations have 
been found, pointing to the importance of PALB2/BRCA2 interaction in HR. Indeed, the 
depletion of PALB2 leads to DNA damage hypersensitivity and PALB2 is also 
considered as a tumor suppressor protein as it has been found mutated in tumors 
106,107. In vitro, PALB2 cooperates with BRCA2 to promote homologous DNA pairing by 
RAD51 108,109. Cells expressing either BRCA2 truncated at the N-terminus or C-
terminus show a milder phenotype in response to genotoxic agents than cells 
expressing BRCA2 lacking both termini, suggesting that the recruitment of BRCA2 to 
the chromatin by PALB2 may compensate for the absence of BRCA2 C-terminal 
domain 109. However, the results in the work presented here show that the lack of the 
C-terminal DNA binding domain might be compensated by a novel DNA binding 
domain in the N-terminal region (Chapter 2). 
The PALB2 interaction site at the extreme N-terminus is shared with the transcriptional 
repressor EMSY that suppresses BRCA2 transactivation activity located in exon 3 110. 
EMSY’s amplification has been observed in sporadic breast cancer suggesting a link 
between BRCA2 and these types of cancers111.  
Downstream the primary sequence lays the Polo-like kinase 1 (PLK1) interaction site at 
amino acid T77. PLK1 phosphorylates BRCA2 at residue S193 and this 
phosphorylation is important in mitosis 112,113. Phosphorylated BRCA2 is recruited to the 
midbody where it interacts with Myosin IIC 114. The binding of PLK1 to T77 is regulated 
by CDK1/2 kinases and subsequently brings RAD51 in complex together with BRCA2 
Figure 14: Probability of folding of BRCA2 amino acids 1-1000 as predicted by 
FoldIndex. BRCA2 is highly disordered (red) and bears only some folded regions 
(green). FoldIndex Webtool kindly provided by Prilusky et al., 2005103. 
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to ensure repair of DNA damage before entering mitosis 115. Residues 290-453 of 
BRCA2 specifically interact with the transcriptional co-activator P/CAF that exhibits 
histone-acetyltransferase activity 112,116. BRCA2 acts as a scaffold for P/CAF and 
BUBR1, an important player for the Spindle Assembly Checkpoint (SAC) at the 
kinetochore. Acetylation of BUBR1 by P/CAF activates the SAC ensuring proper 
chromosome segregation once they are aligned 117. The midbody proteins CEP55, Alix 
and Tsg101 were found to immunoprecipitate with a BRCA2 fragment of amino acids 
271-836. These proteins interact at the midbody for the formation of the contractile ring 
facilitating abscission to complete cytokinesis. Depletion of any of these factors causes 
multinucleation. BRCA2 depletion leads to disruption of localization of Alix and Tsg101 
to the midbody as well as the interaction of CEP55 with these proteins causing defects 
in cytokinesis 118.  
The central region of the protein harbors the BRC repeats as well as one nuclear 
export signal (NES). The NES is responsible for the export of BRCA2 together with 
chromosomal region maintenance 1 protein (CRM1) from the nucleus to the cytoplasm 
to regulate centrosome duplication during mitosis. Depletion of the NES causes 
centrosome amplification 119.  
The BRC repeats span the central region of the protein between amino acids 1009 and 
2082. They constitute the principal RAD51 interaction site with BRCA2 and all possess 
a similar sequence motif of about 35 amino acids 101,120. The sequence fingerprint of 
the amino acids that interact with RAD51 in the BRC repeats is highly conserved 
among BRCA2 orthologs, emphasizing their importance in HR 99,121,122. BRCA2 
association with RAD51 monomers via the BRC repeats promotes RAD51 binding to 
ssDNA over dsDNA for the promotion of unidirectional nucleoprotein filament formation 
of RAD51. The first four BRC repeats bind RAD51 with high affinity to facilitate its 
assembly on the ssDNA, whereas BRC 5-8 bind to the RAD51 nucleoprotein filament 
to stabilize its growth 70,123,124. In Chapter 4 of my PhD I will present the work in which 
we describe that BRCA2 interacts with DMC1, the meiotic counterpart of RAD51, 
through the BRC repeats. HMG20b or BRAF35, a kinesin-like coiled-coil high mobility 
group protein, binds to amino acids 1628-2190 in the BRC repeats of BRCA2. This 
interaction seems to regulate HMG20b function in the completion of cell division 125,126.  
The crystal structure of the mouse C-terminal DNA binding domain (CTD) shows that it 
consists of five adjacent domains: a helical domain, three 
oligonucleotide/oligosaccharide binding (OB) folds and a tower domain that protrudes 
from OB2 (Figure 15). The DNA binding domain exerts high ssDNA binding affinity but 
low affinity for dsDNA 127. This domain can enhance the DNA strand exchange activity 
of RAD51 and this is further promoted in a fusion peptide with one BRC repeat 128. The 
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small 70 amino acids protein DSS1 (depleted in split hand split foot syndrome) binds to 
BRCA2 in the region between the helical domain and OB1 and confers stability to 
BRCA2 129, an observation we also made during the purification of the CTD in this 
study (see chapter 2). Cells depleted for DSS1 exhibit a HR-deficient phenotype in 
response to DNA damage implying an important function of DSS1 in HR 130. Recently it 
was demonstrated that together with BRCA2, DSS1 targets RPA, decreases its affinity 
for ssDNA and facilitates RPA displacement by RAD51 69. A second NES is present in 
the C-terminus between the helical domain and OB fold 1. It is masked by binding of 
DSS1 to BRCA2, thus preventing the export of BRCA2/DSS1/RAD51 complex to the 
cytoplasm. A cancer associated BRCA2 variant (D2723H) in the CTD prohibits DSS1 
binding and renders BRCA2 cytoplasmic 131.  
The C-terminal domain also associates with the transactivation domain of the 
transcriptional regulator p53 which might be needed as a control mechanism for HR 
and apoptosis 132.  
The midbody component Filamin A binds to OB2/OB3 and this association is required 
for the proper localization of BRCA2 to the midbody 118. A second RAD51 binding site 
exists at the extreme C-terminus of BRCA2 68. Phosphorylation of this site at S3291 by 
CDK1/2 in G2/M phase disrupts BRCA2-RAD51 interaction, which is thought to be a 
Figure 15: View of the mouse BRCA2 CTD DBD-DSS1 crystal structure. In 
magenta: Helical domain (H), in green, red and blue, OB1, OB2 and OB3. The tower 
domain in red originates from OB2. Orange: DSS1 is associated to BRCA2 between  
H and OB1. From Yang et al., 2002 127.  
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switch-off mechanism to control HR 133. The RAD51 binding site at the C-terminus can 
also stabilize RAD51 filaments for the protection from degradation of the newly 
synthesized strand at stalled replication forks, but this function is independent of DSB 
repair 35. Finally, BRCA2 localization to the nucleus is dependent on two Nuclear 
Localization Signals (NLS) that close to the C-terminal RAD51 binding site 134. 
A detailed description of the functions and interactions of BRCA2 in the various 
pathways shortly touched here, are further detailed in the respective chapters.  
1.8 BRCA2 ACTS AS MEDIATOR PROTEIN OF RAD51 RECOMBINASE IN HR 
The first piece of evidence for BRCA2’s role in HR came from the DNA damage 
sensitivity observed in brca2 deficient mouse embryonic cells upon γ-radiation. Similar 
to rad51 mutants, brca2 deficiency is embryonic lethal 68. RAD51 and BRCA2 were 
then found to physically interact in mice and human, suggesting a role for BRCA2 in 
DSB repair as an auxiliary protein for RAD51 function 127. Indeed, the interaction of 
BRCA2 with RAD51 is important for RAD51 foci formation in response to irradiation 
and mutations in the BRC repeats found in cancer patients are sensitive to DNA 
damage 136–138. In accordance with these findings, BRCA2 deficient cells exhibit gross 
chromosomal rearrangements (GCR) as a result from defective DSB repair presumably 
because the breaks are repaired by error-prone pathways such as NHEJ or SSA that 
are not affected by loss of BRCA2 139,140. First, BRCA2 is responsible for the 
localization of RAD51 to the nucleus. Overexpression of the BRC repeats blocks 
RAD51 assembly in a dominant-negative manner, suggesting that the BRC repeats 
sequester RAD51 monomers for the transport to the site of DNA damage 141. The direct 
involvement of BRCA2 in HR was demonstrated when using a HDR-reporter assay as 
overexpression of BRCA2 in truncated CAPAN-1 cells and Brca2Tr/Tr MEFs rescued HR 
proficiency 142,143. 
The HR mechanism involves the central strand exchange reaction by RAD51. The 
recombinase forms a nucleoprotein filament with the ssDNA in an ATP-dependent 
manner to search for homology in a homologous template. Once it is found, RAD51 
filaments can invade the template and DNA synthesis is primed to repair the DSB. The 
role of recombination mediator proteins in pre-synapsis is to facilitate the loading of the 
recombinase on the ssDNA that is tightly bound by the ssDNA binding protein RPA 
posing a kinetic barrier for RAD51. The mediators also favor the binding to ssDNA 
rather than to dsDNA that is more abundant in the cell. Once the strand exchange 
protein is bound to the ssDNA, the mediator stabilizes the filament growth by inhibiting 
the ATPase activity of the recombinase 60,74,80,143,144. The phenotype exhibited by 
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BRCA2 deficient cells as well as many in vitro and in vivo studies using fragments of 
the protein suggested that BRCA2 is the central mediator of RAD51 recombinase. 
The required ssDNA binding function of BRCA2 was demonstrated in the crystal 
structure of mouse Brca2 C-terminus in a complex with Dss1 and DNA (Figure 15). 
Between OB2 and OB3, a tower domain comprising a three-helix bundle structure is 
consistent with the idea that CTD could associate with dsDNA, however, no dsDNA 
binding activity has been reported for this fragment. This complex is also able to 
promote strand exchange activity by Rad51 confirming Brca2 mediator function in vitro 
by facilitating RAD51 assembly on the ssDNA through interaction with the BRC repeats 
127. Insights into the mechanism by which the BRC repeats regulate RAD51 function in 
HR came from the crystallographic structure determination of the RAD51-BRC4 
complex: BRC4 blocks the oligomerization interface of RAD51, thus allowing 
polymerization of RAD51 monomers. Specifically, the FxxA motif of the BRC repeats 
occupies a highly conserved interface of the catalytic domain of RAD51 120. A distant 
LFDE module present in all BRC repeats was also proposed to be important for RAD51 
binding146. This region will become relevant in the context of the DMC1 work presented 
in Chapter 4.  
The loading of RAD51 to the resected ssDNA would normally be hampered by 
RAD51’s propensity to strongly bind to dsDNA. Several studies showed that the BRC 
repeats promote the RAD51 binding to ssDNA while blocking the association with 
dsDNA as a regulatory mechanism 83,123,147. Important findings of how exactly the 
regulation of RAD51 by the BRC occurs were made by my PhD supervisor: Using 
purified BRC4, she found that by binding to RAD51 it reduces its ATP hydrolysis to 
keep it in an active state and prevent the ADP-RAD51-ssDNA complex from 
dissociation. This permits ATP-ADP exchange within the filament without dismantling it. 
BRC4 also prevents nucleation of RAD51 on the dsDNA and stimulate its strand 
exchange activity 123. To assess the role of each of the BRC repeats in RAD51 filament 
formation, she investigated the roles of the individual BRC repeats. BRC1-4 bound with 
much higher affinity than BRC5-8 to free RAD51. Likewise, only BRC1-4 were able to 
reduce the rate of RAD51 ATP hydrolysis to stabilize the ssDNA-RAD51 nucleus. 
However, BRC5-8 showed higher affinity for RAD51-ssDNA complex suggesting that 
they are responsible for RAD51 filament stabilization at a later stage. Like BRC4 alone, 
BRC1-4 inhibited the association of RAD51 to dsDNA to promote unidirectional 
filament formation. The same repeats also stimulated strand exchange activity of 
RAD51 124.  
But yet how these functions in HR are achieved in the context of the full-length protein 
remained to be investigated. As said, in 2010 three groups succeeded in the 
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purification of full-length human BRCA2. Their studies revealed that BRCA2 
preferentially binds to ssDNA or tailed substrates that represent a ssDNA/dsDNA 
junction resembling a 3’ resected DSB. In contrast, only a weak affinity to dsDNA was 
observed. The RAD51 strand exchange activity promoted by BRCA2 in presence or 
absence of RPA was assessed in strand exchange reactions. BRCA2 could alleviate 
the inhibition of RAD51 binding posed by RPA bound to ssDNA probably by its high 
affinity to ssDNA. The RAD51 strand exchange activity was increased by BRCA2 even 
in the absence of RPA, confirming that BRCA2 facilitates RAD51 binding to ssDNA, 
probably by inhibiting dsDNA association. Quantification of BRCA2-RAD51 interaction 
revealed that approximately six RAD51 monomers can bind to one BRCA2 molecule 
70–72. As shown in the mouse crystal structure, the small acidic (70 aa) protein DSS1 
binds to the CTD of BRCA2 (2472–2957 aa) and is important for BRCA2 stability 127,129 
(Figure 15). In humans, DSS1 depletion causes defects in DSB repair as BRCA2 
mutant defective in DSS1 binding render BRCA2 and RAD51 cytoplasmic by exposing 
RAD51 NES, usually masked by BRCA2-RAD51 interaction 131. Recently, DSS1 was 
shown to mimic the DNA reducing the affinity of RPA for ssDNA and thus allowing its 
displacement by RAD51 69. DSS1 is also a component of the proteasome, suggesting 
that DSS1 regulates DSB repair by proteolytic turnover of repair proteins 148.  
The results summarized above contributed to the following model for the mediator 
protein role of BRCA2 in HR (Figure 16): 
After the 3’ end resection of the DSB, an ssDNA/dsDNA tail is coated by RPA. BRCA2 
binds to the DNA junction, thereby replacing RPA and delivering RAD51 bound to 
BRC1-4 which facilitates its nucleation on the ssDNA. The same group of repeats 
enables RAD51 filament formation by inhibiting its ATP hydrolysis and avoiding its 
association with dsDNA. The further extension of the RAD51 filament is stabilized by 
BRC5-8. BRCA2 could then be released and RAD51 starts the invasion of the 
homologous template strand 124. RAD51 binding to BRCA2 is regulated by CDK 
phosphorylation of the RAD51 binding site at the extreme C-terminus in a cell-cycle 
dependent manner. DNA damage induces dephosphorylation and stabilizes the 
RAD51 filaments in order to complete HR before entering mitosis 149,150. 
Which BRCA2 domains are thus crucial for the repair of DSBs? Studies showed that 
fusion proteins comprising one or two BRC repeats and a DBD (CTD of BRCA2 or the 
DNA binding domain of RPA) was sufficient to restore HR activity 151–153. In U. maydis, 
mutants expressing a truncated version of Brh2 that were missing the CTD/Dss1 
region were resistant to DNA damage 154. This was explained by the presence of a 
second DNA OB-fold like structure downstream the BRC with DNA binding activity. 
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Surprisingly, this domain exhibited higher affinity for DNA than the CTD suggesting it to 
be the primary interaction site for DNA. 
The same authors reported that the binding of the CTD to DNA is negatively regulated 
by Dss1, explaining the presence of two DNA binding sites. In their model the authors 
propose that the NTD unaffected by Dss1 makes the first contact with the DNA while 
the action of the CTD is inhibited by Dss1. Then, Dss1 is released due to an allosteric 
change and the CTD can tightly bind to the ssDNA, thereby stabilizing the exposed 
strand for Rad51 loading 155. It should be noted that the observations were made in 
Brh2, a protein with a size of only one third of BRCA2, even though it possesses the 
Figure 16: Model for the interaction between RAD51 and BRCA2 in presynapsis. 
Explanations can be found in the text. Adapted from Carreira & Kowalczykowski, 2011. 
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domains assumed to be necessary for the function in HR, namely one BRC repeat and 
the CTD. No sequence similarity was observed between Brh2 and BRCA2 N-terminal 
domains to ascribe a similar function or domain to BRCA2.  
Nonetheless, a resembling situation to the one in Brh2 was found in the studies with 
small BRCA2 constructs: Peptides including a BRC repeat and the CTD are slightly 
proficient in HR but require DSS1 binding in vivo. However, the HR activity is 
reestablished to nearly wild type levels when expressing a fragment containing the N-
terminal PALB2 binding site, two BRC repeats as well as the C-terminal RAD51 
binding domain. The authors suggested that the ssDNA binding activity is achieved by 
PALB2 instead of BRCA2 156. If the PALB2 DNA binding is only needed when the 
canonical CTD is missing or if these functions are interdependent, was investigated in 
an in vivo study in DT40 chicken cells. It was observed before that when exposing 
DT40 cells expressing a truncated version of BRCA2 (BRCA2BRC3tr) and C-terminal 
domain deficient cells (BRCA2BRCΔCTD) to DNA damage, they have a significantly milder 
phenotype than BRCA2-/- cells. Likewise, when evaluating the phenotype of BRCA2ΔN, 
the expressing cells could survive the damage and showed a modest phenotype in 
stark contrast to cells depleted of the C-terminus and N-terminus (BRCA2ΔN+ΔC). This 
genetic study also supported the hypothesis of the C- and N-terminus sharing a similar 
function which is, most probably, the interaction with the DNA. They also argued that 
the DNA binding activity of BRCA2BRC3tr is dependent on PALB2 activity as the activity 
was not enhanced when overexpressing BRCA2BRC3tr in BRCA2-/-/PALB2-/- cells or 
when introducing mutations in the PALB2 binding site of BRCA2 109. 
In an earlier study researchers used human CAPAN-1 cells that lack a wild-type 
BRCA2 allele but express a truncated version of the protein due to a deletion 
(6174delT) including the N-terminus and six BRC repeats to investigate the mechanism 
by which cells become resistant to PARP inhibitors. CAPAN-1 cells are usually highly 
sensitive to PARP inhibitors, displaying HR deficiency. The lab succeeded in deriving 
PARP inhibitor- and cisplatin-resistant CAPAN-1 clones (PIR) by continuous treatment 
and inferred the resistance to originate from a restored HR proficiency. When they 
looked at the expression profile of BRCA2 in the PIR clones, they observed new 
species of BRCA2 expressing the extreme C-terminal domain but not the CTD. 
Sequencing of the PIR clones confirmed these results and revealed a restoration of the 
ORF leading to the expression of a protein containing the N-terminus, five BRC 
repeats, the NLS and the C-terminal RAD51 binding domain. A DR-GFP-reporter 
assay showed that HR proficiency was reconstituted in these cells to nearly wild type 
levels 157. This study not only emphasizes the risk of therapy resistance when applying 
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PARPi monotherapy to patients, but confirms that human BRCA2 devoid of the CTD 
can still fulfill its function in HR also in human cells in response to DNA damages.  
Mechanistic insights in how the BRCA2-RAD51 interaction for the promotion of ssDNA 
binding is achieved came from recent three-dimensional EM constructions, visualizing 
the assumptions from the in vitro assays discussed above. These revealed the 
structure of the BRCA2-RAD51 complex that reconstitutes a BRCA2 dimer binding to 
two sets of RAD51 molecules consisting of four or five monomers each as it was 
described before 71. As these sets are orientated in opposite directions, only one set 
could start nucleation imposed by the polarity of the DNA. Binding of BRCA2 to ssDNA 
was once more confirmed by EMSAs showing that longer patches of more than 66 
nucleotides are needed for maximal binding. Although not with more affinity than for 
ssDNA, BRCA2 bound a gapped DNA substrate mimicking the 3’ overhang at the 
resected end. EM reconstitution showed that the BRCA2 dimer can accommodate the 
gapped DNA close to the C-termini of the BRCA2 monomers where the DNA binding 
sites are located, indicating that these act together for ssDNA binding. The 
visualization of RAD51 recruitment by EM confirmed earlier results that RAD51 
filaments are only formed in presence of BRCA2. As expected, BRCA2 bound to the 
end of the RAD51-ssDNA filament to allow the growth of the filament in the 3’-5’ 
direction. Presence of BRCA2 also increased the number of RAD51 filaments (40-100 
nm in length) and importantly, the nucleation events on the same ssDNA molecule, 
indicating that BRCA2 initiates the filament formation at several sites to allow 3’-5’ 
growth in a gap-filling manner. However, RAD51 filament growth was not extended for 
which rather other mediator HR factors such as RAD54 or RAD51 paralogs are needed 
158.  
Thanks to the impressive amount of research we can now draw a clearer picture of 
how BRCA2 mediates RAD51 filament formation. 
However, it is still questionable of how BRCA2 can load RAD51 to the site of DNA 
damage in absence of its CTD as it has been observed in the studies discussed above. 
Hence, there must be a different mechanism of BRCA2 action involving the N-
terminus. PALB2 was proposed to overtake BRCA2 DNA binding function in the 
absence of its C-terminus. So far, this is the only known protein interaction that could 
explain a DNA binding mechanism. A secondary DNA binding site was revealed in the 
ortholog Brh2, but the N-termini of the two proteins do not resemble each other in 
sequence or structure. The DNA binding domain of Brh2 is constituted of an OB-fold 
like domain similar to RPA but this structure cannot be found in the N-terminus of 
BRCA2 159 (CN own data). It is also notable that BRCA2 homologs from C.elegans and 
D.melanogaster do possess an N-terminal domain, one and three BRC repeats, 
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respectively, but no DNA binding domain similar to the CTD even though they both 
function in HR 101. Further structural and functional investigation of this region of 
BRCA2 is needed for the proper understanding of how cells expressing a BRCA2 C-
terminal truncation product can promote HR for which a DNA binding activity is vital.  
In the main study of my PhD, we set out to investigate hitherto unknown functions of 
the N-terminal domain. We focused on the quest for a secondary DNA binding domain 
like it was revealed for Brh2 and to which all the studies using truncated versions or 
BRCA2 mutants missing the CTD point. Further explanation of our research plan will 
be given in the objectives (1.14). Here, I will continue in focusing on the functions of 
BRCA2 apart from its role in HR such as meiosis and mitosis.  
1.9 BRCA2 AS A REGULATOR IN MITOSIS  
Despite the remarkable progress achieved in elucidating the role of BRCA2 in HR, the 
multitude of chromosomal aberrations observed in BRCA2 deficient cells could not only 
be ascribed to a defective DSB repair or unresolved replication stress. In particular, the 
numerical aberrations of chromosomes could also emerge from a defective mitosis. 
Several studies have provided evidence for a role of BRCA2 in mitosis. BRCA2 
expression is regulated throughout the cell cycle; it peaks at the entry to S phase, stays 
upregulated in M phase, but is low in interphase and G1 phase 160. Structural 
aberrations such as chromatid breaks as well as quadri- and triradial chromosomes are 
signs of defects in HR. This phenotype is also displayed in the cancer susceptibility 
syndrome Fanconi anemia. BRCA2 codes for FANCD1 protein and its absence 
renders cells hypersensitive to crosslinking agents due to a defective ICL repair. In 
contrast, translocations, deletions or fusions between non-homologous chromosomes 
and aneuploidy rather result from incorrect chromosome segregation to the spindle 
poles 161.  
Aberrant chromosomal segregation and aneuploidy can derive from centrosome 
amplification, a hallmark of various solid tumors including BRCA2-mutated associated 
tumors 25.  
Centrosomes are the microtubule-organizing centers in the cell, consisting of two 
centrioles surrounded by a pericentriolar matrix that harbors a plethora of proteins. 
They duplicate once per cell cycle and migrate in opposite directions to form the poles 
of the mitotic spindle for the trustful segregation of the chromosomes. When the 
nuclear envelope breaks down in metaphase, the centrosomes form the mitotic 
spindles from where the microtubules can extend and capture the chromosomes 162,163.  
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Mouse cells expressing Brca2 truncated in Exon 11 (BRC repeat region) exhibit 
defective centrosome duplication resulting in multinuclated cells that contain lagged 
chromosomes which leads to aneuploidy 139. Aberrant centrosomes are also observed 
in BRCA2 deficient VC8 hamster and FANC-D1 cells and are nowadays used as a 
measure for chromosome instability and BRCA2 activity for the evaluation of variants 
of unknown clinical significance 39,164,165. Immunofluorescence studies in cycling HeLa 
cells with a BRCA2 antibody confirmed the assumption that BRCA2 localizes to the 
centrosomes. The localization is dependent on a centrosome localization signal (CLS) 
in the C-terminus of BRCA2, explaining also why cells expressing a truncated version 
of BRCA2 show centrosome amplification. When overexpressing the CLS motif and in 
turn suppressing BRCA2 association with the centrosomes, cells were multinucleated 
163. The localization of BRCA2 to the centrosome is also dependent on the Nuclear 
Export Signal (NES) interaction with CRM1 protein in Exon 11. Mutations inhibiting the 
proteins’ nucleoplasmic shuttling give rise to centrosome amplification and 
multinucleation 119. The removal of BRCA2 from centrosomes during mitosis is thought 
to be achieved by the membrane type-1 matric metalloprotease 1 (MT1-MMP) that 
cleaves BRCA2 in M phase at centrosomes and targets it for proteolysis 160. Taken 
together, these findings suggest a role of BRCA2 in centrosome duplication but the 
exact mechanism by which BRCA2 regulates this process remains to be elucidated.  
Faithful repair of DNA damage is vital for the cell before entering mitosis, which is 
surveilled by the G2/M checkpoint. The kinases AURORA A/BORA and PLK1 provoke 
a downstream cascade to activate cyclin B-CDK1 that promotes entry into mitosis 166. 
First hints of BRCA2 having a role in G2/M checkpoint maintenance came from studies 
in which the overexpression of BRC4 in MCF-7 breast cancer cells not only impaired 
the interaction between RAD51 and BRCA2, but also led to a failure in radiation-
induced G2/M checkpoint control 167. The notion that the interaction of RAD51 with the 
C-terminal RAD51 binding domain of BRCA2 was important for the mitotic entry came 
from studies in DT40 chicken cells. Point mutations in the C-terminus of BRCA2 
abolishing its phosphorylation and thus interaction with RAD51 lead to a faster fading 
of RAD51 foci and entry into mitosis even before repair was completed. CDK-
phosphorylation of the C-terminus might thus be a control mechanism for the G2 
checkpoint 149,150,168. Moreover, BRCA2 and its interaction partner PALB2 were 
identified in a RNA interference screen for DNA repair proteins that regulate the G2 
checkpoint induced by radiation. Depletion of BRCA2 and PALB2 individually and 
together abrogated the G2 checkpoint and unrepaired DNA damage persisted into 
mitosis. It was proposed that BRCA2/PALB2 controls the activity of the mitotic 
regulator PLK1/AURORA A/BORA activity to regulate the checkpoint 169.  
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Unequal segregation of duplicated chromosomes during anaphase can occur when the 
spindle assembly checkpoint (SAC) is defective. This phenotype has been described in 
Brca2 deficient cells displaying micronuclei as a consequence of aneuploidy 170. The 
spindle assembly checkpoint ensures the correct attachment of the chromosomes to 
the bipolar spindles before separation so that the two daughter cells receive the same 
number of chromosomes. If the chromosomes are not correctly attached, the SAC 
halts the progression into anaphase by inhibiting the APC/C E3 ligase responsible for 
the proteolysis of cyclin B. 
BUBR1 is a component of the SAC and is involved in the regulation of the spindle-
chromosome interaction by inhibiting APC/C upon its acetylation by P/CAF 
acetyltransferase 117,171. BRCA2 was shown to interact with BubR1 and also associates 
with P/CAF via its N-terminus 172. This interaction confers associated histone acetyl 
transferase activity to BRCA2 that serves as a platform for the acetylation of BubR1 by 
P/CAF at the kinetochore in prometaphase, important for the control of the SAC 117 
(Figure 17E). P/CAF associates with BRCA2 in interphase to regulate BubR1 
acetylation. P/CAF only binds to hypophosphorylated BRCA2, implicating that it 
dissociates in M phase upon BRCA2 hyperphosphorylation by PLK1 which is inhibited 
by DNA damage, halting mitotic entry 113,172. 
Several studies suggested regulatory roles for BRCA2 by interacting with proteins 
important for midbody formation and abscission during cytokinesis114,118,173. The 
formation of the midbody starts in anaphase by generation of a contractile actin-myosin 
ring and furrow ingression at the spindle midzone. The ingression divides the cell into 
Figure 17: BRCA2 controls the SAC activity in M phase (E) and interacts with 
proteins for the formation of the midbody (F). Adapted from Martinez et al., 2015102. 
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two daughter cells but they remain connected via the midbody structure, an 
intercellular bridge composed of microtubule bundles 174. For the final stage of 
cytokinesis, the separation of the two daughter cells is mediated by the Flemming 
body, a protein ring at the center of the midbody. Abscission is then achieved by the 
action of the endosomal sorting complex (ESCRT) that is responsible for the cleavage 
of the remaining intercellular bridge. The ESCRT complex components are recruited by 
CEP55 when it is associated with the microtubule binding protein MKLP1 at the 
midbody. The ESCRT machinery is needed for the bending of the membrane away 
from the cytoplasm and the cleavage of microtubules is subsequently accomplished by 
the AAA-ATPases Spastin and Vps4. CEP55 is the central organizer of the midbody as 
it recruits also Aurora B, MKLP2, PRC1, ECT2, Anillin and Syntaxin 2 for the 
completion of cytokinesis. CEP55 itself is regulated by the kinases CDK1 and PLK1 for 
the proper completion of cytokinesis 174–177. 
The scaffold protein Filamin A, a component of the actinmyosin ring of the Flemming 
body, localizes with BRCA2 to the midbody upon its phosphorylation at S193 by PLK1 
114. Some BRCA2 cancer-associated missense variants mutated in the Filamin A 
binding region disturb the interaction of the two proteins, indicating that the association 
with Filamin A is crucial for localization. At the Flemming body, BRCA2 interacts with 
Nonmuscle Myosin IIC (NM-IIC), an important regulator of the IIC ring formation. 
Depletion of BRCA2 with siRNA impairs the localization of Myosin II to the actomyosin 
contractile ring at the cleavage furrow and leads to delayed or incomplete cytokinesis. 
Since many cells could eventually complete cytokinesis many, BRCA2 was suggested 
to serve as a regulatory factor at the midbody but is not essential for abscission 
114,118,173,178 (Figure 18). 
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Immunoprecipitation studies with BRCA2 revealed interactions with more midbody 
markers such as Aurora B kinase, PRC1, CEP55 and MLKP1. Brca2-/- cells displayed 
unresolved cytokinetic bridges and multinucleation. As shown before, absence of 
BRCA2 negatively influenced the localization of Myosin II as well as MKLP1, MKLP2, 
PRC1 and the ESCRT-associated components Alix, Tsg101 and Endobrevin to the 
midbody, whereas CEP55, Plk1, Aurora B, Eg5, CENP-E, Anillin, F-actin and Filamin A 
were not disturbed. BRCA2 formed complexes with CEP55, Alix and Tsg101 via 
different site at the N-terminus, and it was suggested that BRCA2 guides the formation 
of the complexes CEP55-Alix and Tsg101-CEP55 for the recruitment of the proteins to 
the midbody. In accordance with this, cancer-associated missense mutations in the N-
terminus of BRCA2 disrupting the interactions with CEP55, Alix and Tsg101 increased 
the percentage of multinucleated cells and cytokinetic bridges.  
Moreover, BRCA2 interacts with BRAF35 (BRCA2-associated factor 35 or High 
Mobility Group 20b HMG20b) BRCA2 as part of a large multidomain complex via 
BRC5. Overexpression of BRC5 inhibits the interaction of HMG20b and BRCA2 
Figure 18: BRCA2 modulates midbody abscission. Once BRCA2 is phoshorylated by 
PLK1, it associates with NM IIC and activates the IIC-ring formation at the Flemming 
body and ensures proper abscission (right). Inhibition of this interaction leads to failure 
in ring formation and abscission (left). Adapted from Takaoka et al., 2014 114. 
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causing defects in cell division and binucleated cells, showing that the role of HMG20b 
in cytokinesis is dependent on an interaction with BRCA2, although the role of this 
interaction needs to be further investigated since the BRCA2/BRAF35 complex was 
also proposed to bind to condensed chromatin and injection of anti-BRCA2 or anti-
BRAF35 caused a G2 delay 125126.  
Although not without controversy 179, these studies identified BRCA2 as an important 
regulator of midbody components, supposedly to position important regulators of 
cytokinesis and components of the ESCRT complex at the correct site. Absence of 
BRCA2 from the midbody results in cytokinetic failure and can cause numerical 
chromosomal abnormalities, a hallmark of cancer development. Notably, this function 
is not related to its role in recombinational DNA repair 118.  
In Chapter 3, I will describe the part of my PhD project dedicated to the 
characterization of BRCA2 VUS located in the N-terminus. Some of these VUS cause 
cytokinetic defects.  
1.10 BRCA2 IN MEIOTIC RECOMBINATION 
A role for BRCA2 in meiosis was suggested when it was found that mice with a 
defective Brca2 gene show infertility due to incomplete recombination. Likewise, 
human spermatocytes lacking BRCA2 do not progress beyond prophase I, probably 
because of defective DMC1/RAD51 foci formation 180,181. Studies from U. maydis gave 
rise to a role of the BRCA2 ortholog Brh2 in meiotic recombination, where they found 
that brh2 null mutants were not only defective in HR but also in meiosis when exposing 
them to radiation 182. Investigations in the plant A. thaliana that encodes a shorter form 
of BRCA2 (AtBRCA2), showed interaction with the meiotic-specific recombinase 
AtDMC1 via the BRC repeats and the downregulation of AtBRCA2 highly disturbed 
meiotic recombination 181,183,184. RAD51 and DMC1 are related recombinases with 
strand exchange activity that cooperate in meiotic recombination. The proteins 
resemble each other in structure (54% amino acid identity) and biochemical function 
namely the formation of a nucleoprotein filament, promotion of homology search in the 
duplex template and strand invasion by forming a D-loop structure to prime DNA 
synthesis 185,186. While RAD51 is central in mitotic recombination, it plays only a 
supportive role for the meiotic-specific recombinase DMC1 during meiosis 93.  
A direct interaction between DMC1 and BRCA2 was later shown in humans however 
the interaction site with BRCA2 was proposed to be distant to the BRC repeats unlike 
AtBRCA2 and was mapped down to a PhePP motif (2340–2472) that does not bind 
RAD51 92. Purified full-length BRCA2 also bound DMC1 in pull-down assays, but the 
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functional relevance of this interaction has not been studied 70,92,184. Although the 
PhePP motif was described to be responsible for DMC1 binding in vitro, homozygous 
knockout mice expressing Brca2 mutated in one of the conserved phenylalanine 
residues of the PhePP domain showed normal meiotic progression and Dmc1 foci 
formation 187. Since BRCA2-deficient mutants exhibit meiotic recombination defects 
and BRCA2 was shown to interact with DMC1, it is conceivable that it assumes the 
same mediator function in meiosis as it was shown for RAD51 in mitosis. Nevertheless, 
RAD51 and DMC1 are regulated by different accessory proteins: DMC1 localization to 
the site of DNA damage and assembly in foci is accompanied by the Swi5–Sfr1 
complex in yeast. RAD51 and DMC1 D-loop formation in meiosis is stabilized by 
HOP2/MND2 complex. In contrast to DMC1, RAD51-dependent D-loops are rapidly 
dissolved by RAD54 91,186,188,189.  
Even though the interaction between BRCA2 and DMC1 has been shown, it is unclear 
how exactly the two proteins collaborate in meiotic recombination and if there are other 
regions of BRCA2 that would bind DMC1 accounting for the lack of phenotype on 
PhePP domain mutation. In collaboration with Juan S. Martinez in the laboratory, we 
set out to address this question 190. The objective of this project is described in Chapter 
1.14 and the publication concerning this work can be found in Chapter 4.  
1.11 BRCA2 AND ITS ROLE IN CANCER DEVELOPMENT 
Germline mutations in BRCA2 can give rise to hereditary breast, ovarian, prostate and 
also pancreatic cancer 191,192. Although these types of cancers occur mostly 
spontaneously, mutations in BRCA2 account for about 20% of all hereditary breast 
cancer cases 193. Individuals with heterozygous mutations in BRCA2 have an estimated 
risk of 45% to develop breast, and of 15% to develop ovarian cancer by the age of 70. 
The tumor development starts early and the cancer risk increases with age 194,195. The 
existence of the cancer predisposing gene was proven by genomic linkage analysis of 
families at high risk to develop breast or ovarian cancer. BRCA2 was found to be 
transcribed from chromosome 13q and was later on cloned for the first time in 1995 
192,196. The hope to deduce the biological role of BRCA2 from its protein product was 
not fulfilled as BRCA2 showed no homology to any other protein described 197.  
As explained in the previous chapters, several findings demonstrated the role of 
BRCA2 as a tumor suppressor protein by maintaining the chromosome stability both in 
structure and number in DNA repair and during the cell cycle. Brca2 deficient embryo 
mouse models were not viable and very sensitive to γ-radiation, speaking for a role in 
DNA repair that was further supported by mouse models expressing truncated Brca2 
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that exhibited impediment of proliferation, problems in cell cycle progression, sensitivity 
to DNA damaging agents and increasing number of chromosomal aberrations such as 
chromatid breaks 68,98,198 (Figure 19). Human BRCA2 was later confirmed to be a 
nuclear protein of 390 kDa that serves as a central mediator during HR 140,142. The 
exact mechanism by which BRCA2 mediates RAD51 activity at the site of DNA double 
strand breaks was only established in recent years 70–72, and is essentially described in 
Chapter 1.4 and 1.8. Absence of BRCA2 due to mutations forces the cell to repair the 
DSBs by other mechanism like non-homologous end joining or single strand annealing 
(NHEJ and SSA, further described in Chapter 1.2). These error-prone pathways can 
cause translocations and other chromosomal rearrangements. BRCA2 deficient tumors 
show mutations such as short deletions at the break junctions. The mutations are likely 
to result from error-prone repair like NHEJ which can trigger the somatic mutations in 
the second allele of BRCA2 leading to its complete inactivation. 
This may subsequently promote the accumulation of mutations in other genes 
responsible for cell cycle control such as p53 which might lead to early-onset 
development of cancers 106,137,139,140,142,161,199,200. 
The structural aberrations and gross chromosomal rearrangements observed when 
DNA repair is impaired can also result from defective rescue of stalled replication forks 
during S phase 201. The polymerase complex halts when it encounters lesions, breaks, 
DNA adducts or DNA-bound proteins that impede its progression as extensively 
Figure 19: Metaphase spreads from Brca2 truncated MEFs show A) Multiple structural 
aberrations such as B) chromatid breaks (ctb) C) triradial (tr) and D) quadriradial (qr) 
structures. From Patel et al., 1998 98. 
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described in Chapter 1.2. Because of its replication fork protective role (detailed in 1.3), 
absence of BRCA2 also increases replication stress during S phase, a hallmark of 
cancer 153. 
In addition to the different kinds of cancers mentioned above, bi-allelic BRCA2 
mutations causes 3-5% of Fanconi Anaemia (FA) cases, a rare autosomal recessive 
disorder characterized by leukemia, bone marrow failure, congenital disorders, short 
stature and short life expectancy 39. The numerous FA protein factors act in DNA 
interstrand cross-link repair (see 1.3) and patients are hypersensitive to cross-linking 
agents such as mitomycin C. BRCA2 was found to be identical to the FA factor D 
(FANCD1) and cooperates with FANCR (RAD51) in the last steps of the FA pathway to 
repair the toxic interstrand cross-link lesions that inhibit replication and transcription. 
FA cells show the same chromosomal structural aberrations as BRCA2 deficient cells 
(Figure 19) 98,102,161.  
BRCA2 biallelic mutation carriers show also changes in chromosome number, 
speaking for separation problems in cytokinesis 173. Many studies have implicated roles 
for BRCA2 at late steps in cytokinesis as cells deficient in BRCA2 accumulate display 
aberrant chromosome structures and polyploid nuclei that result from delayed or 
incomplete cytokinesis. This might be explained by the mis-localization or deregulation 
of important midbody components in absence of BRCA2 leading to impaired midbody 
and Flemming body formation which are needed for proper abscission of the two 
daughter cells98,114,118,173. 
The aneuploidy observed could also originate from defects in BRCA2 at other stages in 
the cell cycle such as chromosome segregation. The spindle assembly checkpoint 
(SAC) is responsible for the accurate attachment and segregation of the chromosomes 
to ensure the maintenance of correct chromosome number in each daughter cell. 
Anaphase onset is deregulated in some cancers with defective SAC leading to 
aneuploidy. Also, during metaphase to anaphase transition, centrosome amplification 
results in unequal segregation, a hallmark of many tumors 165,171,202,203.  
Collectively, the research presented above illustrates how BRCA2 acts as a caretaker 
of genome integrity. The chromosome instability caused by defective BRCA2 is the 
driving force of carcinogenesis in BRCA2-associated tumors. Moreover, mounting 
evidence show that the increasing mutational rate observed in “gatekeeper” genes that 
control cell division and apoptosis is sufficient to predispose carriers to tumorigenesis. 
As an example, there is a higher frequency of p53 mutations in BRCA2-deficient 
cancers 153,161,199. The continuous effort to understand the different functions of BRCA2 
will help to elucidate further the mechanisms by which mutations in BRCA2 drive 
tumorigenesis.  
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1.12 BRCA2 VARIANTS OF UNKNOWN CLINICAL SIGNIFICANCE AND THEIR 
CLASSIFICATION  
Mono-allelic mutations in BRCA2 increase the risk to develop breast, ovarian or 
pancreatic cancer as described in Chapter 1.11. Genetic screening for known 
deleterious mutations is offered to cancer patients and individuals with a family history 
of cancer. However, the prerequisite to predict the impact of a missense mutation in 
BRCA2 remains that this mutation has already been described and characterized 204. 
Mutations classified as deleterious can be the reason for the mislocalization of the 
protein, expression of a non-functional truncated protein version or interference with an 
important domain. Neutral mutations do not affect BRCA2 function and in turn do not 
confer an elevated risk to develop cancer. Many missense mutations identified are 
classified as “variant of unknown clinical significance” as their impact on the protein 
function is not known 205. This poses problems in genetic counselling as persons 
carrying variants of unknown clinical significance (VUS) cannot be provided with 
appropriate clinical advice. In an early study with breast cancer patients, 13% of the 
women were diagnosed with a VUS, emphasizing the need for better classification and 
screening systems 206.  
A multifactorial likelihood posterior probability model was developed in order to classify 
VUS. The model integrates the frequency of the mutation in carriers and controls, the 
co-occurrence with deleterious mutants, the co-segregation with disease in pedigrees, 
family history, the nature and position of the amino acid substitution, the degree of 
conservation of the amino acid among species, and the results of functional assays for 
which the VUS was already tested 207. However, many of these VUS are rare and their 
pathogenicity cannot be predicted based on a likelihood model but needs to be 
evaluated by applying functional assay. The missense mutations are introduced in 
BRCA2 and the capacity of the variants to fulfill BRCA2 functions is tested 208. To 
improve the accuracy of classification, there are several international initiatives to 
collect clinical and functional data from VUS, not only for BRCA2 but also BRCA1 and 
other tumor suppressor genes. One of them is the Evidence-based Network for the 
Interpretation of Germline Mutant Alleles (ENIGMA) consortium of which our team is 
part. We meet twice a year to share data, methods and facilities for the classification of 
variants. Information is collected from different working groups who analyze clinical 
data, perform functional assays, analyze tumor histopathology and perform large-scale 
splicing studies on VUS. This information is then available through a dedicated 
database. My host laboratory has several ongoing collaborations from members of the 
functional working group in which I have participated. This work is presented in 
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chapters 3 and 5 of this thesis and will contribute to the classification of rare VUS 
whose impact cannot be assessed due to the lack of genetic evidence. The Breast 
Cancer Information Core (BIC) and the BRCAshare databases gather more than 2000 
entries for BRCA2 VUS that have been found in clinical screening of cancer patients or 
family members at high risk to develop breast, ovarian or pancreatic cancer 209,210. 
Unlike truncating mutations of which the influence on BRCA2 function can be clearly 
assessed, mutations, the impact of missense variants is not easily predictable as they 
result in a single amino-acid change. Genetic analyses (co-occurrence with pathogenic 
mutation in trans) combined with in silico predictions allow variants classification; 
however, the majority of BRCA2 variants (62%) remain unclassified. This represents a 
very important clinical drawback as it complicates cancer risk assessment. To cope 
with this problem, many groups develop and optimize functional assays 211,212. 
Because of the complexity of BRCA2 protein in size and little homology with other 
proteins, the application of functional assays has been limited to the VUS that are 
located in known functional regions such as the CTD needed for HR, the PALB2 
binding site or the BRC repeats and C-terminal RAD51 binding domain 165.  
Indeed, many highly penetrant pathogenic missense mutation have been found in the 
CTD 212. With the discovery of new interacting proteins in other less explored regions 
such as the N-terminus, there is now the possibility for the evaluation of other VUS. For 
example, the laboratory of Fergus Couch could localize the interacting region of 
BRCA2 with midbody proteins to the N-terminal domain and characterized VUS that 
disrupt this interaction result in defective abscission and multinucleated cells 118. As 
part of my PhD (Chapter 2, 3, 5), I have contributed to the evaluation of VUS found in 
the N-terminal region, and used DNA binding assays or DNA strand exchange assays 
that could contribute to infer the impact of VUS in causality. 
A very common assay that has been applied for the evaluation of BRCA2 VUS is the 
homology directed repair assay (HDR). In this test, a DSB is induced by SceI nuclease 
in a GFP-reporter construct that is expressed together with wild type or variant BRCA2 
in BRCA2 deficient cells. The DSB can only be repaired when wild type or variant 
BRCA2 are proficient in HR which can be assessed by the percentage of GFP positive 
cells 142,211,212. Missense mutations can impair BRCA2 function at the centrosomes that 
leads to a phenotype showing multiple instead of two daughter centrioles. The 
centrosome amplification assay visualizes possible centrosome amplification when 
expressing BRCA2 variants in Brca2 deficient cells (VC8) in situ immunofluorescence 
with centrosome markers165. 
BRCA2 deficient cells are hypersensitive to DNA damaging agents such as Mitomycin 
C and can be rescued by overexpression of BRCA2. VC8 BRCA2-/- cells 
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complemented with wild type or variant BRCA2 can be tested for DNA damage 
sensitivity by using clonogenic survival assay where cells proficient in the repair of 
DNA damage will form colonies 165,213.  
The treatment of BRCA2-/- cells with PARP inhibitors leads to cell death as the cells are 
neither proficient in SSB nor HR 214,215. In survival assays with PARP inhibitors, BRCA2 
or variant complemented VC8 cells are treated with the inhibitor and cell viability is 
measured by using the MTT colorimetric assay. 
The embryonic stem cell-based assay applies mouse ES cells with a defective Brca2 
allele and one functional allele than can be switched off and reconstituted by BAC 
clone carrying WT or mutant DNA of BRCA2. Evaluation of the impact of the mutation 
is based on its ability to rescue the lethality in biological assays (DNA damage 
sensitivity, HR, chromosome instability). One big advantage of this assay is the non-
mutagenic background in ES cells 212.  
One important feature of BRCA2 to exert its function is the localization to the nucleus, 
an important aspect to test as many variants are mis-localized due to mutations in the 
NLS, mis-folding of the protein or disrupted interaction with PALB2 that localizes 
BRCA2 106,163,187. Likewise, in vivo and in vitro biochemical assays to test the interaction 
of purified BRCA2 with its protein partners or its DNA binding capacity are a good 
measure for BRCA2 function. In the laboratory, we make use of the DNA binding 
assays (EMSAs) to test one of the most important functions of BRCA2 in HR, the 
association with DNA.  
Another assay involves the assessment of aberrant splicing variants, which is a major 
cause for the expression of a non-functional protein product. The impact of aberrant 
splicing mutants on BRCA2 function is difficult to deduce especially because many of 
these variants lead to partial exon skipping. The use of functional assays is becoming 
more powerful in the absence of sufficient genetic evidence 212. However, because of 
the plasticity of BRCA2 demonstrated in studies with BRCA2 fragments 108,109, the 
evaluation of the impact of one variant on a certain function, e.g. HR, may not imply 
increased cancer risk. The improvement of functional assays and the growing 
knowledge about BRCA2 function will further help characterize and classify VUS. This 
will facilitate genetic counseling and cancer risk assessment. 
1.13 PREVENTION AND THERAPY MANAGEMENT OF BRCA2 PATHOGENIC 
MUTATION CARRIERS 
Women with a high risk of developing BRCA2-associated cancer either because they 
carry a known deleterious mutation or having a strong family background, are 
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medically accompanied to reduce the risk of developing cancer, morbidity and 
mortality. In general, the first measure is the regular screening to detect a tumor at an 
early stage. One can also reduce the risk to develop cancer by prophylactic surgery of 
one or both breast (risk-reducing mastectomy) or apply chemoprevention by using 
hormonal drugs such as Tamoxifen. Surgical approaches are currently the most 
successful, reducing the risk to develop a cancer by up to 90%, but unsurprisingly, 
many women refuse to take advantage of these methods 97. Individuals who have 
developed BRCA2-associated breast or ovarian cancer are treated in the same way as 
patients with sporadic breast cancer. This therapeutic approach consists of surgery to 
remove the cancer, followed by chemotherapy and radiotherapy, the latter being still 
responsible for about 40% of the cured cases 216.  
Importantly, BRCA2-associated tumors respond particularly well to chemotherapeutic 
treatment that induce DNA damage, such as cross-linking agents mitomycin C or 
cisplatin, because of the impaired HR in these tumors 216,217. These observations led to 
the development of targeted therapies to specifically attack cancer cells without 
harming normal cell tissues by exploiting their impaired DNA damage response. The 
first DNA damage response inhibitors were topoisomerase inhibitors, which cause DNA 
breaks. Other inhibitors target checkpoint kinases (CDK, CHK), protein kinases (DNA 
PK, ATM, ATR), or telomerases 218,219. The idea behind this strategy lies on the fact 
that when a DNA repair pathway is defective in a tumor, it becomes dependent on 
other pathways 1. Thus, the absence of a gene important for one DDR pathway such 
as BRCA2 in HR will be synthetically lethal with the inactivation of another protein 
working in an alternative repair pathway such as BER 220. This concept was first 
successfully exploited in the case of PARP inhibitors 215. PARP-1 detects gaps, breaks 
or base changes in ssDNA and activates the BER pathway that is comprised in the 
absence of PARP-1 214. As a consequence, the ssDNA breaks are converted into 
dsDNA breaks and repaired by HR. In BRCA2-/- cells, HR is inactive and as a 
consequence, lethal DSBs accumulate and ultimately lead to tumor cell death whereas 
normal cells can repair the DNA damage. Many different PARP inhibitors are currently 
in clinical trials, one of them has been approved for monotherapy recently after 
successful trials in the treatment of BRCA1 and BRCA2-associated tumors 219. 
Nevertheless, several studies showed resistance mechanisms of cancer cells to PARP 
inhibitors such as the restoration of BRCA2 open reading frame and expression of a 
protein version functional in HR 157,221.  
Over the last decade, the research for the development of specialized therapies for 
cancers with a “BRCAness” imprint, that is mutations in genes involved in the HR 
pathway, has progressed a lot 200. The detection of inherited mutations in this pathway 
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using next generation sequencing technologies together with improved functional 
assays will enable widespread genetic testing and personalized risk assessment for 
breast and ovarian cancer 222.  
1.14 HYPOTHESES AND OBJECTIVES OF THIS WORK  
Inactivating germ-line mutations in BRCA2 predispose to breast and ovarian cancer. A 
wealth of evidence suggests that BRCA2 exerts its tumor suppressive function through 
its role in DNA repair by Homologous Recombination (HR). HR is the most reliable 
pathway to repair DNA double strand breaks. In this pathway, BRCA2 acts as a 
mediator protein by recruiting the recombinase RAD51 onto the DNA and promoting its 
HR function to repair the breaks. Thus, malfunction of BRCA2 can lead to genomic 
instability, a hallmark of tumor formation. BRCA2 deficiency also leads to centrosome 
amplification and failure in the late steps of cytokinesis, suggesting a function of 
BRCA2 in these processes that could account for the aneuploidy found in BRCA2 
associated cancers. To date, several functional domains of the 390 kDa BRCA2 
protein have been described. However, the roles of other domains such as the N-
terminus remain enigmatic. Thus, the functions, modifications and interaction partners 
of BRCA2 are under extensive scrutiny.  
OBJECTIVE 1: INVESTIGATION AND CHARACTERIZATION OF A PUTATIVE 
DNA BINDING DOMAIN IN THE N-TERMINUS OF BRCA2 
The first 40 amino acids of BRCA2 are well conserved and contain a PALB2 interacting 
domain, a protein that localizes BRCA2 to the chromatin. However, little is known 
about the remaining N-terminal region, which constitutes one third of the protein 
(~1000 aa) as described in Chapter 1.4. Interestingly, studies with PARP inhibitor 
resistant clones in human cells as well as with the BRCA2 ortholog in U. maydis (Brh2) 
showed that mutants lacking the C-terminal DNA binding domain (CTD) substantially 
restore recombination proficiency when challenged with DNA damage157,159. In the case 
of Brh2, the restoration of HR is likely to arise from a secondary DNA binding domain 
found downstream the BRC repeat. These indications prompted us to hypothesize that 
the HR proficiency and resistance to DNA damage observed in cells expressing a 
truncated version of BRCA2 missing the CTD may come from a second DNA binding 
domain outside the C-terminus. An in silico search for functional domains using the 
primary sequence of BRCA2 using SMART 223 performed in the laboratory revealed a 
putative zinc-finger like domain, frequently found in DNA binding proteins. Thus, the 
first objective of my PhD project was to investigate this putative DNA binding domain in 
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the N-terminus of human BRCA2. For this purpose, I used in silico tools to further 
validate the first findings and then planned to search for the DNA binding domain in 
vitro. With the identification and characterization of a secondary DNA binding site we 
would address the following questions: 1) Could it promote DNA strand exchange by 
RAD51 together with a BRC repeat in vitro as it was shown for other truncations of 
BRCA2 containing a DBD and a BRC repeat? 2) Could it rescue the sensitivity of 
BRCA2 deficient cells to DNA damaging agents? 3) Would BRCA2 missense 
mutations (VUS) found in this domain impair these functions and hence infer their 
probability of causality? (Chapter 2). 
 
OBJECTIVE 2: CHARACTERIZATION OF VUS LOCATED IN THE N-TERMINAL 
DNA BINDING DOMAIN OF BRCA2 
To further characterize the functional relevance of the N-terminus and in particular the 
identified putative zinc-finger domain, we chose to study BRCA2 missense mutations 
present in families at high risk of breast cancer (found in BRCAshare and BIC 
database 209,210) located in this region. The purpose of this strategy is two-sided: on the 
one hand, we could study the relevance of the new domain by looking at the impact of 
the variants in its function, and on the other hand, we could evaluate variants of 
unknown significance (VUS) which are by definition rare and difficult to assess its 
causality in breast cancer.  
We selected several VUS located in the predicted zf-PARP like domain that based on 
their amino acid conservation and sequence alignments in silico, as well as the 
chemical nature of the amino acid change and their location in hydrophobic clusters, 
are more likely to be deleterious 207,224. Indeed, all variant residues are highly 
conserved in mammalian species and predicted to have DNA binding activity by using 
BindN software225. In this work, I aimed to first introduce the selected missense 
mutations in the BRCA2 wild type protein, establish stable cell lines in BRCA2 deficient 
cells and assess their subcellular localization. We wanted to evaluate their sensitivity to 
DNA damage such as MMC and PARP inhibitors, indirect measures for functional HR. 
As BRCA2 is implicated in cytokinesis (see section 1.9) BRCA2 deficient cells exhibit 
chromosomal aberrations, centrosome amplification and abnormal cytokinesis 118,173. 
To test a possible effect of the variants on cytokinesis I planned to use time-lapse 
microscopy, immunofluorescence with markers against centrosomal proteins, co-
immunoprecipitation studies with midbody proteins, as well as their progression 
through the cell cycle.  
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One very interesting question we would like to address is whether possible 
abnormalities of VUS in mitosis and/or cytokinesis are related to the impaired DNA 
repair function or if these functions are independent from each other. Our ultimate goal 
was to better understand the function of NTD region of BRCA2 and at the same time, 
evaluate the impact of unique variants on the DNA binding activity of the protein 
(Chapter 3). 
I also contributed to a side project in which we address whether intermediate functional 
phenotype corresponds to intermediate cancer risk. This was done in collaboration with 
members of the ENIGMA consortium and the Breast Cancer Association Consortium 
(BCAC). In the study, 20 BRCA1 and 33 BRCA2 missense variants were genotyped on 
~40,000 breast cancer cases and 40,000 matched controls using the Collaborative 
Oncological Gene-Environment Study (iCOGS) custom genotyping array. Because the 
intermediate phenotype variants observed previously by a cell-based homologous 
recombination assay (211) are located in the C-terminal DNA binding domain, we tested 
whether the intermediate phenotype in HR is due to a decreased but not abolished 
DNA binding ability. We purified VUS proteins and used DNA binding assays to proof 
this hypothesis (Chapter 5). 
OBJECTIVE 3: STUDY THE ROLE OF BRCA2 IN MEIOTIC RECOMBINATION 
In somatic cells, BRCA2 catalyzes RAD51-mediated homologous recombination. The 
meiosis-specific DNA-strand exchange protein, DMC1, promotes DNA strand invasion 
generating what is termed a displacement-loop (D-loop) and DNA strand exchange 
between homologous molecules in a fashion similar to RAD51226. A direct physical 
interaction was established for purified full-length human BRCA2 and DMC170. In 
plants this interaction was mapped to the BRC repeats whereas in humans, a 
conserved PhePP motif was suggested to be responsible for DMC1 binding92 
Substitution of the residues that disrupt the interaction with PhePP domain were found 
negligible for meiosis in mice, indicating that there could be another site of interaction 
for DMC1187. In addition, the sequence alignment of RAD51 paralogs including DMC1 
indicate that the site of interaction of the BRC repeats to RAD51 is very well conserved 
in DMC1101. Therefore, we investigated whether the BRC repeats could also bind 
DMC1 and if so, the functional relevance of this interaction (Chapter 4). 
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RESULTS 
BRCA2 is a multifunctional protein that acts in different pathways in the cell as outlined 
in the introduction. In our lab, we are interested in the functional characterization of 
domains and interaction partners of BRCA2 that have not been described yet. 
Moreover, we aim to characterize and evaluate variants of unknown clinical 
significance found in breast cancer patients located in these unexplored regions as 
explained in the project description (1.14).  
The results of my PhD are presented in the following chapters. Since I worked on 
several related projects focusing on BRCA2 function, I dedicated each of them a 
separate chapter for easier understanding (2-5). The results that differ from the main 
topic of the thesis and have been already published or submitted for publication are 
presented in paper format. 
A final conclusion about the thesis presented here can be found in the last section (6). 
All materials or methods not already listed in the methods sections are included in the 
appendix. 
CHAPTER 2  
2.1 FUNCTIONAL CHARACTERIZATION OF A PUTATIVE DNA BINDING 
DOMAIN IN THE N-TERMINUS OF BRCA2 
As outlined in the project description (1.14) and in chapter 1.7, several lines of 
evidence led us to hypothesize that the HR proficiency and resistance to DNA damage 
observed in cells expressing a truncated version of BRCA2 missing the C-terminal 
DNA binding domain (CTD) come from a DNA binding activity exhibited by the N-
terminus: First, the lab of Alan Ashworth described the phenotype of human pancreatic 
BRCA2 deficient (CAPAN-1) clones with acquired resistance to PARP inhibitors. Some 
of these clones did not contain the CTD but could still form RAD51 foci and significantly 
increased the HR frequency to nearly wild type levels. Moreover, they also reduced the 
number of MMC-induced chromosomal aberrations compared to CAPAN-1 cells 157. 
Second, mutants of the BRCA2 ortholog Brh2 (U. maydis) missing the canonical CTD 
were able to survive DNA damage. An OB-like DNA binding domain downstream the 
BRC repeat region termed N-terminal DNA binding domain (NTD) was found 
responsible for the rescue of this phenotype. The authors consider this domain as the 
primary interaction site with DNA. In their model, the NTD binds first the resected 3’ tail 
DNA, leading to a conformational change in the CTD that releases Dss1 and 
subsequently associates with the ssDNA 155,159.  
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Third, experiments in DT40 chicken cells showed that overexpression of a BRCA2 
construct missing the CTD led to a milder phenotype than BRCA2-/- cells when 
exposed to different DNA damaging agents. The complemented cells also retained 
some HR activity, suggesting that the N-terminal part of BRCA2 is capable of restoring, 
at least partially, HR function in these cells 109. Fourth, BRCA2 peptides containing the 
N-terminus, the BRC repeats and the extreme C-terminus but not the CTD, were 
efficient in restoring the HR proficiency in Brca2 deficient VC8 cells 156. Last, my host 
laboratory had started a search for new functional domains in BRCA2 by applying the 
amino acid sequence of the entire BRCA2 sequence to the web tool SMART (Simple 
Modular Architecture Research Tool). SMART is a web resource for the detection of 
protein domains using Hidden Markov Models (HMM) that are based on multiple 
sequence alignments with known protein domains223. This analysis revealed a putative 
zinc finger-PARP like (zf-PARP) domain located in the region between amino acids 
265 and 349 of the N-terminus (Figure 1A), although the score of the E-value (2.4) was 
below the threshold.  
Zinc finger domains were originally identified as DNA binding motifs, but are now 
known to bind RNA, proteins and lipids. Some of these zinc fingers modules coordinate 
a zinc ion to form the finger-like motif that contacts the target, however, most of them 
do not bind zinc and have evolved individually for their specialized function 227.  
Thus, the goal of my PhD project was to search for a potential DNA binding domain in 
human BRCA2 that could explain the phenotypes observed. 
Furthermore, we decided to select variants of unknown clinical significance located in 
this region that have been found in breast cancer patients to examine their impact on 
DNA binding, HR and cell cycle progression. This way, we would be able to 1) 
characterize and evaluate VUS to help infer causality and 2) find out if the putative 
DNA binding domain in the N-terminus plays an important role for BRCA2 function in 
homologous recombination. This work is presented in chapter 3. 
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2.2  RESULTS 
The N-terminal region has no similarity to any other protein domain described and is 
intrinsically disordered, making it difficult to deduce a function of this region from 
sequence or secondary structure comparison (see also 1.7).  
To identify possible DNA binding residues in the zf-PARP like domain, I used the web-
based tool BindN that predicts possible DNA and RNA binding residues based on the 
biochemical properties of the amino acids 225. I identified two clusters predicted to 
contain DNA binding residues. Using Clustal Omega multiple sequence alignment tool 
228 I found that these clusters are conserved among several mammalian species 
suggesting that these residues might be important for BRCA2 function (Figure 1B).  
The in silico analysis led us to investigate a possible DNA binding activity in this region. 
To ascertain this activity in vitro, we designed expression fragments of the N-terminus 
of BRCA2. First we used an expression construct of BRCA2 1-1000 amino acids 
Figure 1A) SMART results showing a zinc-finger PARP like domain between amino 
acids 265 and 349 of the N-terminus of BRCA2. B) The region of the zf-PARP like 
domain contains residues predicted to bind DNA by the BindN prediction tool 
(highlighted in green). The same regions are also highly conserved in mammals as 
shown by the multiple sequence alignment using Clustal Omega. Conserved residues 
in two or more species are indicated by asterisks (*). 
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tagged with a 2x MBP tag and His-tag at the N-terminus that was cloned into a 
pFASTBac vector for the expression in insect cells. With the plasmid in hands, I went 
to the Eukaryotic Expression Facility at the EMBL Grenoble. Under the supervision of 
Frederic Garzoni, I learned how to use the MultiBac Expression System that was 
developed at the EMBL for the expression of recombinant eukaryotic proteins from 
Insect cells. This system has the advantage of expressing proteins in an eukaryotic 
host system that does not require additional safety measures and allows large-scale 
expression to obtain a high yield of protein. First, the gene of interested is transferred 
into the baculoviral genome by transposition and positive clones can be selected by 
blue-white screening. Adhesive Sf21 insect cells are then transfected with the 
baculovirus DNA and the successful infection of the cells can be observed under the 
microscope after 60 hours. The expression of the protein can be controlled by 
measuring the expression of YFP protein from the expression construct. This V0 culture 
is then used for the amplification of the virus in a liquid culture until cells stop to 
proliferate and expression continues for about 3-4 days by diluting the cultures. Once 
the expression reaches a plateau observed in the YFP measurements, cells are 
harvested, lysed by sonication and the expression of the protein of interest is visualized 
by SDS PAGE and Western Blot.  
We observed expression of the N-terminal fragment and could detect it in SDS PAGE 
after lysis. However, after several attempts to purify the protein, it was neither visible in 
SDS PAGE nor detectable by western blot. This probably implies that the protein was 
not correctly folded and thus precipitated during purification. 
Hence, we decided to apply the purification protocol we successfully had used for the 
full-length BRCA2 protein before, although this meant that we would obtain much fewer 
quantities of the protein as expected.  
For this purpose, we designed the following expression constructs of the N-terminus: 
BRCA2LT3 (1-750 aa), BRCA2LT2 (1-500 aa), BRCA2T2 (250-500 aa), BRCA2T1 (1-250 
aa) with a 2x MBP tag and purified them from human HEK293 cells (Figure 2A). As 
shown in Figure 2B, 10x P150mm plates were transiently transfected with the 
respective expression construct and incubated for 30 hours. The cell lysate was 
incubated with amylose resin to let the 2x MBP tag bind to the beads and eluted with 
maltose. The eluate was further subjected to a weak ion exchange resin and step 
eluted in three fractions using a NaCl  
64 
 
 
Figure 2: A) Structure of BRCA2 with functional domains and interacting partners. Below 
are shown the scheme of the size of N-terminal fragments used for purification. B) 
Purification protocol for fragments. C) 7.5% SDS gel (stain-free) with purification of 
BRCA2LT3: M: molecular weight marker 1) Load 2) unbound 3)amylose beads 4) elution w. 
maltose 5) flow through 6) elution 250 mM NaCl 7) 450 mM NaCl 8) 1M NaCl. D) Purified 
NT fragments on 7.5% SDS gel (stain-free) 0.5 μg loaded (left) and western blot of the 
latter using an antibody for MBP tag (right). 
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gradient. The fractions of the purification steps were loaded on a SDS gel for 
visualization and we obtained protein with up to  
95% purity in sufficient concentration for DNA binding tests (see Figure 2C for 
BRCA2LT3 and Figure 2D left for all fragments). The authenticity of the protein 
fragments was verified by western blot using an antibody against the MBP tag (Figure 
2D right). We started our in vitro analysis by testing the largest fragment BRCA2LT3 for 
its DNA binding capacity by using Electrophoretic mobility Shift Assays (EMSA). Here, 
a DNA substrate (dT40 homopolymer) is radioactively labeled with γ-
32P and incubated 
with the protein to allow binding. The samples are loaded on a 6% native 
Figure 3: A) Scheme of the EMSA reaction: radiolabeled ssDNA is incubated with the 
protein of interest (BRCA2LT3) and reactions are loaded on 6% PAGEgel. ssDNA-protein 
complexes migrate slower on the gel than free DNA. B) Autoradiograph of EMSA with 
BRCA2LT3 using increasing concentrations. C) Quantification of EMSA with BRCA2LT3 
and 2x MBP tag as negative control from three independent experiments using 
GraphPad Prism. 
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polyacrylamide (PAGE) gel to separate DNA-protein complexes from free DNA that 
migrate faster (Figure 3A). BRCA2LT3 was indeed capable of forming complexes with 
the DNA that became more evident with increasing protein concentration and reached 
40% of DNA-protein complexes (Figure 3B).  
As a control, we performed the same assay using the MBP tag alone which did not 
associate with the DNA (4% complex formation), indicating that the DNA binding 
activity observed with BRCA2LT3 is specific (Figure 3C). To map the DNA binding 
activity further, we used the same assay with the shorter N-terminal fragments (Figure 
4A). While BRCA2LT2 and BRCA2T2 bound ssDNA to almost the same extent as 
BRCA2LT3 (20-25%), BRCA2T1, comprising the first 250 amino acids did not. Thus, the 
DNA binding domain lies 
in the region of BRCA2T2 between amino acids 250 and 500. This result coincided with 
the  
DNA binding residues found in the in silico analysis of the N-terminus. By examining 
the partition of BRCA2T2 compared to BRCA2T1 between biotinylated ssDNA (dT80) 
immobilized on streptavidin magnetic beads challenged with excess dT40 ssDNA as a 
Figure 4: EMSA with N-terminal fragments and ssDNA A) Autoradiograph of reactions 
using BRCA2T1, BRCA2T2, BRCA2LT2 with ssDNA in increasing concentrations and B) 
quantification of EMSAs with ssDNA and all fragments from three individual 
experiments.  
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control experiment, we could confirm our results; only BRCA2T2 and not BRCA2T1 was 
titrated out by adding excess dT40 indicating that BRCA2T2 binds specifically to DNA 
(Figure 5).To verify the DNA binding activity of this region, the laboratory of Xiaodong 
Zhang used the longer fragment BRCA2LT3 to visualize the direct interaction with DNA 
by electron microscopy. Our collaborators could observe the association of the N-
terminal domain to a gapped DNA substrate mimicking a daughter strand gap 
generated after the replication fork encounters a DNA lesion. The BRCA2LT3-DNA 
complexes adopted V or Y-shaped structures, suggesting that the protein binds to the 
gap segment or to the ssDNA/dsDNA junction. Interestingly, PARP-like fingered 
enzymes have been described to bend the DNA upon binding to gap sites adopting a V 
shaped structure 229. Using an antibody against the MBP-tag we confirmed that the 
density on the tip of the V or Y shaped particles corresponds to BRCA2LT3. Collectively, 
these results indicate that the N-terminal region of BRCA2 binds DNA and that the 
region of aa 250-500 of BRCA2 (BRCA2T2) comprising the putative zf-PARP domain is 
sufficient for this activity.  
Figure 5: Pull down experiment with BRCA2T2 or BRCA2T1 using 
biotinylated ssDNA (dT80) immobilized on streptavidin magnetic beads 
challenged with excess dT40 ssDNA (up) and quantification of 3 individual 
experiments using GraphPad Prism (bottom). 
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Zinc-finger PARP like motifs are DNA or protein-binding domains that have first been 
identified in Poly(ADP)ribose proteins (PARPs) but can be found in many enzymes. 
One or more zinc ions are coordinated via Cysteine and Histidine residues allows to 
adopt and stabilize a finger-like structure that contacts the DNA 230,231.  
Because the DNA binding activity was assumed to originate from a zinc finger motif, 
we tested the NTD activity in presence of different cations to see if they intensified the 
DNA binding affinity. 
We incubated BRCA2T2 (1 μM) with ssDNA in presence or absence of different cations 
(Figure 6). Adding no metal or EDTA as a chelating agent to the reaction reduced the 
DNA binding activity of about 10% compared to the binding activity in our standard 
conditions with 1 mM Mg2+ & 2 mM Ca
2+ (22-30%). Ca2+ (1 mM or 10 mM) stimulated 
the reaction (22%) but did not reach the highest level achievable, while Mg2* at 1 mM 
stimulated the reaction to similar levels but was decreased 10 mM. Surprisingly, Zn2* 
ions decreased the DNA binding activity by 2% at 10 mM. These results indicate that 
the DNA binding activity of the N-terminus of BRCA2 is not dependent on Zinc, 
however it is moderately enhanced by Ca2+ and Mg2+.   
Since BRCA2 contains a canonical DNA binding domain in the C-terminus, we next 
sought to investigate how the NTD differs from the CTD in terms of function and 
binding specificity. For this, we purified recombinant human CTD (aa 2474-3190, 
Figure 7A) from bacterial cells using a 6x His-tag for affinity chromatography and in 
fusion with SUMO protein to enhance the product yield. 
Figure 6: Left panel: EMSA with BRCA2T2 (1 µM) and ssDNA (dT40) in the presence or 
absence of no metal, EDTA (25 mM), Zn2+, Mg2+, Ca2+, Mg2+(1 mM) + Ca2+ (2mM) at the 
indicated concentrations. Right panel: Quantification of the EMSA (n=3). 
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The experimental set up for the expression and purification was achieved in 
collaboration with Patricia Duchambon and Ahmed El Marjou from the recombinant 
protein platform (I. Curie). The CTD was co-expressed with its protein partner DSS1 
(see chapter 1.7) to confer stability and solubility to the protein as we observed 
massive degradation during purification attempts without it. DSS1 might be needed for 
proper folding of the CTD. This was also observed by Yang et al. (2002) who purified 
the mouse CTD in complex with DSS1 for crystallization studies 127. E. coli cells were 
transformed with expression constructs for CTD and DSS1 and 7L of culture were 
induced for protein expression. The first purification step involved the incubation of the 
protein with Ni-NTA resin to which the His-tag binds. The protein was eluted with 
Imidazole and verified on a SDS gel (Figure 7B, left). After dialysis, the protein was 
subjected to a heparin column as this type of column is generally used for DNA binding 
proteins. The protein was eluted using a NaCl gradient (Figure 7B, right). The 
chromatogram showed several protein peaks when loading the fractions on a SDS gel 
but only the purest fractions (2-4) were pooled and dialysed against storage buffer and 
stored at -80C. DSS1 stayed bound to the CTD as verified by western blot using an 
antibody against the His-tag for the CTD and an antibody against DSS1 (Figure 7C). 
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Figure 7: Purification of the C-terminal DNA binding domain of BRCA2. A) Scheme of 
the structure and size of the protein fragment purified. B) Left: SDS gel of first 
purification step with Ni NTA resin. Lane: 1) Sample loaded 2) unbound fraction 3) 
wash 4) elution with Imidazole 5) dialysed protein. Right: SDS gel of the second step of 
purification using a Heparin chromatography column: 1) unbound fraction, 2-9) 
fractions from elution with NaCl gradient indicating the fractions pooled for dialysis (2-4) 
C) 1) Purified protein (5 μg) loaded on a 4-15% SDS-PAGE gel. 2) Western blot with 
antibodies against His-tag for CTD and anti-DSS1 antibody.  
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We then used the CTD and NTD to compare their DNA binding activities and affinities 
to different DNA substrates mimicking recombination intermediates of DSBs and 
daughter strand gaps.  
Using EMSAs as described above, we first tested the binding of both proteins to a 
Figure 8: EMSA comparing the DNA binding activity of NTD and CTD. A) Binding of NTD 
and CTD to radiolabeled ssDNA (167mer) B) to short dsDNA substrate and C) to long 
dsDNA substrate. D-F) quantification of at least three experiments for all DNA substrates. 
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ssDNA substrate (167 nt polymer). It was shown before that the binding of the CTD to 
short substrates is very weak and increases from 60 nucleotides onwards 127,158. Both 
proteins bound ssDNA but BRCA2T2 formed a maximum of ~40% protein-ssDNA 
complexes at its highest attainable concentration (1.5 μM), whereas the concentration 
of CTD to reach that % of protein-ssDNA complex was 10 μM (Figure 8A and C). Thus, 
BRCA2T2 shows either higher affinity or more stable complexes with ssDNA than CTD. 
Next we tested the binding of the two domains to substrates that mimic the ds/ssDNA 
junction at DSBs and daughter strand gaps. For this, we designed DNA substrates with 
3’ or 5’ overhang as well as a DNA gap substrate and performed EMSAs. The CTD 
showed higher complex formation (~35%) with the 3’overhang DNA substrate however 
the BRCA2T2 bound with higher affinity at low concentrations (Figure 9 A, C). A similar 
pattern was observed in EMSAs using a 5’ overhang DNA substrate: Both proteins 
reached similar levels of complex formation of ~40% at the highest attainable 
concentration although CTD reached that yield at 6 times higher the concentration of 
the NTD (Figure 9 B, E). Last, BRCA2T2 showed high affinity for the gapped DNA 
substrate reaching ~60% protein-DNA complex. In contrast, the CTD bound less tightly 
(~25%) even at concentrations 10 times higher than the ones used for the NTD (Figure 
9 C, F). Taken together, our results from these DNA binding assays indicate that 
BRCA2T2 comprising the NTD has an overall higher affinity for all DNA substrates 
tested, especially the substrates mimicking the ds/ssDNA junction or a daughter strand 
gap. Moreover and in contrast to the CTD, NTD binds dsDNA.  
The crystal structure of the mouse CTD has been solved 127, however, because the 
mouse sequence shares only 68% homology with human BRCA2 and there are 
questions still unsolved regarding the DNA binding modes of this region, we also aimed 
to solve the structure of the CTD in complex with DNA by crystallization in collaboration 
with the group of Xiaodong Zhang (Imperial College London). Hence, we produced the 
CTD in a 7 liters bacterial culture in a fermenter and we were able to obtain the protein 
in sufficient purity and amount for the crystallography.  This work is ongoing. 
Some of the zinc finger proteins described do not coordinate a zinc ion for stabilization 
instead, they establish salt bridges for their association with DNA 232. Since we did not 
observe a stimulation of DNA binding in the presence of Zn+2 we reasoned this could 
be the case of NTD. Even though cysteine residues do not form salt bridges, they 
could be  
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 required for the shaping and stabilization of the zinc finger structure via disulfide bond 
formation. To find out the residues important for DNA binding, we mutated three of the 
cysteines present in the domain. We chose to mutate two cysteines that have been 
found substituted for serine in breast cancer patients (C315S, C341S) (BIC and 
BRCAshare databases209,210). The third one is an artificial alanine substitution of C279 
Figure 9: EMSA with different DNA substrates to compare NTD and CTD binding 
specificities. Autoradiographs of A) reaction with 3’ overhang substrate B) 5’ overhang 
substrate C) gapped DNA and D-F) quantification of A-C from at least three individual 
experiments.  
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(Figure 10 A). Single or combinations of double mutations were introduced in the 
BRCA2T2 fragment by site-directed mutagenesis and purified to nearly homogeneity as 
described for the other fragments (Figure 10 B).  
The fragments were then used for DNA binding assays as described before. First we 
tested the fragments containing the single missense mutations and compared their 
binding with the wild type fragment BRCA2T2. 
Figure 10: A) Amino-acid sequence comprised in the zf-PARP like domain 
showing the selected variants (red)/ mutations (black) mutated alone or in 
combination in BRCA2T2 cDNA. B) Protein fragments expressed in HEK293s and 
purified using affinity chromatography and ion exchange as described for the other 
fragments. 1 μg of each protein loaded on a 7.5% SDS gel. 
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As shown in Figure 11A and C, all fragments containing the single mutations were able 
to bind ssDNA, although the percentage of complex formation was slightly reduced for 
about 10-20% compared to BRCA2T2. In contrast, the double mutants drastically 
decreased the ssDNA binding capacity to 5% at the highest attainable concentration in 
comparison to BRCA2T2 that reached up to 60% ssDNA-protein complex formation 
(Figure 11B; D). This indicates that the cysteine residues tested are important for the 
ssDNA binding activity of the N-terminus, probably by conferring stability to the binding 
domain formed. Next, we evaluated the binding capacity of the single and double 
Figure 11: EMSA using BRCA2T2 and variant fragments with dsDNA (40mer). 
Autoradiographs of A) Binding of BRCA2T2 and single mutants to dsDNA B) Binding of 
BRCA2T2 and double mutants to ssDNA in EMSAs. Quantification of C) (n=3) D) At least 
three individual experiments with BRCA2T2 and double mutants. 
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mutants to dsDNA. As shown before, unlike CTD, BRCA2T2 readily binds dsDNA 
(Figure 8). The binding of the single mutants C279A and C341S was only slightly 
reduced in comparison to the wild type protein (30% dsDNA-protein complex 
formation). However, C315S almost abolished the binding activity (Figure 12A, C). In 
addition, the double mutants reduced the dsDNA binding activity even further, 
especially in the case of the double mutants containing  C315S mutation (Figure 12 B, 
D). These results indicate that the C315 is particularly required for the association of 
the NTD to dsDNA, a function specific to this domain and probably of high importance 
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Figure 12: DNA binding assays (EMSAs) using BRCA2T2 and variant fragments with 
dsDNA (40mer). Autoradiographs of A) Binding of BRCA2T2 and single mutants to dsDNA. 
B) Binding of BRCA2T2 and double mutants to dsDNA in EMSAs. Quantification of C) 
(n=3). D) at least three individual experiments with BRCA2T2 and double mutants. 
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for the proper positioning of RAD51 on the DNA (see discussion 2.3). These results 
might also explain why C315S is frequently mutated in breast cancer patients although 
its clinical relevance is still unknown. 
It has been shown that fusion peptides of one BRC repeat important for RAD51 binding 
and the CTD or RPA70 subunit are sufficient to enhance RAD51 recombination activity 
151,152. Thus, having shown the existence and functionality of a DNA binding site in the 
N-terminus, we wanted to know if a fusion peptide consisting of BRCA2T2 and BRC4 
would have the same effect. We first fused BRC4 at the C-terminus of BRCA2T2 in the 
expression construct however the protein was not stable and rapidly degraded after 
purification. In a second attempt we cloned BRC4 between the N-terminal 2x MBP tag 
and BRCA2T2. This expression construct was stable and we obtained a pure fusion 
peptide after the purification procedure as described for all other fragments (Figure 
13A). 
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To test the recombination activity of RAD51 we used an in vitro short oligonucleotide 
DNA strand exchange assay as described before 70; RAD51 is incubated with a 3’ 
overhang substrate that mimics the 3’ tail generated after DSB resection. After 
incubation, a radiolabeled dsDNA substrate is added that is complementary to the 3’tail 
and RAD51 will perform strand exchange between the two substrates. RAD51 strand 
exchange activity can be observed by loading the reactions on a native PAGE gel:  
Figure 13: A) Purified BRCA2BRC4-T2 (1ug on SDS gel). B) Top. Experimental set up for 
strand exchange assays: Scheme of the reaction. Autoradiograph of DNA strand 
exchange reaction using a 3’ ssDNA overhang substrate at the indicated 
concentrations of RAD51 (left). DNA strand exchange reaction with increasing 
concentrations of RAD51 (left) or RPA (right). C) Pull-down experiment with BRCA2T2, 
BRCA2BRC4-T2 with RAD51 and RAD51 alone loaded on a 7.5% SDS gel stained with 
SYPRO Orange.  
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The strand exchange product is larger and migrates slower than the free dsDNA (see 
Figure 13B). We first titrated RAD51 to find the optimal concentration for the reaction 
(Figure 13B left). The ssDNA overhang resulting from resection of the DSB is rapidly 
coated by the ssDNA binding protein RPA to avoid further resection and formation of 
secondary structures. However, RAD51 activity is inhibited by RPA as it binds ssDNA 
with higher affinity. The mediator activity of BRCA2 is based on two mechanisms: First, 
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it blocks RAD51 the unproductive assembly of RAD51 on dsDNA. Second, it alleviates 
RPA inhibition by facilitating its displacement by RAD51. To test a possible mediator 
activity of NTD we titrated RPA in the strand exchange reaction to find the optimal 
concentration for RAD51 inhibition (Figure 13B right).  
We first tested the promotion of strand exchange activity of RAD51 in presence of 
BRCA2BRC4-T2 and RPA. The 3’ tail substrate was incubated with RPA before adding 
Figure 14: DNA strand exchange assays. A) Reaction scheme (up) and autoradiograph 
of the assay using BRCA2BRC4-T2 or full length BRCA2 B) BRCA2T2 or CTD in the 
indicated concentrations. Quantification of C) BRCA2BRC4-T2 or full length BRCA2 and D) 
BRCA2T2 or CTD (n=3) 
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RAD51 and BRCA2BRC4-T2. After a short incubation, the radiolabeled dsDNA was 
added. As shown in Figure 14A (left gel), BRCA2BRC4-T2 was able to alleviate the 
inhibitory effect of RPA (lane 3). The addition of increasing concentrations of 
BRCA2BRC4-T2 almost restored the level of RAD51 strand exchange activity that RAD51 
reaches in the absence of RPA (lane 2, Figure 14C). When comparing the stimulatory 
activity to that of the full length BRCA2, the stimulatory effect of the proteins was 
similar, although at a concentration of BRCA2BRC4-T2 10 times higher than that of 
BRCA2 (Figure 14A, right and 14C).  
The CTD alone was shown before to have a stimulatory effect in strand exchange 
reactions 127. We thus wanted to see if BRCA2T2 is also capable to promote strand 
exchange activity without BRC4 by using strand exchange assays As BRCA2T2 
showed high affinity for dsDNA and ds/ssDNA junction substrates in DNA binding 
assays (Figure 8&9) we presumed that it could promote RAD51 binding to ssDNA over 
dsDNA in absence of a BRC repeat by outcompeting RPA. 
Interestingly, BRCA2T2 alone stimulated RAD51 activity to a similar extent as 
BRCA2BRC4-T2 (Figure 14B; D). To make sure that this activity does not stem from an 
interaction between BRCA2T2 and RAD51, we performed pull-down experiments 
comparing the binding of BRCA2BRC4-T2 and BRCA2T2 to RAD51 and showed that 
BRCA2T2 doesn’t bind RAD51 (Figure 12C). Hence, we could show that under our 
experimental conditions (saturating RAD51 concentration and short DNA substrate) 
BRCA2T2 without BRC4 is sufficient to facilitate RAD51 recombination maybe by 
counteracting RPA binding to ssDNA. We next tested the proteins for the stimulation of 
strand exchange activity by RAD51 in absence of RPA. In contrast to BRCA2T2, the 
fusion peptide with BRC4 stimulated the strand exchange reaction also in absence of 
RPA to the same extent as full length BRCA2 (Figure 15C, D).  
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This activity probably stems from the ability of BRC4 to stabilize RAD51 filaments on 
the ssDNA by inhibiting its ATP hydrolysis. When we tested the CTD in strand 
exchange assays, we observed only little stimulation (4%) of the activity in presence of 
RPA as it was shown with the mouse CTD 127 (Figure 14B, D). Consistent with previous 
results127, in the absence of RPA, the CTD had no effect on RAD51 DNA strand 
exchange activity, confirming that CTD-DSS1 complex removes RPA from the as it has 
been recently described 69 (Figure 15A, B). Also the concentration needed to achieve a 
small stimulatory effect was 10 times higher than for BRCA2T2 similar to our 
observations in the DNA binding comparison (Figure 8 & 9).  
Figure 15: Effect of BRCA2 fragments on RAD51 DNA strand exchange activity in 
the absence of RPA. A) Autoradiogram showing the reaction with BRCA2T2 and CTD 
alone B) quantification of A, (n=3). C) Autoradiogram showing the reaction with 
BRCA2BRC4-T2 and full length BRCA2. D) Quantification of C, (n=3). 
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Because we observed stronger enhancement of the strand exchange reaction by 
BRCA2T2 compared to the CTD, we wondered if this activity could stem from the 
dsDNA binding activity of NTD. The single missense mutant C315S and the double 
mutants had shown a defective phenotype in dsDNA binding (Figure 12C; D). We thus 
tested the DNA strand exchange activity of BRCA2T2 carrying C315S and C279C315S 
mutations when using the 3’tail substrate that has a ds/ssDNA duplex structure. 
Indeed, the C315S mutant and to a higher extent the C279AC315S mutant reduced 
RAD51 strand exchange activity suggesting that the dsDNA binding activity is 
important for the DNA strand exchange stimulatory effect observed with this type of 
substrate (Figure 16 A; B). To control that this effect stems from the inability of C315S 
to associate with ss/dsDNA and not from a folding defect due to the mutation, we 
conducted the same strand exchange assay using a ssDNA (167mer) substrate. Here, 
Figure 16: DNA strand exchange assays A) comparing BRCA2T2 with C315S and 
C279AC315S double mutant, quantification in B). Strand exchange assay using  
ssDNA as a substrate C) comparing BRCA2T2 with C315S D) quantification of C (n=3). 
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the C315S variants showed the same stimulatory activity on DNA strand exchange 
activity and product formation than wild type BRCA2T2 (Figure 16 C; D).  
2.3  DISCUSSION 
In this work we demonstrate for the first time a DNA binding activity specific to the N-
terminal domain of BRCA2. Our research was based on the assumption that the N-
terminus must inherit a function similar to the CTD to rescue the HR proficiency in 
absence of the C-terminus as it was observed in several studies 108,109,151,156,157 (see 
2.1).  
PALB2 binds to the N-terminus of BRCA2 and can bind to DNA as well as promote HR 
by RAD51 in vitro. BRCA2 and PALB2 form a complex to localize to and cooperate at 
the DSB sites to promote D-loop formation 106,108,233. It was suggested that in the 
absence of the CTD, BRCA2 is dependent on PALB2 interaction to restore HR 109.  
However, the discovery of a second DNA binding domain in the BRCA2 ortholog Brh2 
(U. maydis) 159 led us to investigate whether a similar function was present in human 
BRCA2.  
This DNA binding domain is located next to the unique BRC motif in this organism. 
Brh2 mutants lacking the CTD can rescue the sensitivity to DNA damage and both 
DNA binding domains seem to collaborate in this function 155,159. 
The unstructured nature of the N-terminal domain of BRCA2 makes difficult to foretell 
possible functions based on secondary structure prediction. However, it is known that 
the function of intrinsically disordered proteins (IDPs) depends mostly on their flexibility 
and ability for structural changes. Often, their active structure forms upon binding to an 
interacting protein or nucleic acid partner 234. DNA-binding proteins often contain 
intrinsically disordered regions with which they contact the DNA 235. Interestingly, unlike 
in the case of Brh2 NTD, the CTD of human BRCA2 or RPA70, where the DNA binding 
domain is an OB-fold like structure, the NTD revealed in this study is a zinc-finger 
PARP like domain.  
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The cysteine and histidine residues located in this zinc finger PARP domain in the N-
terminus do not exactly follow any of the proposed patterns found in the motifs of zinc 
finger protein families, however, it could resemble or have evolved from the C2HC-type 
(Zinc finger, C2HC-type (IPR002515 – InterPro 
227) (Figure 17). In any case, using DNA 
binding assays with purified fragments of the N-terminus we could confirm the 
hypothetical DNA binding site and map it to BRCA2T2 (250-500 aa), consistent with the 
in silico localization of the zinc finger PARP domain. Our results were supported by the 
identification of two clusters of putative DNA binding residues using BindN software 225 
(Figure 2, 3). Importantly, BRCA2T2 does not comprise the PALB2 binding site at the 
extreme N-terminus eliminating PALB2 as the possible mediator of the interaction with 
DNA. Indeed, we could not detect a DNA binding activity in the first 1-250 amino acids 
of BRCA2 (BRCA2T1) (Figure 3) and this was further confirmed by examining the 
partition of BRCA2T2 compared to BRCA2T1 between biotinylated ssDNA (dT80) 
immobilized on streptavidin magnetic beads challenged with excess dT40 ssDNA. In 
this experiment, only BRCA2T2 and not BRCA2T1 was titrated out by adding excess dT40 
indicating that BRCA2T2 binds specifically to DNA (Figure 5). 
In addition, in negatively stained EM pictures, the N-terminal fragment bound to the 
gapped DNA and changed its conformation upon DNA binding into Y or V-shaped 
structures, a conformation that has been described for zinc finger motifs 232. Being a 
zinc finger like motif, we examined whether NTD requires zinc ions to stabilize the 
binding of the finger to its target DNA 230. However addition of Zinc ions did not 
stimulated but rather inhibited the reaction at the two concentrations tested. It’s 
possible that this domain establishes salt bridges for its association with DNA as it is 
the case in other zinc finger proteins 227. 
By purifying the CTD in complex with DSS1 we could confirm for the first time the 
observations made with mouse CTD127  in the human homologue that the CTD is 
proficient in binding to several DNA substrates except dsDNA, even though it was 
suggested that the tower domain could be responsible for this function 127. In contrast 
Figure 17: Amino acid sequence (249-349) of the N-terminus of BRCA2 predicted to 
contain a zinc-finger PARP like domain. Cysteine (C) and Histidine (H) residues are 
highlighted in red, the residues in yellow could constitute the C2HC zinc-finger DNA 
binding motif. The residues C315S and C341S found in breast cancer patients are 
indicated with arrowheads.  
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to what was observed with the CTD and Brh2, the NTD bound efficiently long and short 
dsDNA substrates. In addition, it showed high affinity for gapped and 3’- or 5’-overhang 
DNA substrates, pointing towards a possible functional role of the NTD in binding to the 
ssDNA/dsDNA junction at resected DSBs or daughter strand gaps arising during 
replication (Figure 7-9). We examined the cysteine residues comprised in the zf-like 
domain. Although we could not find evidence of zinc coordination, these residues could 
be needed for shaping and stabilizing zinc finger folds via disulfide bonds. Interestingly, 
C315S showed a strong defect in dsDNA binding. The fact that this mutation is listed 
19 times in the BRCA2 VUS databases BRCAshare and BIC 209,210 may indicate that 
this function is important for BRCA2. If the NTD can compensate for the absence of the 
CTD, it should do so by not only binding to DNA but also by mediating RAD51 
localization to and unidirectional nucleation on the ssDNA. To test this, we performed 
DNA strand exchange assays by first incubating a 3’tail DNA substrate with RPA that 
binds with high affinity. RAD51 binding to the DNA and thus strand exchange activity is 
inhibited by RPA and can only be relieved when a mediator such as BRCA2 is present 
enabling association with DNA by displacing RPA 70. Since at least one BRC repeat is 
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required for the binding to RAD51, we created a fusion construct consisting of BRC4 
and BRCA2T2 to test if the activity of BRCA2BRC4-T2 was sufficient to promote strand 
exchange activity in comparison with full-length BRCA2 and the CTD (Figure 14 & 15). 
Surprisingly, not only BRCA2BRC4-T2 but also BRCA2T2 alone was capable of promoting 
RAD51 strand exchange activity in the presence of RPA. Because this stimulatory 
effect was only seen when RPA was incubated first with the DNA, this activity may 
come from the ability of BRCA2T2 to bind dsDNA at the ssDNA/dsDNA junction, 
competing out RPA and facilitating RAD51 loading on the ssDNA. In line with this idea, 
we observed that the variant C315S, defective in dsDNA binding, could only promote 
strand the DNA strand exchange activity of RAD51 when using ssDNA but not when a 
3’tail DNA was used as substrate. As previously described, the CTD had a small 
stimulatory effect on RAD51 DNA strand exchange activity and only in the presence of 
RPA 127. As suggested for BRCA2T2, the CTD probably aids RAD51 assembly on 
ssDNA by replacing RPA but does not stabilize the filament. Our findings are in 
agreement with a recent publication where it was shown that DSS1 in complex with the 
CTD interacts with RPA reducing its affinity for ssDNA to allow its displacement 69. We 
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verified that DSS1 was indeed present in our CTD preparation as it was co-expressed 
with it (Figure 7).  
The important question originating from this study is why there are two DNA binding 
sites in BRCA2. Our study is compatible with two possibilities: 1) The NTD has an 
independent of CTD to allow the loading of RAD51 at specific DNA damage sites, 
especially those containing a duplex DNA. 2) The two DNA binding domains cooperate 
at the same DNA damage sites as it is the case in Brh2. In this scenario, when a 
ssDNA/dsDNA junction is generated upon resection of a DSB or at a daughter strand 
gap occurring during replication, the ssDNA is subsequently covered by RPA rendering 
it inaccessible for RAD51 (1). BRCA2 binds RAD51 via interaction with the BRC 
repeats and delivers it at the ssDNA/dsDNA junction thanks to the NTD (2). This 
facilitates RAD51 nucleation on the ssDNA by the BRC repeats class I (BRC1-4) and 
the stabilization of the nascent RAD51 filaments by BRC repeats class II (BRC5-8) 124 
(3). The CTD-DSS1 complex would bind next to the ssDNA facilitating RAD51 filament 
growth by displacing RPA (4). Whether the NTD is released after RAD51 loading 
remains to be elucidated (Figure 18). Our model suggests that in the context of the full 
Figure 18: Model for interaction of the two DNA binding domains at daughter strand 
gaps (DSG) or double strand breaks (DSBs). Explanations can be found in the text.  
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length protein, both DNA binding domains have independent functions but also work 
consecutively at the pre-synaptical stage to facilitate RAD51 filament formation and 
growth, a rate limiting step in recombination, enhancing the subsequent steps of the 
DNA strand exchange process. This could explain why full-length BRCA2 is only 
needed in substochiometric concentration to stimulate the DNA strand exchange 
activity of RAD51 whereas the isolated NTD and CTD stimulate the reaction only at 
stoichiometric concentration (observations from this study and 70). 
In addition, the compensating DNA binding function of NTD when CTD is not present 
explains why NTD or CTD can rescue the hypersensitivity to DNA damage in cells 
deficient in BRCA2. Whether the small construct of BRCA2BRC4-T2 is capable of 
promoting HR in vivo as in the case of U. maydis Brh2 remains to be studied. In the 
human BRCA2, other domains such as the PALB2 interaction site or the extreme C-
terminus important for RAD51 filament stabilization and cell cycle regulation might be 
required in vivo. Nevertheless, this study offers an explanation for the CTD being 
dispensable for HR function 157. We also provide a functional approach to study VUS 
found in breast cancer patients located in the NTD region that might affect the DNA 
binding capacity of the protein. This could impair their HR function and predispose to 
the development of cancer. The possibility to characterize these variants will contribute 
to the classification of VUS in BRCA2 and help in genetic counseling.  
2.4  OUTLOOK  
In this study we found a novel DNA binding site in the N-terminus of BRCA2 that 
promotes RAD51-dependent homologous recombination. This works provides a 
possible explanation for the fact that cells lacking the canonical CTD can survive 
treatment with DNA damaging agents and restore HR. In the future, it will be of great 
interest to further investigate why two DNA binding sites co-exist in BRCA2. In our 
model (Figure 18), we propose that the NTD is the initial interaction domain at the 
ssDNA/dsDNA junction of resected DSBs or of daughter strand gaps to allow RAD51 
nucleation on RPA covered ssDNA. The CTD-DSS1 complex is then needed for the 
active removal of RPA from the ssDNA to allow further RAD51 nucleation and/or 
filament extension. We propose that the ssDNA/dsDNA junction specificity is likely 
acquired by the dsDNA binding activity of the NTD. A bias towards this type of DNA 
intermediate is also observed in Brh2 and the functional homolog of BRCA2 in 
bacteria, RecFOR 236. 
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It remains to be investigated whether the NTD alone is able to restore HR in vivo or 
reduce the sensitivity to DNA damage in vivo. To examine this possibility in our lab we 
are currently establishing a system in HEK293 cells in which we can downregulate 
endogenous BRCA2 and conditionally induce the expression of protein fragments or 
full-length variants of BRCA2. We will establish stable clones expressing fusion 
constructs of BRCA2LT3-BRC4, BRCA2LT2-BRC4, BRCA2T2-BRC4 and BRCA2T1-BRC4 and test 
them for their HR proficiency using a GFP-reporter homologous recombination assay. 
We will use these cell lines to monitor their ability for RAD51 foci formation and their 
sensitivity to DNA damage by clonogenic survival. Indeed, it is possible that the DNA 
binding activity and promotion of RAD51 recombination activity of the NTD we observe 
in vitro, is not sufficient for the survival of the cells after DNA damage because of the 
lack of the PALB2 binding site. PALB2 is required for the formation of the BRCA1-
PALB2-BRCA2 complex and for the localization of the proteins to the DSB. 
Furthermore, PALB2 cooperates with BRCA2 to stabilize the D-loop structure. This is 
reflected in the HR defect of cells mutated in the PALB2 binding site 108,109. If this is the 
case, we would expect that BRCA2LT3-BRC4 and BRCA2LT2-BRC4, will show better survival 
than BRCA2T2-BRC4. 
It would be interesting to know how the interplay of the two domains is achieved 
structurally. It was shown that BRCA2 forms a dimer and ssDNA binds across the two 
dimers via the CTD158.  
The human CTD-DSS1 complex purified, to our knowledge, for the first time in our 
work, and the crystalization study ongoing in collaboration with the group of Xiaodong 
Zhang will help us get further insights into the structural composition of the complex in 
association with DNA.  
In Brh2, cells lacking the NTD or the CTD can repair UV-induced lesions, however, 
DNA lesions induced for example by HU treatment at replication forks require the 
interplay of both domains in the absence of the RecQ helicase Blm. In contrast to 
human NTD, the NTD in Brh2 forms a OB-like structure similar to the CTD and the two 
DNA binding domains show similar binding specificity for DNA substrates and the 
same affinity as the full length protein 237. In human BRCA2 the full-length protein binds 
readily to DNA with much more affinity than NTD (~10 fold) and especially the CTD 
(~100 fold) alone. This is consistent with our working model in which both domains act 
consecutively to promote HR. How this mechanism is regulated to allow the two 
domains to exert their functions remains to be established. 
During my PhD thesis, I also worked on the evaluation of variants of unknown clinical 
significance (VUS) found in breast cancer patients that are located in the NTD region 
(Exon 10). In this chapter, we already characterized the DNA binding features of single 
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and double mutants of conserved cysteine residues that are thought to be important for 
the protein’s function. Simultaneously to the functional characterization of the NTD, we 
evaluated the phenotype of VUS of conserved residues located in the two DNA binding 
clusters predicted by in silico analysis in both HR and cell cycle regulation. Using the 
now established protocols for DNA binding and strand exchange assays in vitro and 
the cell-based assay for the characterization of VUS, we hope to obtain a more 
complete perception of the functions impaired in BRCA2 variants showing a deleterious 
phenotype in this region.  
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BRCA2 tumour suppressor protein is well known for its role in DNA repair by 
homologous recombination (HR); assisting RAD51 recombinase loading at DNA 
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double strand breaks (DSB)1-3. This function is executed by the C-terminal DNA 
binding domain (CTD) which binds single-stranded (ss)DNA4, and the BRC 
repeats, which bind RAD51 and modulate its assembly onto ssDNA5,6, an 
important step in HR. However, intriguing results highlighting the apparently 
redundant function of distinct regions of the protein raise questions about the 
functional domains of BRCA2 and their interdependencies 7-10.  
In this work, we identified a region in the N-terminus of BRCA2 comprising a 
putative zinc finger-PARP domain that exhibits DNA binding activity (NTD). In 
comparison to the CTD, the NTD has stronger affinity for all forms of DNA 
structures tested and, in contrast, also binds to double-stranded (ds)DNA. 
Importantly, the NTD can stimulate RAD51-dependent DNA strand exchange 
between RPA coated single-stranded (ss)DNA and homologous duplex DNA, 
which defines a mediator11. These results point to NTD as a novel functional 
domain with mediator activity in recombination. A missense variant of BRCA2 
detected in breast cancer patients located in the NTD exhibits defective dsDNA 
binding activity and impairs the recombination function of RAD51 on substrates 
containing a ds/ssDNA junction, but not on ssDNA, providing a molecular basis 
for the mediator function of the NTD at these sites. 
 We propose that the NTD provides BRCA2 with the specificity to load RAD51 
onto dsDNA/ssDNA junctions while both CTD and NTD enable BRCA2 binding 
to ssDNA facilitating multiple nucleation events of RAD51 onto RPA-coated 
ssDNA. In addition, these findings shed light on the functional relevance of the 
N-terminus of BRCA2 and have implications for the evaluation of breast cancer 
variants identified in this region. 
The DNA binding activity of BRCA2 is essential to load RAD51 at DNA breaks. 
This function is ensured by the DNA binding domain located at the C-terminus 
of the protein (CTD)4. Yet, cells resistant to DNA damage devoid of the entire 
CTD can still function in HR7,10 suggesting that additional functional domains in 
BRCA2 could take over CTD’s function. To test this hypothesis we used protein 
secondary structure prediction tools (see Extended Data Methods) and 
identified a zinc finger (zf)-PARP like domain containing residues predicted to 
bind DNA in the N-terminus of BRCA2 that are conserved in mammals 
94 
 
(Extended Data Fig.1). This analysis prompted us to test the functional 
relevance of this domain. 
We expressed and purified from human cells several fragments of the N-
terminus of BRCA2; BRCA2T1 (aa 1-250), BRCA2T2 (aa 250-500), BRCA2LT2 
(aa 1-500) and BRCA2LT3 (aa 1-750) (Extended Data Fig.1c, d) and tested their 
DNA binding activity by Electrophoretic Mobility Shift Assay (EMSA). Incubation 
of a ssDNA homopolymer, dT40, and increasing concentrations of BRCA2T2, 
BRCA2LT2 or BRCA2LT3, but not BRCA2T1, generated a slower mobility species 
corresponding to DNA-protein complexes. Their DNA binding activity reached 
20- 40% of ssDNA-protein complex at 300 nM (Fig. 1a, b). These results 
suggest that the domains comprising BRCA2T2 bind to ssDNA.  
To further validate the DNA binding activity of this region, we used negatively 
stained electron microscopy (EM) with the larger N-terminal fragment, 
BRCA2LT3. BRCA2LT3 alone adopted a globular structure (Fig. 1c and Extended 
Data Fig. 2a). Incubation of BRCA2LT3 with a gapped DNA substrate resulted in 
V or Y-shaped particles (Fig. 1d and Extended Data Fig. 2c) that were not 
observed in samples containing either protein or DNA substrate alone (Fig. 1d 
and Extended Data Fig. 2a, b) suggesting that this structure results from DNA-
protein complex formation. We confirmed that the density on the tip of the V or 
Y shaped particles corresponds to BRCA2LT3 with an antibody against the tag 
(Fig. 1e and Extended Data Fig. 2d). The V or Y-shaped particles suggest 
protein binding to the ssDNA (gap) segment or to the ssDNA/dsDNA junction. 
Interestingly, PARP-like fingered enzymes have been described to bend the 
DNA upon binding to gap sites adopting a V shaped structure12.  
Collectively, these results indicate that the N-terminal region of BRCA2 binds 
DNA and that the region of aa 250-500 of BRCA2 (BRCA2T2) comprising the 
putative zf-PARP domain is sufficient for this activity. 
To examine the possible function and specificity of the DNA binding domain 
identified in the N-terminal region (NTD), we compared the DNA binding affinity 
of BRCA2T2 with that of the CTD (aa 2474-3190) (Fig. 2a) for different DNA 
substrates. 
As described for the mouse CTD4, human CTD bound to all DNA forms except 
dsDNA (Fig. 2b-f). Remarkably, at the attainable concentration (1.5 µM), 
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BRCA2T2 showed higher yield of DNA-protein complexes than the CTD for all 
DNA substrates tested (Fig. 2b-f). In contrast to the CTD, BRCA2T2 also bound 
to dsDNA resulting in a yield of protein-dsDNA complex of ~40 % at 1.5 µM, 
similar to that of ssDNA (Fig. 2c, Extended Data Fig. 3a, b). Moreover, 
BRCA2T2 exhibited significantly higher yield of DNA-protein complexes when 
bound to gapped DNA compared to CTD, reaching a ~40-fold difference at 1 
µM of protein concentration (Fig. 2f). 
These results indicate that BRCA2T2 exhibits an increased relative affinity or 
higher complex stability for all DNA substrates compared to CTD, especially 
those containing dsDNA or a dsDNA/ssDNA junction.  
NTD comprises a putative zf-fold, which are usually stabilized by cysteine and 
histidine residues13,14. To find out the residues important for DNA binding, we 
mutated three of the cysteines present in the domain (Extended Data Fig.1) and 
tested their effect on DNA binding. We chose to mutate two cysteines that have 
been found substituted for serine in breast cancer patients (C315S, C341S) 
(Breast Cancer information Core and BRCAshare databases). The third one is 
an artificial alanine substitution of C279 (Fig. 3a). Single or double mutations 
were introduced in the BRCA2T2 fragment and purified (Extended Data Fig. 4). 
The single mutations, C279A and C341S, only mildly affected the ssDNA 
binding activity of BRCA2T2 (Fig. 3b, Extended Data Fig. 4b). Importantly, the 
three double mutations, C279A/C315S, C279/A341S and C315S/C341S, all 
reduced the yield of ssDNA-protein complex formation by ~7-fold (Fig. 3c, 
Extended Data Fig. 4c). We next tested the effect of the single or the double 
mutations on dsDNA binding. Interestingly, the single substitution C315S 
reduced the dsDNA binding by ~6.5 fold whereas the other single mutations did 
not or very mildly affected it (Fig. 3d, e). Accordingly, the double mutations 
containing the C315S substitution potentiated this effect (Fig. 3f, g). Moreover, 
C315S mutation mildly reduced the ability of BRCA2T2 to bind a 3’overhang 
ssDNA by ~1.7 fold (Fig. 3h, i). 
These results imply that the three cysteine residues tested are important for the 
interaction of NTD with DNA. Moreover, C315S, a missense mutation frequently 
observed in breast cancer, highly impairs the interaction of BRCA2 with dsDNA.  
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A fusion peptide containing a single BRC repeat of BRCA2 and the CTD or the 
large subunit of replication protein-A (RPA), which also binds to ssDNA, is able 
to enhance RAD51 recombination activity15,16. In the recombination process, 
replication RPA coats first the ssDNA to remove secondary structure, an 
interaction that is inhibitory for RAD51 assembly onto ssDNA due to the 
stronger affinity of RPA for ssDNA17,18. Mediator proteins like BRCA2 counteract 
the inhibitory effect of RPA. In view of the DNA binding activity exhibited by 
BRCA2T2, we assessed whether a fusion of BRCA2T2 and BRC4, BRCA2BRC4-T2 
(Extended Data Fig. 5a), could promote the DNA strand exchange activity of 
RAD51.  
We used the optimal RAD51 and RPA concentrations (Extended Data Fig. 5b) 
in an in vitro short oligonucleotide DNA strand exchange assay1. RPA was 
incubated first with a 3’overhang ssDNA substrate (scheme in Fig. 4a), and as 
expected, RAD51 recombination activity was compromised (Fig. 4a, third lane). 
Importantly, BRCA2BRC4-T2 was able to overcome the inhibition by RPA and 
stimulate the reaction by ~6-fold at 300 nM protein concentration (Fig. 4b). 
Strikingly, BRCA2T2 alone also stimulated the reaction to a similar extent (Fig. 
4d) though it does not interact directly with RAD51 (Extended Data Fig.5c).  
These results suggest that at saturating concentration of RAD51 and with a 
short DNA sequence, the binding of BRCA2T2 to DNA is sufficient to facilitate 
RAD51 recombination. One explanation is that BRCA2T2 counteracts the 
competition of RPA for ssDNA allowing assembly of RAD51 onto the ssDNA 
(Fig. 4c, d). Consistent with this idea, BRCA2T2 did not stimulate the DNA strand 
exchange reaction in the absence of RPA (Extended Data Fig.5d, e). In 
contrast, the fusion peptide BRCA2BRC4-T2 showed a stimulatory effect of ~1.8 
fold, comparable to that of full length BRCA2 although at 10 times higher the 
concentration (Extended Data Fig. 5f, g). Similar to mouse CTD4, human CTD 
did not stimulate the DNA strand exchange reaction in the absence of RPA 
(Extended Data Fig.5d, e) but stimulated the RPA-containing reaction by ~3-fold 
at 10 µM (Fig. 4c, d).  
In conclusion, BRCA2BRC4-T2, BRCA2T2 and to a much lesser extent the CTD 
can all promote the RPA-dependent DNA strand exchange activity of RAD51.  
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Considering the binding of BRCA2T2 to duplex DNA-containing structures, we 
reasoned that this activity might be required for the stimulation of DNA strand 
exchange when using dsDNA-containing substrates. We conducted a DNA 
strand exchange reaction using a 3’ overhang ssDNA in the presence of the 
single mutant BRCA2T2 C315S with reduced dsDNA binding activity. Indeed, 
BRCA2T2 C315S decreased the stimulation of DNA strand exchange activity of 
RAD51 by ~3-fold compared to BRCA2T2, an effect that was further potentiated 
by the double mutation C279A/C315S (Fig. 4e, f). To confirm that the defective 
stimulation of DNA strand exchange is due to the inability of BRCA2T2 C315S to 
bind dsDNA and not to a faulty folding due to the mutation, we performed the 
same reaction using a ssDNA substrate. Indeed, C315S mutation stimulated the 
ssDNA-based strand exchange of RAD51 as much as BRCA2T2 (Fig. 4g, h) or 
full length BRCA2 (Extended Data Fig. 6), suggesting that the single 
substitution C315S affects the stimulation of DNA strand exchange with the 3’ 
ssDNA overhang substrate because of its defective dsDNA binding activity. 
A bias towards ssDNA/dsDNA junctions has been described for the functional 
homologs of BRCA2, the bacterial RecFOR, and its orthologue in U. maydis, 
Brh2 but not for human BRCA21. Although the helix-turn-helix motif present in 
CTD suggested dsDNA-binding4, the interaction with this type of substrate has 
not been detected for CTD 4,19. Our findings suggest that NTD specifically 
contributes the binding of BRCA2 to dsDNA allowing the association with 
dsDNA/ssDNA junctions.  
Combining our results with previous findings 1-3,5,20,21 we propose a model 
whereby in the context of a ssDNA/dsDNA junction-containing lesion (Extended 
Data Fig. 7); NTD binds at the dsDNA/ssDNA junction first, facilitating the 
loading and stabilization of RAD51 nucleoprotein filament onto RPA-coated 
ssDNA by the BRC repeats21. CTD binds along the ssDNA and actively 
facilitates the displacement of RPA22 allowing multiple nucleation events and 
RAD51 nucleoprotein filament extension. These activities enhance the 
subsequent steps of homologous recombination.  
It is possible that both NTD and CTD are required for assembly of RAD51 onto 
ssDNA in the context of full length BRCA2. Alternatively, the two DNA binding 
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sites may act on different substrates depending on the DNA damage 
encountered. How the two DNA binding modules of BRCA2 are coordinated in 
vivo warrants further investigation.  
Methods 
Cloning, expression and purification of recombinant proteins  
All BRCA2 N-terminal expression constructs containing the sequence coding for 
BRCA2 amino acids 1-250 (BRCA2T1), 251-500 (BRCA2T2), 1-500 (BRCA2LT2) 
and 1-750 (BRCA2LT3) were amplified by PCR from a 2xMBP-BRCA2 phCMV1 
vector1 and cloned by restriction digest with XhoI and NotI into a phCMV1 
vector containing an N-terminal 2x MBP tag with  two Nuclear Localization 
Signals (NLS) downstream the tag.  
Point mutations were introduced using QuikChange II site-directed mutagenesis 
kit (Agilent) and verified by sequencing. BRCA2BRC4-T2 fusion construct was 
generated by HIFI Gibson Assembly (NEB) in the phCMV1 2x MBP 2 NLS 
vector. 
All the constructs mentioned above including the vector containing the MBP tag 
and the NLS used as control were amplified with NucleoBond Xtra Midi kit 
(Macherey Nagel) and used for transfection.  
10 150 mm confluent plates of HEK293 cells were transiently transfected with 
TurboFect (Thermo Scientific) following the manufacturer specifications and 
harvested 30 h post-transfection. After lysis with 50 mM HEPES (pH 7.5), 250 
mM NaCl, 5 mM EDTA, 1% NP40, 1 mM DTT, 1 mM PMSF and EDTA-free 
Protease Inhibitor Cocktail (Roche), the suspension was incubated for 3 h with 
amylose resin (NEB). 2x MBP tagged BRCA2 fragments were eluted with 10 
mM maltose. The eluates were further purified with Bio-Rex 70 cation-exchange 
resin (Bio-Rad) by NaCl step elution (50 mM HEPES pH 7.5, 0.5 mM EDTA, 
10% glycerol, 1 mM PMSF, 1 mM DTT, and 250 mM, 450 mM or 1 M NaCl). 
The size and purity of the BRCA2 fragments were verified by loading the final 
fractions on a SDS-PAGE gel and detecting the MBP tag by Western Blot (mAB 
R29, Invitrogen).  
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The protein concentration of the nuclease-free fractions was determined using 
NanoOrange Protein Quantitation Kit (Thermo Fisher) and by density 
determination in SDS-PAGE gel using BSA as a standard.  
The C-terminal DNA binding domain (aa 2474-3190) of human BRCA2 (CTD) 
was cloned into pET28 6His SUMO vector. pCDF DSS1 expression vector was 
generated by HIFI Gibson Assembly (NEB) from a pFASTBAC Dual-DSS1 
vector (kind gift from R. B. Jensen). The CTD was co-expressed with DSS1 to 
ensure stability of the protein. E.coli BL21 DE3 pISO Dscb cells (kind gift of A. 
el Marjou) were transformed and grown at 37 °C in 7 litres of Terrific Broth and 
induced with 0.5% arabinose and 1mM IPTG overnight at OD (optical density) 
2. Cells were collected in 20 mM Tris-HCl pH 8, 300 mM NaCl, 10% glycerol, 
0.5 mM EDTA, 5 mM β-mercaptoethanol, 1x Protease Inhibitor Cocktail EDTA-
free (Roche), 10 mM MgCl2, 1x DNase, 0.5 mg/ml Lysozyme (Sigma Aldrich), 
and the suspension was lysed by disintegration at 1.7 kbar.  
The His-tagged protein was incubated with Protino Ni-NTA agarose (Macherey 
Nagel) and eluted with 200 mM imidazole. After dialysis overnight against 20 
mM Tris-HCl pH 8, 100 mM NaCl, 10% glycerol, 0.5 mM EDTA, 5 mM β-
mercaptoethanol, the eluate was loaded onto a 5 ml HiTrap Heparin HP column 
(GE) and eluted using a continuous NaCl gradient (100-1M NaCl) in the same 
buffer. 
The protein was visualized on a 7.5% SDS gel and the protein concentration 
was determined by Bradford assay. 
To generate EGFP-MBP-BRCA2, one MBP-tag of a phCMV1 2x MBP-BRCA2 
vector (kind gift from S.C. Kowalczykowski) was substituted by an EGFP tag 
amplified by PCR from a pEGFP-C1 vector (Invitrogen) and cloned by 
restriction digest with KpnI. EGFP-MBP-tagged BRCA2 was purified as 
described above for the BRCA2 fragments. 
Human RAD51 was cloned into pCDF 6his SUMO vector. E. coli BL21 BRL 
were transformed and grown in 7 L of Terrific Broth at 37 °C in a fermenter. At 
OD =1, the temperature was decreased to 20 °C and protein expression was 
induced with 0.5 mM IPTG overnight at 700 RPM. Cells were harvested by 
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centrifugation at 6000 RPM for 10 min at 4°C and resuspended in 1xPBS, 350 
mM NaCl, 20 mM imidazole, 10% glycerol, 0.5 mg/ml Lysozyme, 1x Protease 
Inhibitor Cocktail (Roche), 0.5 mM PMSF, 10 mM MgCl2, DNase and extracted 
using a disintegrator at 1.8 kbar and collected by centrifugation at 20.000 RPM 
for 30 minutes. The His-tagged protein was incubated with Protino Ni-NTA 
agarose (Macherey Nagel) and washed with 20 mM Tris-HCl pH 8.0, 20 mM 
imidazole, 10% glycerol, 100 mM NaCl, 5 mM β-mercaptoethanol. The His-tag 
was cleaved by incubating the resin with 0.4 mg/ml SUMO Protease at 4 °C 
overnight. The supernatant from the Ni-NTA resin containing the cleaved 
RAD51 protein was then loaded onto a 5 ml HiTrap Heparin HP 
chromatography column (GE) in 20 mM Tris-HCl pH 8, 10% glycerol, 100 mM 
NaCl and 5 mM β-mercaptoethanol. RAD51 protein was eluted using a 
continuous NaCl gradient (100 mM-2M NaCl) in the same buffer. The eluate 
was dialysed against RAD51 storage buffer (20 mM Tris HCl pH 8, 50 mM KCl, 
0.5 mM EDTA, 1 mM DTT, 10% glycerol, 0.5 mM PMSF) and visualized on a 
7.5% SDS-PAGE gel stained with Coomassie Brilliant Blue. The protein 
concentration was determined by Bradford assay.  
His-tagged RPA was a kind gift from M. Modesti (IGH, Marseille). 
BRCA2T2-BRC4, fusion construct was generated by Gibson HIFI assembly (NEB) 
in the phCMV1-EGFP-MBP 2NLS BRC4 vector background (pAC138). 
After purification, all proteins and fragments were aliquoted, frozen in liquid 
nitrogen and stored at -80C. 
Electrophoretic Mobility Shift Assay (EMSA)  
DNA substrates were purchased PAGE-purified from MWG Eurofins. The 
following oligonucleotides were used: oAC379: dT40 homopolymer. oAC423 
(167mer): 
5’CTGCTTTATCAAGATAATTTTTCGACTCATCAGAAATATCCGTTTCCTATA
TTTATTCCTATTATGTTTTATTCATTTACTTATTCTTTATGTTCATTTTTTATAT
CCTTTACTTTATTTTCTCTGTTTATTCATTTACTTATTTTGTATTATCCTTATC
TTATTTA-3’ 
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oAC403 (42mer): 5’-
CGGATATTTCTGATGAGTCGAAAAATTATCTTGATAAAGCAG-3’; oAC490 
(42mer): 5’-TAAATAAGATAAGGATAATACAAAATAAGTAAATGAATAAAC-3’; 
oAC405 (40mer): 5’-TAA TAC AAA ATA AGT AAA TGA ATA AAC AGA GAA 
AAT AAA G-3’; oAC406 (40mer): 5’-CTT TAT TTT CTC TGT TTA TTC ATT 
TAC TTA TTT TGT ATTA-3’. The ssDNA substrates used in EMSA were 
oAC379 and oAC423 32P labelled at the 5’ –end.  To generate the dsDNA 
substrates, oAC405 was 32P labelled at the 5’-end and annealed in a 1:1 molar 
ratio to oAC406. The 3’ and 5’ overhang substrates were produced by 
annealing 32P labelled oAC490 (42mer -3’) to oAC423 (167mer) or oAC403 
(42mer -5’) to oAC423 in a 1:1 molar ratio, respectively. oAC423, oAC403 and 
oAC490 were annealed in a 1:1:1 ratio to produce the gapped DNA substrate. 
The long dsDNA substrate was a PCR product (134 bp) amplified from pAC138 
by PCR using the oligonucleotides oAC596 and oAC597 and 32P-labeled at the 
5’ end.  
The proteins were incubated at the indicated concentrations with 0.2 µM 
nucleotides 32P labelled DNA substrates for 1h at 37°C in EMSA reaction buffer 
(25 mM Tris Acetate pH 7.5, 1 mM DTT, 1 mM MgCl2, 2 mM CaCl2). The 
protein-DNA complexes were resolved on 6% native polyacrylamide gels in 1x 
TAE buffer (40 mM Tris Acetate, 0.5 mM EDTA) at 70V for 75 min. The gels 
were dried and analysed with a Typhoon PhosphorImager (Amersham 
Biosciences) using Image Quant software (GE Healthcare). In EMSAs in all 
figures except for Figure 3, the ratio of DNA-protein complexes was calculated 
as the percentage of bound DNA compared to the free DNA. In figure 3, the 
percentage of protein-DNA complexes was quantified as the free radiolabelled 
DNA remaining in a given lane relative to the protein-free lane. The protein-free 
lane defined the value of 0 % complex. 
Electron Microscopy 
BRCA2LT3 (2xMBP-tagged fused to BRCA2 aa 1-750) was stored at a 
concentration of 0.25 μM in buffer comprising 50 mM Hepes pH 7.5, 250 mM 
NaCl, 0.5 mM EDTA, 10% glycerol, 1mM PMSF and 1 mM DTT. The sample 
was diluted five-fold to 50 nM for subsequent electron microscopy studies. The 
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complex with gapped DNA was prepared by mixing the diluted protein at 50 nM 
with 100 nM gapped DNA (final concentration). The 65 bp-70 nt-65 bp gapped 
DNA was based on the following sequence (5’–3’): 
 
GAGTTTTATCGCTTCCATGACGCAGAAGTTAACACTTTCGGATATTTCTGAT
GAGTCGAAAAATTATCTTGATAAAGCAGGAATTACTACTGCTTGTTTACGAA
TTAAATCGAAGTGGACTGCTGGCGGAAAATGAGAAAATTCGACCTATCCTT
GCGCAGCTCGAGAAGCTCTTACTTTGCGACCTTTCGCCATCAACT. 
The gapped DNA used in the control experiment had also been diluted to 100 
nM (in the same buffer as the diluted protein). The antibody complex was 
prepared by incubating the protein-DNA complex with anti-MBP antibody (NEB) 
for 1-2 hours on ice at 50 nM and 100 nm final concentration, respectively.   
2–3 μl of each sample was applied to either carbon-coated Quantifoil R2/2 
(fragment, fragment + gDNA) or 300-mesh TAAB continuous carbon grids 
(gDNA, fragment + gDNA + anti-MBP), previously glow discharged for 30 s. 
After allowing adsorption for 1 min, the grids were washed twice with water and 
stained with 2% uranyl acetate solution. Excess stain was blotted and the grids 
air-dried at room temperature. 
Images were collected with an FEI Tecnai T12 (120 kV) transmission electron 
microscope equipped with the TVIPS TemCam-F216 (2k x 2k) CMOS camera. 
A magnification of 52,000x (corresponding to 2.1 Å/pixel in the recorded 
images) was employed throughout. Defoci in the range of –2 to –2.5 μm were 
utilised in the case of protein complexes, and –4 μm for gapped DNA. An 
electron dose of ~ 40 e–/Å2 was used in all cases. 
DNA strand exchange assay  
For DNA strand exchange assays without RPA, proteins were incubated at the 
indicated concentrations with 4 nM molecules 3’tail DNA or ssDNA (oAC379 or 
oAC423) for 5 min at 37°C in 25 mM Tris Acetate pH 8.0, 1 mM DTT, 2 mM 
ATP, 1 mM MgCl2, 2 mM CaCl2, 0.1 mg/ml BSA before adding 4 nM molecules 
dsDNA (oAC405 and oAC406 1:1) and further incubation for 30 min at 37 °C. 
When RPA was added, the protein was incubated for 5 min with ssDNA or 3’tail 
DNA, then RAD51 alone or with BRCA2 was added and incubated for 5 min 
and the dsDNA was added last and further incubated for 30 min at 37 °C. The 
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reaction was stopped by incubation with 0.25% SDS and 0.5 mg/ml Proteinase 
K for 10 minutes. Samples were loaded on a 6% Polyacrylamide gel and 
migrated at 70V for 75 minutes. The gels were dried and analysed with a 
Typhoon PhosphorImager (Amersham Biosciences) using Image Quant 
software (GE Healthcare). The percentage of DNA strand exchange product 
was calculated as labelled product divided by total labelled input DNA in each 
lane. 
 
Affinity pull-down with amylose beads 
Prior to pull-down assays, amylose resin (NEB) was equilibrated with binding 
buffer: 50 mM HEPES (pH 7.5), 250 mM NaCl, 0.5 mM EDTA, and 1 mM DTT. 
Purified 2XMBP-BRCA2BRC4-T2 or 2xMBP-BRCA2T2 proteins (1.25 μg) were 
incubated with 1 μg purified RAD51 for 30 minutes at 37 °C and then batch 
bound to 30 μl of amylose resin for 1 h at 4 °C. The complexes were washed with 
binding buffer (50 mM HEPES (pH 7.5), 250 mM NaCl, 0.5 mM EDTA, and 1 mM 
DTT) containing 1% NP-40. Proteins were eluted with 30 μl 10 mM maltose in 
binding buffer, resuspended in 1x SDS sample buffer, heated at 54°C for 5 min 
and loaded onto a 4-15% gradient SDS-PAGE gel. The gels were stained with 
SYPRO Orange. 
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FIGURES 
 
 
Figure 1: The N-terminus of BRCA2 binds DNA. a, EMSA showing 
BRCA2LT3, BRCA2LT2, BRCA2T1 and BRCA2T2 binding to ssDNA (dT40). b, 
Quantification of a. Error bars, s.d. (n = 3). c, Electron microscopy (EM) 
visualization of selected particles of BRCA2LT3 alone d, or in complex with 
gapped DNA (blue dots). The duplex DNA arms presumed to be flanking the 
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bound fragment are delineated (orange dots). e, EM visualization of selected 
particles of BRCA2LT3 in complex with gapped DNA and incubated with an 
antibody against MBP. The additional mass due to the antibody is delineated 
(red dots); the DNA is delineated as before. 
 
Figure 2: BRCA2T2 binds to different DNA substrates and with stronger 
affinity than CTD. a, M. size markers. 1. SDS-PAGE showing purified CTD (5 
µg) loaded in a 4-15% acrylamide gel. 2. Western blot of the gel shown in 2. 
with an antibody against the His tag of the CTD and an antibody specific to 
DSS1 protein co-purified with it. b, EMSA and quantification comparing the 
binding of BRCA2T2 and CTD to ssDNA, c, dsDNA, d, 3' ssDNA overhang, e, 5' 
ssDNA overhang, f, gapped DNA. Error bars, s.d. (n = 3).  
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Figure 3: Cysteine residues located in the putative zf-PARP like domain 
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and mutated in breast cancer patients affect the DNA binding activity of 
BRCA2T2. a, amino-acid sequence comprised in the putative zf-PARP like 
domain defined by SMART showing the mutated cysteine residues. The ones 
found in breast cancer patients are highlighted in red. b, Quantification of EMSA 
displayed in Extended Fig. 4b, c showing the binding of BRCA2T2, the indicated 
single mutants c, and the double mutants to ssDNA. d, EMSA showing the 
binding of BRCA2T2 and the indicated single mutants e, and the double mutants 
to dsDNA. f, Quantification of d. g, Quantification of e. h, EMSA showing the 
binding of BRCA2T2 and BRCA2 C315S to 3’ overhang ssDNA. i, Quantification 
of h. Error bars, s.d. (n = 3). 
110 
 
 
Figure 4: BRCA2T2-BRC4 and BRCA2T2 stimulate RAD51-promoted DNA 
strand exchange. a, DNA strand exchange reaction using a 3' overhang 
ssDNA substrate (scheme on top) in the presence or absence of RPA, RAD51, 
and increasing concentrations of BRCA2BRC4-T2 or BRCA2. b, Quantification of 
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a. c, same reaction as in a with increasing concentrations of BRCA2T2 or CTD. 
d, Quantification of c. e, same reaction as in a with increasing concentrations of 
BRCA2T2 or BRCA2T2 mutated in C315S, or C279A/C315S, as indicated. f, 
Quantification of e. g, same reaction as in a using a ssDNA substrate (scheme 
on top) with increasing concentrations of BRCA2BRC4-T2 or BRCA2T2 mutated in 
C315S, as indicated. h, Quantification of g. Error bars, s.d. (n = 3).  
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Extended Data 
Extended Data Methods 
Secondary structure prediction and alignment 
Using SMART secondary structure prediction tool (http://smart.embl.de/) we 
identified a putative zinc finger-PARP-like domain between amino acids 265-
349 of BRCA2 (Extended Data Figure 1a), a domain thought to assist on the 
recognition of DNA secondary structures1. The same query sequence was used 
in a web-based prediction tool for DNA binding residues, BindN2, which 
predicted two clusters in this region highly enriched in residues with a strong 
propensity for DNA binding. A multiple sequence alignment using Clustal 
Omega3 revealed that the DNA binding region is well conserved in mammals 
(Extended Data Fig.1b).  
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Extended Data Figure 1: Bioinformatics analysis of the N-terminal DNA 
binding region in BRCA2 and purified fragments. a, SMART result showing 
the putative zf-PARP like domain in BRCA2. b, Multiple alignment using the 
query sequence indicated in a showing the probable DNA binding residues in 
the indicated species as defined by BindN online software (in green). The 
numbers corresponds to the human protein sequence. c, Schematic 
representation of BRCA2 and the fragments derived from the N-terminal region 
used in this work. d, Purified fragments of the N-terminal region of BRCA2 
shown in a SDS-PAGE gel and detected by stain-free imaging (Bio-Rad) and by 
western blot revealed with an antibody against the MBP tag. 
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Extended Data Figure 2: Representative electron micrographs of 
BRCA2LT3 bound to DNA 
a, Electron microscopy visualization (orange arrows) of the gapped DNA used 
in Figure 1. b, DNA alone, c, BRCA2LT3 in complex with DNA d, and that of the 
complex of  BRCA2LT3 with DNA with an antibody against MBP. White boxes 
indicate particles while brown circles in a indicate possible aggregates. Arrows 
in b indicate DNA. 
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Extended Data Figure 3: BRCA2T2 binds dsDNA and shows similar 
preference for dsDNA containing structures and ssDNA as opposed to the 
CTD. a, Comparison of the affinities of BRCAT2 or b, CTD for binding to the 
different DNA substrates utilized in Figure 2. Error bars, s.d. (n = 3).  
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Extended Data Figure 4: ssDNA binding actvity of single or double 
cysteine mutated BRCA2T2. a, 1 µg of each purified wild type or mutated 
BRCA2T2 fragment as indicated is shown in an SDS-PAGE gel and detected by 
stain-free imaging. b, Autoradiogram of EMSA of BRCA2T2 or the single 
mutants indicated binding to ssDNA and quantified in Figure 3b. c, same as b 
Autoradiography of EMSA of BRCA2T2 or the indicated double mutants and 
quantified in Figure 3c. 
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Extended Data Figure 5: BRCA2BRC4-T2 but not BRCA2T2 nor CTD can 
stimulate the DNA strand exchange activity of RAD51 in the absence of 
RPA. a, SDS PAGE gel showing purified BRCA2BRC4-T2. b, Autoradiogram of 
DNA strand exchange reaction using a 3’ ssDNA overhang substrate at the 
indicated increasing concentrations of RAD51 (left) or RPA (right). c, Pulldown 
of purified BRCA2BRC4-T2 or BRCA2T2 and RAD51. d, Autoradiogram of a DNA 
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strand exchange reaction in the presence of RAD51 alone or with increasing 
concentrations of BRCA2T2 or CTD. e, Quantification of d. f, Autoradiogram of a 
DNA strand exchange reaction in the presence of RAD51 alone or with 
increasing concentrations of BRCA2BRC4-T2 or BRCA2. g, Quantification of f. 
Error bars, s.d. (n = 3).  
 
Extended Data Figure 6: BRCA2 stimulates the DNA strand exchange 
activity of RAD51 using a ssDNA substrate 
a, Autoradiogram of a DNA strand exchange reaction in the presence of RAD51 
alone, RPA and RAD51, or RPA, RAD51 and increasing concentrations of 
BRCA2 using a ssDNA substrate. b, Quantification of a. Error bars, s.d. (n = 3).  
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Extended Data Figure 7. Model for BRCA2 NTD and CTD coordination in 
the context of homologous recombination. (1) RPA binds the ssDNA 
generated upon resection of a DSB or the ssDNA flanking a DNA lesion during 
replication. (2) NTD binds at the dsDNA/ssDNA junction, facilitating the loading 
of RAD51 onto RPA-coated ssDNA by class I of the BRC repeats (BRC1-4)4. 
(3) Class II BRC repeats (5-8) stabilize the nascent RAD51 nucleoprotein 
filament 4. (4) CTD binds along the ssDNA and actively facilitates the 
displacement of RPA5,6 allowing multiple nucleation events and filament 
extension of RAD51. These activities enhance the subsequent steps of 
homologous recombination. These coordinated activities subsequent homology 
pairing and DNA strand exchange required for the template-driven repair in the 
context of both a DSB or in daughter strand gapped repair during replication. 
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2.5 METHODS 
2.5.1 CLONING OF CONSTRUCTS USED FOR EXPRESSION, PURIFICATION 
AND CELL BASED ASSAYS 
All BRCA2 N-terminal expression constructs containing the sequence coding for 
BRCA2 amino acids 1-250 (pAC097; BRCA2T1), 251-500 (pAC098; BRCA2T2), 1-500 
(pAC101; BRCA2LT2) and 1-750 (pAC102; BRCA2LT3) were amplified by PCR from a 
2xMBP-BRCA2 phCMV1 vector (Jensen et al., 2010) and cloned by restriction digest 
with XhoI and NotI into a phCMV1 vector containing an N-terminal 2x MBP tag with two 
Nuclear Localization Signals (NLS) downstream the tag.  
Point mutations in BRCA2T2 to produce 2xMBP 2 NLS BRCA2T2C279A, 2xMBP 2 NLS 
BRCA2T2C315S, 2xMBP 2 NLS BRCA2T2C341S and 2xMBP 2NLS BRCA2T2C315SC315s, 
2xMBP 2 NLS BRCA2T2C315SC341s, 2xMBP 2 NLS BRCA2T2C315SC315s were introduced 
using QuikChange II site-directed mutagenesis kit (Agilent) and verified by sequencing.  
BRCA2BRC4-T2 fusion construct was generated by HIFI Gibson Assembly (NEB). A PCR 
(see below for reaction setup) to create overlapping ends with NotI 2NLS BRC4 and 
BRC4 T2 was made from the pAC138 plasmid. A PCR reaction using pAC098 as a 
template to create T2 sequence overlapping with end of BRC4 and stop-XhoI was 
done. The BRC4, T2 and phCMV1 2x MBP 2 NLS vector cut with NotI and XhoI were 
then used for Gibson Assembly reaction. The correct assembly was verified by 
restriction digest and sequencing.  
To generate eGFP-MBP-BRCA2, one MBP-tag of a phCMV1 2x MBP-BRCA2 vector 
(kind gift from S.C. Kowalczykowski) was substituted by an EGFP tag amplified by 
PCR from a pEGFP-C1 vector (Invitrogen) and cloned by restriction digest with KpnI.  
Point mutations to create BRCA2 with missense mutation were created with 
QuikChange XL site-directed mutagenesis kit (Agilent) and verified by sequencing.  
All constructs mentioned above including the vector 2xMBP-NLS used as control were 
amplified with NucleoBond Xtra Midi kit (Macherey Nagel) and used for expression and 
purification.  
The C-terminal DNA binding domain (aa 2474-3190) of human BRCA2 (CTD) was 
cloned into pET28 6His SUMO vector. 
pCDF DSS1 expression vector was generated by HIFI Gibson Assembly (NEB) from a 
pFASTBAC Dual-DSS1 vector (kind gift from R. B. Jensen). 
All the constructs mentioned above were amplified with QIAprep Spin Maxiprep kit 
(Qiagen) and used for expression and/or purification.  
2.5.2  PURIFICATION OF RECOMBINANT PROTEINS  
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2x MBP-tagged proteins proteins were purified using the following protocol: 
20x150mm confluent plates of HEK293 cells were transiently transfected with 20 μg 
DNA and 40 μl TurboFect (Thermo Scientific) following the manufacturer’s 
specifications and harvested 30 hours post-transfection. After lysis with 50 mM HEPES 
(pH 7.5), 250 mM NaCl, 5 mM EDTA, 1% Igepal CA-360, 1 mM DTT, 1 mM PMSF and 
1x EDTA-free Protease Inhibitor Cocktail (Roche) for 20 minutes in rotation, the 
suspension was incubated for 3 hours with amylose resin (NEB), pre-equilibrated in 
lysis buffer. 2x MBP tagged proteins were eluted with 50 mM HEPES (pH 7.5), 250 mM 
NaCl, 0.5 mM EDTA, 1 mM DTT, 1x EDTA-free Protease Inhibitor Cocktail (Roche) 
and 10 mM Maltose. The eluates were diluted to 100 mM NaCl and further purified with 
Bio-Rex 70 cation-exchange resin (Bio-Rad), pre-equillibrated in 50 mM HEPES (pH 
7.5), 100 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 1x EDTA-free Protease Inhibitor 
Cocktail (Roche). After 1 hour of incubation with the resin on a rotating wheel, the 
proteins were eluted by NaCl step elution (50 mM HEPES pH 7.5, 0.5 mM EDTA, 10% 
glycerol, 1 mM PMSF, 1 mM DTT, 250 mM, 450 mM or 1 M NaCl) using a disposable 
column.  
The size and purity of the BRCA2 fragments or BRCA2 full-length WT and variant 
proteins were verified by loading the final fractions on a SDS-PAGE gel and detecting 
the MBP tag by Western Blot (MBP Antibody, Invitrogen). All fractions were tested for 
nucleases by performing EMSAs with radiolabeled dT40 oligonucleotide incubated with 
the proteins (see EMSA below). 
The protein concentration of the nuclease-free fractions was determined using 
NanoOrange Protein Quantitation Kit (Thermo Fisher) and by density determination in 
SDS-PAGE gel using BSA as a standard.  
The CTD was co-expressed with DSS1 to ensure stability of the protein. E. coli BL21 
DE3 pISO Dscb cells (kind gift of A. el Marjou) were transformed and grown at 37°C in 
7 liters of culture medium and induced with 0.5% arabinose and 1mM IPTG overnight 
at OD 2. Cells were collected in 20 mM TrisHCl pH 8, 300 mM NaCl, 10% Glycerol, 0.5 
mM EDTA, 5 mM β-Mercaptoethanol, 1x Protease Inhibitor Cocktail EDTA-free 
(Roche), 10 mM MgCl2, 1x DNase (Roche), Lysozyme (Sigma-Aldrich) and the 
suspension was lysed by disintegration at 1.7 kbar (Constant System (CellD)). The 
lysate was centrifuged at 25.000 rpm for 30 minutes at 4°C. The His-tagged protein 
was incubated with Protino® Ni-NTA agarose (Macherey Nagel) pre-equlibrated with 
300 mM NaCl, 20 mM TrisHCl pH 8.0, 5 mM β-Mercaptoethanol, 0.5 mM EDTA, 10% 
glycerol and 10 mM Imidazole at 4 C for 1 hour. The resin was extensively washed in 
300 mM NaCl, 20 mM TrisHCl pH 8.0, 5 mM β-Mercaptoethanol, 0.5 mM EDTA, 10% 
glycerol and 20 mM Imidazole and centrifuged at 500 xg for 5 minutes each time. The 
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protein was eluted in 300 mM NaCl, 20 mM Tris pH 8.0, 5 mM β-Mercaptoethanol, 0.5 
mM EDTA, 10% glycerol and 200 mM Imidazole. Dialysis followed overnight against 20 
mM TrisHCl pH 8, 100 mM NaCl, 10% Gycerol, 0.5 mM EDTA, 5 mM β-
Mercaptoethanol. The eluate was further subjected to a 5 ml HiTrap Heparin HP 
column (GE) in an Aktaprime chromatograph. The column was pre-quilibrated in 20 
mM TrisHCl pH 8.0, 100 mM NaCl, 5 mM β-Mercaptoethanol, 0.5 mM EDTA, 10% 
glycerol prior to loading of the protein. After the protein had bound to the column, it was 
washed with the same buffer and then eluted using a continuous NaCl gradient (20 mM 
TrisHCl pH 8, 1 M NaCl, 10% Gycerol, 0.5 mM EDTA, 5 mM β-Mercaptoethanol). All 
fractions showing to contain protein on the chromatograph were visualized on a 7.5% 
SDS-gel and the fractions with the protein of interested were pooled and dialysed 
against 20 mM TrisHCl pH 8, 150 mM NaCl, 10% Gycerol, 0.5 mM EDTA, 5 mM β-
Mercaptoethanol. The protein was heated in 1x SDS buffer for 5 min at 54°C visualized 
on a 7.5% SDS gel and the protein concentration was determined by Bio-Rad protein 
assay. 
Human RAD51 was cloned into pCDF 6his SUMO vector. E. Coli BL21 BRL were 
transformed and grown in 7 L of terrific broth at 37°C in a fermenter.  
At OD =1, the temperature was decreased to 20°C and protein expression was induced 
with 0.5 mM IPTG overnight at 700 RPM. Cells were harvested at 6000 RPM for 10 
minutes at 4°C and resuspended in 1x PBS, 350 mM NaCl, 20 mM Imidazole, 10% 
Glycerol, Lysozyme 0.5 mg/ml (Sigma-Aldrich), 1x Protease Inhibitor Cocktail (Roche), 
1 mM PMSF, 10 mM MgCl2, 1x DNase (Roche) and extracted using a disintegrator at 
1.8kbar, followed by centrifugation at 20.000 RPM for 30 minutes.  
The His-tagged protein was incubated with Protino® Ni-NTA agarose (Macherey 
Nagel) and washed with TrisHCl 20 mM pH 8.0, 20 mM Imidazole, 10% Glycerol, 100 
mM NaCl, 5 mM β-mercaptoethanol.  
The protein was cleaved from the His-tag by incubating the resin with 0.41 mg/ml 
SUMO protease (Thermo Scientific) at 4°C overnight. The supernatant containing the 
cleaved protein was then subjected to a 5 ml HiTrap Heparin HP chromatography 
column (GE Healthcare) equilibrated in TrisHcl 20 mM pH 8, 10% Glycerol, 100 mM 
NaCl, 5 mM β-mercaptoethanol. 
RAD51 protein was then eluted using a continuous NaCl gradient (20 mM TrisHCl pH 
8, 2 M NaCl, 10% Glycerol, 5 mM β-mercaptoethanol). The eluate was dialysed against 
RAD51 storage buffer (20 mM TrisHCl pH 8, 50 mM KCl, 0.5 mM EDTA, 1 mM DTT, 
10% Glycerol, 0.5 mM PMSF) and visualized on a 7.5% SDS-PAGE gel stained with 
Coomassie Brilliant Blue (Bio-Rad) or SYPRO Orange (Thermo Scientific). The protein 
concentration was determined using Bio-Rad protein assay.  
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His-tagged RPA was a kind gift from M. Modesti (IGH, Marseille). 
 
2.5.3 SDS PAGE AND WESTERN BLOT ANALYSIS  
All proteins 
Samples were heated in 1x SDS sample buffer for 5 min at 54°C, loaded on a stain-
free 7.5% SDS gel (Bio-Rad) with 6x SDS sample buffer and migrated at 130 volts for 
90 minutes in running buffer (1x Tris-Glycine, 0.1% SDS). The gel was visualized using 
a ChemiDoc camera (Bio-Rad).  
For transfer, a nitrocellulose membrane (VWR) was pre-equlibrated in ddH2O and in 
transfer buffer (1x Tris-Glycine, 0.025% SDS, 10% methanol). The proteins were 
transferred for 2 hours at 0.35 ampere in a cold box. The membrane was blocked in 
5% milk in 1x TBS-T at room temperature for 30 minutes and then incubated with the 
respective antibody in 5% milk in 1x TBS-T, shaking overnight at 4°C. After extensive 
washes in TBS-T, the membrane was incubated for 1 hour with the respective 
secondary HRP-antibody at room temperature on a shaker. After more washes, the 
membrane was developed using ECL prime western blotting detection reagent (VWR) 
and visualized using a ChemiDoc camera.  
 
DSS1 Western Blot 
Due to its small size, DSS1 is difficult to detect on WB and risks to be lost during 
transfer.  
Protein samples were heated in 1x SDS loading buffer at 54°C for 5 minutes and 
migrated on a 4-15% stain-free SDS Page Gel (Bio-Rad) for 45 minutes at 100 volt in 
1x SDS running buffer. A PVDF membrane (Dutscher) was activated in methanol for 5 
minutes and equilibrated in 25 mM KH2HPO4 buffer (pH 7.0). The same buffer was 
used for transferring the proteins on the membrane for 1 hour at 0.35 ampere in a cold 
box. The membrane was then fixed for 45 minutes shaking in 0.25% v/v glutaraldehyde 
(Sigma). After washing with 1x TBS-T, the membrane was blocked 5% milk in 1x TBS-
T at room temperature for 30 minutes and then incubated with the respective antibody 
in 5% milk in 1x TBS-T, shaking overnight at 4°C. After extensive washes in TBS-T, the 
membrane was incubated for 1 hour with the respective secondary HRP-antibody at 
room temperature on a shaker. After more washes, the membrane was developed 
using ECL prime western blotting detection reagent (VWR) and visualized using a 
ChemiDoc camera.  
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2.5.4  MOLECULAR CLONING 
All oligos used were purchased from MWG Eurofins and are listed in table in the primer 
list in the materials.  
PCR reactions in the study were performed using Taq DNA Polymerase (NEB) 
according to the manufactures manual and 1 ng of plasmid template.  
The reaction set up was the following: 
 
Component Final reaction 
10x Thermo Pol Buffer 1x 
dNTPs 200 μM 
Primer 1 0.2 μM 
Primer 2 0.2 μM 
Template DNA 1 ng 
Taq DNA polymerase 1.25 Units 
ddH2O To 50 ul 
 
Cycling conditions  
Step Temperature Time 
Denaturation 95°C 30 seconds 
30 cycles 95°C 
53°C 
68°C 
30 seconds 
30 seconds 
2 minutes 
Extension 68°C 5 minutes 
 
For restriction digests, enzymes were purchased from NEB and used according to 
the manufacturer’s manual. Ligation reactions were performed using T4 DNA Ligase 
(NEB) in 10 μl of total volume according to the manufacturer’s manual at 16°C 
overnight in a thermal cycler. The insert:vector ratio was calculated with Ligation 
Calculator (http://www.insilico.uni-duesseldorf.de/Lig_Input.html).  
For small scale plasmid isolation, QIAprep Spin Miniprep kit (QIAGEN) was used.  
For the purification of PCR products and purification of DNA products from agarose 
gels, Wizard SV Gel and PCR clean-up system (Promega) was used.  
For electrophoretic separation of DNA samples, 6x DNA loading dye was added to 
DNA samples and samples were loaded on a 1% agarose (w/v) gels in 1x Tris Acetate 
EDTA (TAE) buffer gel and visualized using an UV transilluminator (Vilber). 
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Site-directed mutagenesis 
For site-directed mutagenesis in small constructs, QuikChange II site-directed 
mutagenesis kit (Agilent Technologies) was used. Mutagenesis primers were designed 
using the QuikChange Primer Design program and purchased from MWG Eurofins. 
Standard reaction for mutagenesis: 
 
 
 
Component Final reaction  
10x reaction buffer 1x 
dNTP mix 1 μl  
Primer 1 125 ng 
Primer 2 125 ng 
Template DNA 45 ng 
PfuUltra HF DNA polymerase 2.5 units/μl  
ddH2O To 50 μl  
 
Cycling conditions 
Segment  Cycles  Temperature  Time  
1  1  95°C  30 seconds  
2  16 95°C  30 seconds  
55°C  1 minute  
68°C  1 minute/kb 
3 1 68C 5 minutes 
 
PCR reactions were cooled down and incubated with 1 μl DPNI for 2 hours at 37°C, 
spun down for 1 minute in a table-top centrifuge and 1 μl of reaction was transformed 
into 45 μl DH5 alpha electro-competent cells by electroporation. Cells were plated on 
LB plates containing the appropriate antibiotic and colonies were picked the next day 
for overnight cultures. Cultures were used for plasmid isolation that was sent for 
sequence verification to MWG Eurofins. 
For site-directed mutagenesis in large constructs, QuikChange II XL site-directed 
mutagenesis kit was used (Agilent). Mutagenesis primers were designed using the 
QuikChange Primer Design program and purchased from MWG Eurofins. 
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Standard reaction for mutagenesis: 
 
Component Final reaction  
10x reaction buffer 1x 
dNTP mix 1 μl  
Primer 1 125 ng 
Primer 2 125 ng 
Template DNA 45 ng 
Quik Solution 3 μl 
PfuUltra HF DNA polymerase 2.5 units/μl  
ddH2O To 50 μl  
 
Cycling conditions 
Segment  Cycles  Temperature  Time  
1  1  95°C  1 minute  
2  18 
95°C  50 seconds  
60°C  50 seconds 
68°C  1 minute/kb 
3 1 68C 8 minutes 
 
PCR reactions were cooled down and incubated with 1 μl DPNI for 2 hours at 37°C, 
spun down for 1 minute in a table-top centrifuge and 1 μl of reaction was transformed 
into 45 μl XL gold ultra-competent according to the manual. Cells were plated on LB 
plates containing the appropriate antibiotic and colonies were picked the next day for 
overnight cultures. Cultures were used for plasmid isolation that was sent for sequence 
verification to MWG Eurofins. 
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Ethanol Precipitation of DNA 
ddH2O was added to a total volume of 100 μl to the ligation or PCR product that was 
mixed with one tenth of volium of Sodium Acetate buffer pH 5.2 (3M). Three volumes of 
cold 100% ethanol was mixed to the solution and kept at -20°C for 2 hours. Sample 
was centrifuged for 15 minutes at 12.000 xg at 4°C. After the supernatant was removed 
without touching the pellet, 900 μl of cold 70% ethanol was added and centrifuged for 
10 minutes at 4°C at 12.000 xg. The supernatant was carefully aspirated and the pellet 
dried on at room temperature or in a heating block at 37°C. The pellet was 
resuspended in the desired volume of TE buffer.  
 
RT PCR 
For extraction of RNA, cells were grown on a 60 mm culture dish and RNA was 
extracted using TRIzol Reagent (ambion RNA – life technologies) according to the 
manual. The yield of the extraction was determined using NanoDrop. 
For the RT-PCR reaction, TITANIUM One-Step RT-PCR kit was used according to the 
manual using 0.5-1 μg of RNA sample and primers for the N-terminus (oAC14 and 
oAC033) as well as C-terminus (oAC041 and oAC188) for BRCA2 were used to ensure 
the presence of the whole cDNA in the stable clones. The PCR reactions were loaded 
on a 1% agarose gel and visualized using an UV transilluminator (Vilber). 
 
2.5.6 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)  
DNA substrates were purchased PAGE-purified from MWG Eurofins. Sequences can 
be found in the oligo list in the materials.  
The following oligonucleotides were used: 
oAC379: dT40 homopolymer. oAC423 (167mer), oAC403 (42mer), oAC490 (42mer), 
oAC405 (40mer), oAC406 (40mer) 
All DNA substrates were 32P radiolabeled at the 5’ –end using T4 Polynucleotide 
Kinase (NEB) and column purified with illustra MicroSpin G-25 columns (GE) The DNA 
concentration was calculated after column purification.  
ssDNA substrates used in EMSA assays were oAC379 and oAC423. To generate the 
dsDNA substrates, oAC405 was annealed in a 1:1 molar ratio to oAC406. The 3’ and 5’ 
overhang substrates were produced by annealing oAC490 (42mer -3’) to oAC423 
(167mer) or oAC403 (42mer -5’) to oAC423 in a 1:1 molar ratio, respectively. oAC423, 
oAC403 and oAC490 were annealed in a 1:1:1 ratio to produce the gapped DNA 
substrate. 
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The long dsDNA substrate was a PCR product (134 bp) amplified from pAC138 by 
PCR using the oligonucleotides oAC596 and oAC597, purified and 32P-labeled at the 5’ 
end.  
For the reaction, the proteins were incubated at the indicated concentrations with 0.2 
µM nucleotides 32P radiolabeled DNA substrates for 1 hour at 37°C in EMSA reaction 
buffer (25 mM Tris Acetate pH 7.5, 1 mM DTT, 1 mM MgCl2, 2 mM CaCl2). The protein-
DNA complexes were mixed with 6x DNA loading dye and resolved on 6% native 
polyacrylamide gels in 1x TAE buffer (40 mM Tris Acetate, 0.5 mM EDTA) at 70 volts 
for 75 minutes. The gels were dried and analyzed with a Typhoon PhosphorImager 
(Amersham Biosciences) using Image Quant software (GE Healthcare). The ratio of 
DNA-protein complexes was calculated as the percentage of bound DNA compared to 
the free DNA. The protein-free lane defined the value of 0 % complex. Statistical 
analysis and graphs were made with GraphPad Prism (version Mac 6.0e). Error bars 
represent the standard deviation derived from at least three independent experiments. 
2.5.7 BIOTINYLATED DNA PULL-DOWN ASSAY 
A dT80 oligonucleotide with a 3’-end biotin modification was purchased from MWG 
Eurofins. The oligonucleotide was incubated with Magnetic streptavidin beads (MyOne 
Dynabeads®, Thermo Scientific) pre-equilibrated in binding buffer (25 mM Tris Acetate 
pH 7.5, 1 mM MgCl2, 2 mM CaCl2, 1 mM DTT) for 2 hours at room temperature. After 
washing the beads extensively in washing buffer (25 mM Tris Acetate pH 7.5, 1 mM 
MgCl2 2 mM CaCl2, 1 mM DTT, 1 M NaCl, 0.3% Igepal-NP40), BRCA2T2 or BRCA2T1 
were incubated with pre-equilibrated beads-DNA (4.2 µM nucleotides) at 37°C for 30 
minutes on a rotating wheel. The samples were extensively washed in washing buffer 
before resuspension in 1x SDS loading buffer, boiled at 95°C and loaded on a 7.5% 
stain-free SDS gel (Bio-Rad). For competition assays, oAC379 (dT40 homopolymer) 
added to the protein sample at the indicated excess concentrations over the 
radiolabeled dT80 and the reaction was performed as described above. 
2.5.8 DNA STRAND EXCHANGE ASSAY  
DNA substrates were purchased PAGE-purified from MWG Eurofins. Sequences can 
be found in the oligo list in the appendix.  
For DNA strand exchange assays without RPA, proteins were incubated at the 
indicated concentrations with 4 nM molecules 3’ overhang DNA (oAC490 annealed to 
oAC423) or ssDNA (oAC423, see above for substrates) for 5 minutes at 37°C in 25 
mM Tris Acetate pH 8.0, 1 mM DTT, 2 mM ATP, 1 mM MgCl2, 2 mM CaCl2, 0.1 mg/ml 
BSA before adding 4 nM molecules dsDNA (oAC405 and oAC406 in 1:1 ratio, not 
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labeled) and further incubation for 30 minutes at 37°C. When RPA was added, the 
protein was incubated for 5 minutes with ssDNA or 3’overhang DNA, before adding 
other proteins. The reaction was stopped by adding 0.25 % SDS and 0.5 mg/ml 
Proteinase K for 10 minutes. Samples were loaded on a 6% Polyacrylamide gel, 
migrated at 70 volts for 75 minutes. The gels were dried and analyzed with a Typhoon 
PhosphorImager (Amersham Biosciences) using Image Quant software (GE 
Healthcare). For quantification, the ratio of DNA strand exchange products was 
calculated as the percentage of product compared to the free ssDNA whereas the 
value for product formation of RAD51 and RPA only reaction (usually lane 3) was 
subtracted from all values as “no product” value. Statistical analysis and graphs were 
made with GraphPad Prism (version Mac 6.0e). Error bars represent the standard 
deviation derived from at least three independent experiments. 
2.5.9 AFFINITY PULL-DOWN WITH AMYLOSE BEADS 
Prior to pull-down assays, amylose resin (NEB) was equilibrated with binding buffer: 50 
mM HEPES (pH 7.5), 250 mM NaCl, 0.5 mM EDTA, and 1 mM DTT. Purified 2XMBP 
2NLS BRCA2BRC4T2 or 2xMBP 2NLS BRCA2T2 protein (1.25 μg) was incubated with 1 
μg purified RAD51 for 30 minutes at 37 °C and then batch bound to 30 μL of amylose 
resin for one hour at 4 °C. The complexes were washed with binding buffer 50 mM 
HEPES (pH 7.5), 250 mM NaCl, 0.5 mM EDTA, and 1 mM DTT containing 1% Igepal 
CA-630. Proteins were eluted with 30 μL 10 mM maltose in binding buffer, the 
supernatant was taken off and 1x SDS sample buffer was added. Samples were 
heated at 54°C for five minutes and loaded onto a 4-15% gradient SDS-polyacrylamide 
gel (Bio-Rad TGX Stain-Free gel). 
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CHAPTER 3 
3.1 CHARACTERIZATION OF VARIANTS OF UNKNOWN CLINICAL 
SIGNIFICANCE IN THE N-TERMINAL DNA BINDING DOMAIN OF BRCA2 
Germ-line mutations in BRCA2 gene give rise to hereditary breast, ovarian or 
pancreatic cancer. Variants of unknown clinical significance remain a major concern in 
genetic counselling of individuals at high risk to develop cancer. Many missense 
mutations do not directly affect the protein’s localization or folding, thus their 
predisposition for tumorigenesis is uncertain. Because missense mutations in BRCA2 
associated with cancer risk can impair BRCA2 protein function, we set out to evaluate 
the phenotype of BRCA2 variants located in or around the N-terminal DNA binding 
domain (NTD) we identified in Chapter 2. Moreover, we were interested if the selected 
variants could also influence the role of BRCA2 in mitosis as it has been described for 
other N-terminal variants located in the same region 118.  
3.2  RESULTS 
3.2.1 SELECTION OF VUS IN EXON 10 COMPRISING THE NTD OF BRCA2 
Using the BRCAshare and Breast Cancer Information Core database209,210, we 
selected a set of variants of unknown clinical significance in the NTD of BRCA2 that 1) 
lie in or around the region where the NTD is located (see chapter 2) and 2) have a 
comparatively high Grantham score that predicts the probability of being deleterious 
based on the amino acid conservation and the chemical nature of the substitution 
207,238. We expect the functional characterization of these variants to help us to assess 
their likelihood to predispose to cancer and in addition, evaluate if the NTD is essential 
for BRCA2 function. We chose the VUS G267E,S273L and N277K as well as an 
artificial mutation (K268R) as their Grantham score is high and they are all located in 
the two DNA binding clusters identified by BindN (see chapter 2) 225. Moreover, the 
amino acids substituted in the selected VUS are highly conserved among mammalian 
species, as demonstrated by the multiple sequence alignment performed with Clustal 
Omega 228 (Figure 1). We also aim to phenotypically characterize the VUS C315S and 
C341S as well as the artificial mutation C279A that are relevant for DNA binding as 
described in Chapter 2.  
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The G267E missense mutation has nine entries in BRCAshare and six in the BIC 
database (Table 1). The K268R mutation is an artificial mutation that was chosen 
because it could affect DNA binding and lies in a putative Walker A motif, a domain 
involved in ATP binding and hydrolysis 239. S273L is recorded once in both databases.  
BRCA2 is implicated in midbody ring formation and in the recruitment of the 
endosomal-sorting complex required for transport (ESCRT) proteins necessary to 
complete cytokinesis 118,240. Some of these interactions map to the NTD region. In 
particular, N277K has been reported to abrogate the interaction of BRCA2 with the 
midbody components CEP55, Alix and Tsg101 118. the overexpression of the variant 
N277K exhibited elevated levels of multinucleation and cytokinetic bridges 118. We 
Figure 1 A) Selected variants in the NTD of BRCA2. Magnification of the region from 
which VUS where selected (shown in arrowheads, amino acid changes are indicated). 
B) Sequence alignment of BRCA2 residues 267-349 containing the missense mutations 
with other organisms using Clustal Omega. Asteriks (*) represent the conservation of 
residues in two or more organisms. Residues highlighted in green are predicted to bind 
DNA (BindN).  
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included N277K in our analysis as it has been listed 12 times in the BIC database and 
ten times in BRCAshare, making it an interesting candidate for further characterization 
in response to DNA damage, which has not been tested in the literature. 
 
VUS designation BIC BRCAshare Grantham score 
G267E 6 9 98 
K268R (artificial) N.A. N.A. N.A. 
S273L 1 1 145 
N277K 12 10 94 
C279A (artificial) N.A. N.A. N.A. 
C315S 15 4 112 
C341S 2 2 205 
Table 1: Selected variants of unknown clinical significance showing the number 
of entries in BIC and BRCAshare databases as well as their Grantham score. 
 
3.2.2  GENERATION OF STABLE CELL LINES IN BRCA2-/- CELLS 
For characterization of the missense variants in vivo, we introduced the point mutations 
by site directed mutagenesis into a BRCA2 wild type construct, coding for cDNA of 
human BRCA2 and a GFP-MBP tag at the N-terminus for visualization and purification 
of the protein. BRCA2-/- chinese hamster cell lines (VC8) 164 were transfected with the 
mutant constructs and put under Geneticin (G418) selection to create clones that 
stably express the wild type and mutant BRCA2 protein with G418 resistance. 
Surviving clones were verified by fluorescence activated cell sorting (FACS) for 
expression of the GFP-tag and further tested by RT-PCR with primers against the N-
terminus as well as the C-terminus of BRCA2 to verify the presence of the whole 
transcript (Figure 2 A, B).  
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A missense mutation may cause splicing defects leading to a deleterious phenotype, 
which could be confounded by the effect of the amino acid change or may lead to a 
compound effect. Thus, it is important to verify if the variants lead to splicing 
aberrations. Ex vivo splicing minigene assays can help to reveal splicing errors due to 
a point mutation 241. Our collaborator A. Martins (Rouen Univ.) tested two of the 
mutations, G267E and S273L, using the minigene assay, however, she did not find a 
defect in splicing as reflected in the mRNA pattern (Figure 2C). K268R was not tested 
as it is not listed as VUS and N277K was shown before as fully expressed in cells and 
at the same levels as the wild type, discarding a splicing defect 118. 
3.2.3 LOCALIZATION TO THE CHROMATIN 
Figure 2: Generation of stable cell lines in VC8 hamster cells: A) Example of 
FACS analysis of stably transfected VC8 (S273L) and untransfected cells to test 
clones for the expression of GFP-MBP BRCA2 (or variant) construct. B) RT-PCR 
using mRNA extracted from clones positive for GFP expression. C) Evaluation of 
exon skipping using minigene assay (Collaboration with Omar Soukarieh & 
Alexandra Martins (Inserm U1079, Rouen). 
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Many missense mutations in BRCA2 cause the inability of the protein to translocate to 
the nucleus. These mutations either lead to the expression of truncated versions or 
deregulate nuclear localization signals (NLS) as well as nuclear export signals (NES) 
131,134. 
Because the mislocalization of the protein per se entails the inability of BRCA2 to fulfill 
its function, this analysis excludes further characterization of the variant if positive. Due 
to the difficulties in the detection of BRCA2 expression in VC8 stable cell lines, we 
used overexpression in human HEK293 cells to assess their nuclear localization. We 
first tested the presence of the variant S273L in the cytoplasm and nucleus in response 
to DNA damaging agent MMC, as BRCA2 is known to accumulate at the sites of DNA 
damage. However, we could not detect a difference in the pool of proteins after DNA 
damage, probably due to the overexpression. In an attempt to do so, we further 
fractionated chromatin from the nuclear soluble fraction. Under our experimental 
Figure 3: BRCA2 localization to the chromatin. A) Overexpression of wild 
type or variant protein in HEK293s in the absence (-) or presence (+) of 
MMC. Presence of the proteins in the cytoplasmic or nuclear fraction 
detected by western blot with markers for BRCA2 and cytoplasmic and 
chromatin fraction markers (Tubulin, Histone). B) Fractionation experiments 
of HEK293 cells expressing wild type BRCA2 or variant proteins. Detection of 
the proteins in cytoplasmic (C), nuclear (N) or chromatin (CHR) fraction by 
western blot.  
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conditions, most BRCA2 was found in the nuclear soluble fraction and the cytoplasm. 
All four variants could localize to the nuclear soluble and chromatin fractions as the 
wild type (Figure 3) excluding the mislocalization and allowing us to continue with the 
functional characterization. 
3.2.4 RESPONSE TO DNA DAMAGE - SURVIVAL ASSAYS WITH MMC AND 
PARP INHIBITORS 
BRCA2 exerts a mediator function during homologous recombination. Absence of 
BRCA2 causes chromosomal aberrations because of a defective repair of DSBs and 
renders cells sensitive to DNA damaging agents 140,142,191. Indeed, BRCA2-/- cells are 
hypersensitive to DNA damage such as genotoxic agents, irradiation, UV light, MMS or 
MMC 39,98. Overexpression of the wild type protein in BRCA2 deficient cells rescues 
this phenotype and can be used as a functional tool to assess the effect of missense 
mutations 164,165.  
We used the VC8 stable clones expressing GFP-MBP-tagged wild type or mutated 
BRCA2, and the GFP-MBP vector alone as a control to test the sensitivity of the 
variants to the cross-linking agent MMC using clonogenic survival assays.  
Although we already tested the stable expression of the variant proteins by FACS and 
RT-PCR we wanted to see the protein expression by Western Blot analysis. We used 
the total cell lysate and visualized the proteins by Western Blot against BRCA2 (OP95). 
Surprisingly, we could only detect the expression of wild type BRCA2 and G267E but 
not of the three other proteins (K268R, S273L and N277K).  
 
However, in other studies using VC8 complementation, the expression could only be 
detected by IP studies 70,165. We will thus do the same tests using our VC8 stable cell 
lines and in addition set up a new human system where the cDNA of the variants is 
integrated into the genome (see 3.4).  
Figure 4: Expression test of stable clones. Equal amounts of total cell 
lysate were loaded on a 7.5% SDS PAGE and proteins were detected by 
Western Blot using an antibody against BRCA2 (OP95). 
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Thus, we resumed to perform the clonogenic survival assays with the VC8 stable cell 
lines. Cells were treated with 0.1–0.5 μM MMC for 1 hour and then seeded in different 
densities in 6-well plates to allow colony formation during eight to ten days. Cellular 
sensitivity to MMC caused by the inability to repair DNA damage is reflected by fewer 
or no colony formation as the cells die from toxic DNA lesions. As expected, ectopically 
expressed wild type BRCA2 led to the survival of VC8 cells in response to DNA 
damage, compared to the vector and VC8 cells alone (Figure 5A, C). Cell expressing 
the G267E variant were able to complement the cells. In contrast, K268R and S273L 
mutants could not rescue the phenotype and showed similar sensitivity to MMC as the 
negative control (vector or VC8 cells, Figure 5A, C). Thus the K268R and S273L 
variants seem to have a defect in DSB repair. Figure 4C shows the colony formation of 
1000 VC8 cells expressing wild type BRCA2, the empty vector or the variants treated 
with 0.5 μM MMC. Clearly, the ability of colony formation for wild type BRCA2 and 
G267E cells is normal, whereas vector control, K268R and S273L cells show almost no 
colony survival. In the case of N277K variant, a MTT assay was used in which cells are 
treated with the same MMC concentrations but the relative survival is measured based 
Figure 5: Response to DNA damage: A) Clonogenic survival assay with stable cell lines 
expressing wild type BRCA2, vector alone (BRCA2-/-) or variant proteins, treated with 
different concentration of MMC (n=3). B) MTT assay of stable cell lines of wild type 
BRCA2, vector alone (BRCA2-/-) or N277K after treatment with MMC (n=3). C) Colony 
formation after survival assay upon treatment with 0.5 μM MMC. 1000 cells were seeded 
for each cell line. 
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on the metabolic activity of the cells 72h after the treatment in a 96-well plate format. 
As shown in Figure 5B, wild type BRCA2 complemented the cells after exposure to 
DNA damage. The N277K mutant cells were sensitive to MMC and showed a 
decreased survival rate.  
BRCA2 deficient cells are not only sensitive to cross-linking agents such as MMC 164 
but also to Poly (ADP-ribose) polymerase (PARP) inhibitors that inhibit the enzyme 
PARP1, important for BER. In the absence of PARP, unrepaired damage can lead to 
the collapse of replication forks that may be converted into DSB 215, thus, the 
resistance to PARP inhibitors can be used as an indirect measure of HR. This principle 
has been exploited as a therapeutic tool for the treatment of BRCA2-deficient tumors 
as they depend on PARP1 to repair these DSBs 214. 
We tested the survival of BRCA2+/+ V79 cells (VC8 parental cell line) as a positive 
control, vector only and variant-complemented VC8 cells in their response to ABT-888, 
a PARP inhibitor in phase II clinical trial for the treatment of various cancers 
(https://clinicaltrials.gov/ct2/home). We monitored the cell survival after treatment with 
ABT-888 in different doses using a MTT assay as described above.  
As expected, cells complemented with wild type BRCA2 and V79 cells survived the 
treatment (Figure 6). In agreement with the results obtained from the clonogenic 
survival assay, cells carrying G267E mutation were resistant to PARP inhibitor 
treatment. In contrast, cells complemented with the variants K268R, S273L and N277K 
could not survive the treatment. 
Figure 6: Relative survival of VC8 stable cell lines expressing wild 
type BRCA2, empty vector (BRCA2-/- 2xMBP) or VUS proteins (as 
indicated), in response to different concentrations of the PARP 
inhibitor ABT-888, n=3. 
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Taken together, our results identify two VUS (S273L and N277K) and one artificial 
mutation (K268R), as being sensitive to the cross linking agent MMC as well as to the 
PARP inhibitor ABT-888, speaking for a defect of these variant proteins for the repair of 
DSBs via HR. The missense mutations seem to affect residues important for BRCA2 
function in HR. In addition, we show that the G267E VUS is capable of repairing DSBs 
induced by MMC and is not affected by PARP inhibition. When we tried to see the 
expression of the proteins from total cell lysates, we could only detect wild type BRCA2 
and G267E sufficiently expressed by western blot analysis (Figure 4). This poses a 
major concern for the results obtained in the survival assays as we now cannot totally 
exclude that the phenotypes observed for K268R, S273L and N277K originate from a 
possible loss of the cDNA and thus, the cells do not express the variants anymore.  
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3.2.5 BRCA2 VUS G267E EXHIBITS A COLONY GROWTH DEFECT  
When we examined the shape and number of the colonies in the absence of treatment 
in the survival assay one of the variants that did not show sensitivity to DNA damage 
exhibited a small colony phenotype in comparison to wild type BRCA2 complemented 
cells The colonies of G267E were not only smaller but exceeded the colony number by 
two fold compared to the wild type (Figure 7). BRCA2 has been shown to have multiple 
roles in mitosis and cells expressing mutant forms of BRCA2 show cytokinetic 
abnormalities resulting in alterations of chromosome number and structure 173. In 
particular, these cells progress slower in mitosis and display defects in the completion 
of cytokinesis. This is probably due to the role of BRCA2 as a scaffold to allow the 
localization of components of the central spindle to the midbody (see 1.9). Thus, one 
possibility to explain G267E phenotype could be that it affects this function. This is the 
case of N277K, a mutation known to disrupt the interaction between BRCA2 and 
CEP55, leading to an increase of multinucleated cells and unresolved cytokinetic 
bridges due to incomplete abscission 118. 
3.2.6 BRCA2 G267E VARIANT SHOWS ABNORMAL CYTOKINESIS 
Because G267E didn’t show a defect in survival after DNA damage, but led to a small 
colony phenotype that could be indicative of a failure in cell duplication we set out a 
time –lapse microscopy experiment to follow cells through mitosis in living cells.  
We synchronized the VC8 stable cells via G1/S phase arrest using double thymidine 
block and released the cells after 48h to monitor their progression through the cell 
Figure 7: Colony formation in the absence of DNA damage in 
clonogenic survival assay of cells complemented with wild type 
BRCA2 (left) or with the mutant G267E. 1000 cells seeded. 
(n=3).  
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cycle. Cells were recorded during 16 hours and pictures were taken every 5 minutes 
from 4 different positions in each well. Time-lapse pictures were analyzed by 
evaluating the time needed for individual cells to complete cytokinesis from the 
beginning of mitosis. Normal progression was based on V79 parental cell line 
(BRCA2+/+).  
Analysis of representative images of the time-lapse microscopy showed that after 
entering mitosis (≥ 10 minutes), wild type BRCA2 cells divided after 45 minutes and 
cytokinesis was eventually completed in about 60-70 minutes (Figure 8A, left panel), 
which is considered as a normal timeframe for mitotic progression 173. In contrast, 
BRCA2 deficient cells complemented with the vector only entered mitosis but started to 
divide at a later time point (≥ 55 minutes) and were not able to separate even after 
~200 minutes. Interestingly, some of the daughter cells failed to separate completely 
(Figure 8A, right panel). Hence, in our experimental conditions, BRCA2 deficient cells 
display a defect in cytokinesis as described before 165 Importantly, when we performed 
the same time-lapse microscopy analysis with variant G267E we observed a similar 
pattern as for the BRCA2-/- cells (Figure 8A lower left panel).The cells entered mitosis 
normally (≥ 15 minutes) and started to separate into two daughter cells (45 minutes). 
However, daughter cells stayed connected until ~300 minutes after entering mitosis, 
when they completed abscission as illustrated for G267E in Figure 8A (lower panel, in 
200 and 300 minutes pictures).In addition, similar to the vector alone-transfected cells, 
60% of the cells expressing G267E took longer than 100 minutes to complete 
cytokinesis (Figure 8B). 
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3.2.7 BRCA2 VARIANT G267E LEADS TO MULTINUCLEATED CELLS  
Incomplete cytokinesis leads to the formation of bi-and multinucleated cells which 
ultimately favors aneuploidy and multiple spindle poles, hallmarks of many tumors 242. 
Thus, we next evaluated the effect of G267E on cell division by performing in situ 
immunofluorescence using an antibody against the microtubule-associated protein 
alpha-tubulin as a marker of cell division. As shown in Figure 9 (panels on the left and 
quantification on the right), wild type BRCA2 complemented cells and V79 (BRCA2+/+ 
control cells) showed almost no multinucleation. In contrast, expression of either the 
vector 
Figure 8: Time-lapse microscopy of stable cell lines after double thymidine block and release 
in G1/S phase during 16h. A) Representative images of cells undergoing mitosis are shown 
for wild type BRCA2, empty vector (BRCA2-/-) and G267E. Arrowheads indicate the 
separation of daughter cells during cytokinesis and individual cells after completion of 
abscission. B) Quantification of time-lapse experiments shown in A). Percentage of cells that 
needed a certain time for division (0-100 minutes, 100-200, 200-300, > 300 minutes or failed 
to divide) were analyzed.  
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or the G267E variant in VC8 resulted in up to seven fold increase of multinucleated 
cells. In addition, G267E stables often stayed connected via microtubule bridges 
(G267E, Figure 9 right panel). This phenotype may result from the failure in cytokinesis 
that was observed in the time-lapse experiments (Figure 8A lower panel and 8B). 
Together, these results show that G267E variant leads to cytokinetic defects as 
observed for BRCA2-/- cells and other BRCA2 variants 118 resulting in multinucleated 
cells.  
 
 
Figure 9: In situ immunofluorescence (IF) microscopy images of the stable cells 
lines showing bi-and multinucleated cells. A) Representative images for each cell 
line, arrows indicate binucleated cells and unresolved cytokinetic bridges. B) 
Quantification of bi-or multinucleated cells from 3 individual experiments. Nuclei 
are stained with DAPI (blue) and microtubules are stained with an antibody against 
alpha-tubulin (red). Images were taken using a 4-5D microscope. 
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3.2.8 G267E DOES NOT AFFECT CENTROSOME DUPLICATION 
Centrosomes are the microtubule organization centers in the cell and are important 
for proper segregation of the chromosomes in mitosis. Centrosome amplification 
might be a consequence of incomplete cytokinesis leading to chromosome 
instability and aneuploidy. BRCA2 deficient cells show centrosome amplification 
and multinuclei, both hallmarks of several tumors 203. BRCA2 localizes to the 
centrosomes via its centrosome-localization signal (aa 2884–2903) and may have 
a role in their duplication by interacting with centrosomal proteins such as CEP55 
163. We evaluated the effect of the variant G267E on centrosome duplication by IF 
using an antibody against the centrosome-associated protein Centrin-2. Unlike 
BRCA2 deficient cells, VC8, cells carrying G267E variant did not exhibit 
centrosome amplification (Figure 10) indicating that the multinucleation phenotype 
does not originate from defective centrosome duplication.  
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Figure 10: In situ immunofluorescence microscopy images showing centrosomes using an 
antibody against centrin-2 (red), DAPI staining is used for DNA A) Representative images 
of cell lines tested. B) Quantification of three independent experiments showing the 
percentage of cells with centrosome amplification (>2 centrosomes). 
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3.2.9 G267E DOES NOT AFFECT THE INTERACTION WITH MIDBODY 
PROTEINS 
 
Cytokinetic failure and multinucleated cells may also arise from defects in midbody 
formation. Filamin A recruits BRCA2 to the midbody, where it interacts with CEP55, 
needed for formation of the midbody ring and the localization of the ESCRT complex 
components required for cell separation. In particular, BRCA2 regulates the complex 
formation of CEP55-Alix and CEP55-Tsg101 at the midbody 118,176 (see Figure 11A). 
Figure 11: BRCA2 is involved in midbody formation. A) Model of BRCA2 
interaction with several midbody proteins (Mondal et al. 2012). BRCA2 localizes 
with Filamin A from the spindle midzone to the midbody where it interacts with 
midbody components CEP55, Alix and Tsg101. Absence of BRCA2 causes 
failure in cytokinesis and multinucleated cells. B) Effect of BRCA2 missense 
variants on interaction with proteins involved in midbody formation and in 
mitotis. Analysis of anti-FLAG IPs with FLAG-BRCA2 WT or variant proteins 
overexpressed in HEK293T cells after double thymidine block and 9h release 
(Collaboration w. F. Couch, Mayo clinic). 
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The group of F. Couch had shown previously that N277K variant favors multinucleated 
cells and unresolved cytokinetic bridges due to the disruption of the interaction with 
CEP55 and Tsg-101. So, we established collaboration with F. Couch group to test 
G267E, K268R and S273L for the interaction with the midbody components. In 
addition, the variants were tested for the ability to interact with PLK1 that 
phosphorylates BRCA2 in order to localize to the midbody 114 as well as the 
acetyltransferase P/CAF for which BRCA2 acts as a scaffold to acetylate BubR1 at the 
spindle assembly checkpoint 117 (see 1.9). Surprisingly, inspite of the cytokinetic 
phenotype, and in contrast to N277K, G267E did not disrupt any of the interactions with 
midbody proteins; neither did K268R and S273L (Figure 11B). 
Thus, cells carrying G267E variant are proficient in the survival after DNA damage, and 
the small colony phenotype observed probably stems from the defective cytokinesis, 
however, it remains unclear what is the mechanism underling the cytokinetic failure 
observed. Because of their localization in the NTD of BRCA2, we are currently testing 
the DNA binding ability of the mutants G267E, K268R, S273L and N277K. 
3.3 CONCLUSIONS 
We applied several functional assays to study variants of unknown clinical significance 
located in a novel N-terminal DNA binding domain we identified. The selection of the 
variants was based on their high probability to have a deleterious phenotype. In Table 
1, I have summarized the results from the functional assays for each variant. More 
assays have to be applied to further study their phenotype.  
The G267E variant has a Grantham Score of 98 and is listed in total 12 times as VUS 
(BRCAshare; BIC). Cells complemented with this variant are not sensitive to DNA 
damage (Figure 4 & 5) excluding an HR defect. They show faster growth than wild type 
BRCA2 cells (Figure 7), but the colonies are small and 60% of them show a delayed 
completion of cytokinesis (Figure 8). This phenotype correlates with an increased level 
of multinucleated cells (Figure 9). Both phenomenons speak for a defect in the late 
steps of cytokinesis. However, this defect is not due to a disrupted interaction with 
important midbody components or centrosome amplification (Figure 11).  
The other variants tested showed deleterious phenotypes in our assays. Since we 
could not detect their expression as for wild type BRCA2 and G267E (Figure 4), we 
cannot conclude that this comes from an impaired function conferred by the variant or 
absence of expression. So far we can only be certain that all variants showed a normal 
localization to the nucleus and interaction with midbody proteins in HEK293 cells.  
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The K268R is an artificial mutation not listed in any database for BRCA2 VUS. In 
survival assay with MMC and after treatment with PARP inhibitors, the cells have a 
DNA damage-sensitive phenotype. They also exhibit a cytokinetic defect in the time-
lapse analysis but we have not analyzed their status of multinucleation and centrosome 
amplification yet. However, the variant protein was able to interact with the midbody 
components. We will need to further test if the HR defect we see might be in 
connection with the growth defect. 
The same phenotype we observed for the S273L VUS, listed two times in the 
databases 209,210. Hence, the same functional analysis will be applied for this variant as 
for K268R. 
We selected the N277K mutant as it has been already tested in functional assays, 
revealing a defective phenotype in midbody formation and cytokinesis 118. We were 
interested in its behavior in functional assays for HR. The MMC and PARP inhibitor 
treatments revealed a defect DSB repair. We are now interested if there could be a  
Variant 
MMC/ 
PARPi 
sensitive 
Cyto-
kinetic 
defect 
Multi-
nucleation 
Centrosome 
amplification 
Interaction 
with 
midbody 
proteins 
DNA 
binding 
proficient 
G267E No yes yes no Yes TBT 
K268R Yes yes TBT TBT Yes TBT 
S273L Yes yes TBT TBT Yes TBT 
N277K Yes yes TBT TBT Yes TBT 
Table 2: Summary of the results from functional assays obtained in this study for each 
variant tested (TBT – to be tested).  
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connection between the defects in HR and mitosis as the BRCA2 protein is also 
involved at different cell cycle checkpoints 117,169,172.   
In addition to these variants, we are currently characterizing the variants located in the 
NTD described in chapter 2, C279A, C315S and C341S by clonogenic survival and 
homologous recombination proficiency 
3.4  DISCUSSION AND OUTLOOK FOR THE CHARACTERIZATION OF VUS 
For the cancer risk assessment of individuals carrying VUS, it is of major importance to 
evaluate their influence on BRCA2 function 207,213. Goldgar et al. (2004) developed a 
multifactorial likelihood-ratio model that predicts the causality of a VUS based on a 
combination of co-segregation, family history of individuals carrying the mutation, co-
occurrence of VUS and deleterious variants in cis, and multiple sequence alignment of 
the protein regarding the amino acid conservation and the biochemical nature of the 
substitution 207. However, this model is only applicable for frequent VUS with enough 
family data available 243. Hence, functional assays that focus on the effect of the amino 
acid changes on the function of the protein are still needed to classify VUS. In the work 
presented here, we assessed the impact on the function of several missense variants 
located in the NTD of BRCA2 that remain unclassified.  
Due to the difficulties to detect the expression of some variant proteins in VC8 cells 
(Figure 6), we are currently setting up a system where the cDNA of the variant is 
integrated into the genome.  
The cDNA of EGFP-BRCA2 or VUS proteins are integrated at the FRT site in the 
genome of HEK293 cells by using the FLP-IN (Invitrogen) system. The expression of 
endogenous BRCA2 can be downregulated by siRNA and expression of the siRNA-
Figure 12: Scheme of TREX Flag eGFP BRCA2 shR construct stably integrated in 
the genome of HEK293 cells using the FLPin system at the FRT site. Upon 
Doxycyclin induction of the Tetracyclin Response Element (TRE) promoter, EGFP-
BRCA2 or variant proteins are expressed while downregulation of endogenous 
BRCA2 with siRNA to which construct is resistant. Courtesy of Å. Éhlen. 
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resistant protein of interested is induced using Doxycyclin that binds to the Tetracycline 
responsive element (TRE) (see Figure 12). 
In these cells we will assess the cellular localization, survival assays with DNA 
damaging agents, time-lapse and immunofluorescence microscopy as described above 
to confirm the cytokinetic defects observed with G267E and to test the phenotype of 
the variants for which the expression was not detected in VC8.  
To further assess the impact of the variants on BRCA2 function we will use a cell-
based recombination assay employing site-specific endonucleases in a modified 
protocol from the one described 244: Briefly, cells are transfected with a pZDonor 
AAVS1-EGFP plasmid as well as zinc-finger nucleases (TALENs) AAVS1R and AAVS1L. 
The nucleases create a DSB at a native AAVS1 locus. The promoter-less mCherry 
gene in the donor plasmid is located between sequences homologous to those flanking 
the AAVS1 site. DSB-promoted gene targeting results in GFP expression from a 
PPP1R12C native promoter when the donor plasmid is repaired at the AAVS1 site by 
HR (see Figure 13). Using this system, we will evaluate the impact of the variants on 
the HR function of BRCA2. 
In addition, because these variants are located in the DNA binding site in the N-
terminus we will use the DNA binding and DNA strand exchange assays described in 
Chapter 2 to evaluate their impact on DNA binding and promotion of RAD51 
recombination activity in vitro. A defect of the mutants in DNA binding, could explain 
the DNA damage hypersensitivity observed in some of these variants. However, as the 
DNA binding activity could be accomplished by the CTD in cells, a reduced DNA 
Figure 13: from Yata et al. 2012: Schematic representation depicting DSB-induced 
gene targeting. Cells are transfected with zinc-finger nucleases (TALENs) AAVS1R 
and AAVS1L that cut at the AAVS1 ZFN site creating DSB. The pZDonor AAVS1-
EGFP plasmid is integrated in the AAVS1 site by HR repair and promoterless GFP 
can be expressed from the PPP1R12C native promoter. 
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binding activity of the NTD might not affect the survival. 
It has been suggested that unsegregated chromosomes due to unrepaired DNA 
damage can persist after anaphase and provoke unresolved chromatin bridges and 
ultra-fine bridges that result in delayed or failed abscission and cytokinesis 174. 
However, these structures were not observed in BRCA2 mutant cells affecting 
cytokinesis arguing that the role of BRCA2 in cytokinesis is independent of its function 
in DNA repair118. Our data with mutant G267E is consistent with this idea as the 
survival after DNA damage was not affected by this mutation whereas it showed a 
clear defect in cytokinesis..  
To obtain a more complete picture of variants in the NTD, we will apply the cell-based 
assays for testing HR and cytokinetic defects in the variants chosen during our 
biochemical study of the NTD (C279A, C315S, C341S). Moreover, there are several 
VUS candidates listed with many entries in the BRCA2 databases that would be also 
interesting to test.  
The advantage of combining cell-based assays to test DNA damage repair and 
cytokinetic defects with in vitro DNA binding assays is clearly the capability to explain 
the phenotype observed and understand the impaired mechanistic behind. 
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3.5 METHODS 
3.5.1  CLONING OF CONSTRUCTS USED FOR EXPRESSION, PURIFICATION 
AND CELL BASED ASSAYS: SEE 2.4 
3.5.2  PURIFICATION OF RECOMBINANT PROTEINS: SEE 2.4 
3.5.3  SDS PAGE AND WESTERN BLOT ANALYSIS: SEE 2.4 
3.5.4  MOLECULAR CLONING: SEE 2.4   
3.5.5 GENERATION OF STABLE CELL LINES  
VC8 brca2-/- deficient hamster cells lines were cultured in HAM’s F10 media with 10% 
FCS and grown to 70% confluency in a P100 mm plate. Cells were transfected with 10 
μg DNA of the respective phCMV1-GFP MBP plasmid containing the WT, variant or 
vector only cDNA using Turbofect transfection reagent (Invitrogen) according to the 
manual. 48 hours later 1 μg ml-1 Geniticin (G418) was added to the cells to select only 
the transfected cells expressing the G418 resistance markers.  
Cells were cultured until individual clones had formed that were transferred to 96-well 
plates and cultured until the stable cell lines grew in P100 mm plates and were ready 
for testing the expression of the proteins. First, the expression of the GFP tag was 
tested in FACS analysis: Cells were harvested from P60 mm plates and washed twice 
in 1x PBS. As a negative control, non-transfected VC8 cells were used. Several clones 
of each cell line created were tested in a FACScalibur using the FL-1: 530/30 (FITC, 
Alexa488, GFP, YFP) laser measuring the GFP content. The clones with GFP 
expression over the threshold were selected and used for RT-PCR analysis. Cells were 
harvested from a confluent P60 mm plate and mRNA was extracted with Trizol as 
described above. mRNA was transcribed into cDNA using RT-PCR protocol (see 
above) and positive clones containing both N-terminus and C-terminus of the protein of 
interested were selected and kept for further in vivo assays. 
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3.5.6  CLONOGENIC SURVIVAL ASSAY WITH MMC 
For clonogenic survival assays with transiently transfected cells, VC8 brca2 deficient 
variant hamster cells were cultivated in HAM’s F10 media (Invitrogen) plus 10 % FBS 
(Invitrogen). The cells were transiently transfected using TurboFect (Thermo Scientific) 
at 70 % confluency with 10 µg of DNA. 30 hours post-transfection, cells were 
transferred to HAM’s F10 media (Invitrogen) plus 10 % FBS (Invitrogen) containing 1 
μg ml-1 G418 for 3 days. The protein expression was verified by incubating 3-5 mg of 
total cell lysate (determined by Bio-Rad protein assay) with amylose beads (NEB) 
overnight at 4°C with rotation. The beads were extensively washed in Lysis Buffer H 
(50 mM HEPES (pH 7.5), 250 mM NaCl, 5 mM EDTA, 1% Igepal CA-360, 1 mM DTT, 
1 mM PMSF and EDTA-free Protease Inhibitor Cocktail (Roche) and resuspended in 
1x SDS sample buffer, boiled and loaded on a 7.5% stain-free SDS PAGE gel. The gel 
was transferred on a nitrocellulose membrane (VWR) and detected by Western Blot 
using anti-MBP antibody (mAB R29, Invitrogen). In survival assays with stable cell 
lines, cells were used directly for the assay. 
For the survival assay, 0.8 x106 cells were seeded in 6 cm dishes and the next day 
were treated with Mitomycin C (Sigma-Aldrich) at the following concentrations: 0.1 µM, 
0.25 µM or 0.5 µM or 1 µM for 1 hour in the dark in media without serum. The cells 
were then counted, serially diluted and plated out in triplicate into 6-well plates. Cells 
were re-fed with media containing penicillin/ streptomycin (Sigma-Aldrich= to prevent 
any contamination during eight to ten days of cell growth. After eight days, the colonies 
were stained with crystal violet solution (Bio-Rad) for 1 hour, washed and dried 
overnight. The colonies were counted on each plate using ImageJ software and the 
surviving fraction was determined for each drug treatment. Statistical analysis and 
graphs were done with GraphPad Prism (version Mac 6.0e). Error bars represent the 
standard deviation derived from at least three independent experiments. 
For survival MTT assays in 96-well format, stable cell lines were seeded in 96-well 
plate and treated the next day with 0 μM, 0.1 μM, 0.25 μM and 0.5 μM MMC for 1 hour. 
The media was removed and cells recovered for 72 hours until 0.5 mg/ml MTT in 1x 
PBS was added and incubated for 4 hours. The media was then removed and DMSO 
was added to the wells, incubated for 5 minutes at room temperature and the 
absorbance was measured in a plate reader at 570 nM.  
 
 
3.5.7  TREATMENT WITH PARP INHIBITORS  
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Stable VC8 cell lines were tested for their survival in response to PARP inhibitor 
Veliparib (ABT-888) purchased from Selleck Chemicals that inhibits PARP-1 and 
PARP-2. Cells were seeded in 96-well plates. The next day, cells were treated with 0 
μM, 10 μM, 50 μM or 100 μM ABT-888 for 24 hours in selection medium. On day three, 
the inhibitor was removed and cells could recover for 72 hours. 0.5 mg/ml MTT solution 
was added to the wells and incubated for 4 hours at 37C before replacing the media by 
DMSO. After 5 minutes of incubation at room temperature, the absorbance was 
measured in a plate reader at 570 nm.  
3.5.8 IMMUNOFLUORESCENCE MICROSCOPY WITH VC8 STABLE CELL 
LINES 
The day before VC8 stable cells (0.8x105 to 1x105) were seeded in 24-well plates on 
coverslips for attachment on the glass. The next day, the media was removed and 
coverslips were washed with 1x PBS and then washed in CSK buffer for pre-extraction 
(10 mM PIPES pH 7.0, 100 mM NaCl, 300 mM Sucrose, 3 mM MgCl2, 1x Protease 
Inhibitor cocktail (EDTA-free, Roche). Cells were incubated for 5 minutes at room 
temperature in CSK buffer (100 mM NaCl, 300 mM Sucrose, 3 mM MgCl2, 10 mM 
PIPES (pH 6.8) plus 0.5% Triton X-100 and washed again in CSK buffer and 1x PBS. 
Cells were then fixed with 3% paraformaldehyde in 1x PBS for 20 minutes at room 
temperature. After washing, cells were permeabilized with 1x PBS + 0.5% Triton X-100 
on ice for 10 minutes and washed. Blocking was done in 5% BSA in PBS for 1 hour at 
room temperature. The primary antibody (1:500 Centrin-2 antibody for centrosome 
amplification assay; 1:500 alpha-tubulin antibody for visualization of bi-and 
multinucleated cells) was added in 5% BSA and incubated overnight. After washing in 
1x PBS, secondary antibodies, coupled to fluorophores (Alexa555 anti-mouse for 
tubulin and Alexa555 anti-rabbit for Centrin-2 at 1:750) were incubated for 1 hour at 
room termperature in the dark. ddH2O was added to the well and after drying, the 
coverslip was mounted on mounting media (ProLong® Gold antifade reagent with 
DAPI). Immunofluorescence microscopy was performed in a 3D deconvolution 
microscope (Leica). 
3.5.9 TIME LAPSE MICROSCOPY 
For time-lapse experiments, stable cell lines were seeded on 12-well plates in 
duplicates in the morning and treated with Thymidine (2 mM) for 16h. After two 
washes, fresh media was added and cells grew for 8h, before adding thymidine for a 
second time (2 mM) to block cells in S phase. After 16h, the media was removed and 
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cells were washed two times before adding normal media and let them grow for 6 more 
hours. Time-lapse microscopy was performed during 17h and pictures of four different 
positions were taken every 5 minutes of each well (two wells per clone) using a 4-5D 
video microscope (Nikon). The data was analyzed using Image J and GraphPad Prism 
for quantification.  
3.5.10  FRACTIONATION EXPERIMENTS  
HEK293 cells were grown to 70% confluency and transfected with 10 μg of the 
respective GFP-MBP plasmid DNA using TurboFect transfection reagent (Invitrogen). 
After 30 hours of expression, cells were harvested in 1x PBS (500 xg, 5 minutes at 
4°C). 
For fractionation experiments with HEK293 cells plus MMC treatment, transfected cells 
were incubated with 1 μM MMC (Sigma-Aldrich) for 1 hour at 37°C and then collected 
in 1x PBS (500 xg 5 minutes at 4°C). 
Cells were resuspended in BAD-T buffer (50 μl buffer per 16  cells): 10 mM HEPES pH 
7.5, 10 mM KCl, 10% glycerol, 1.5 mM MgCl2, 0.34 M Saccarose, 0.1% Triton X-100 
and incubated for 20 minutes on ice. After centrifugation at 1300 xg for 5 minutes at 
4C, the supernatant was taken off and stored on ice (cytoplasmic fraction). The 
nuclear pellet was washed with 2 ml BAD buffer (10 mM Hepes pH 7.5, 10 mM KCl, 
10% glycerol, 1.5 mM MgCl2, 0.34 M Sucrose) and spun down at 1300 xg for 5 minutes 
at 4C. The nuclear pellet was resuspended in Lysis Buffer H (50 mM Hepes pH 7.5, 
250 mM NaCl, 5 mM EDTA, 1% Igepal-NP40, 1 mM DTT, 1mM PMSF and 1x Protease 
Inhibitor Cocktail (EDTA-free, Roche) and lysed for 20 minutes on a rotating wheel at 
4C. After centrifugation at 10.000 xg for 20 minutes at 4C, the supernatant was 
collected (nuclear fraction). The remaining pellet was resuspended in 500 μl no-salt 
buffer (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 0.1 mM PMSF, 1x Protease Inhibitor 
Cocktail (EDTA-free, Roche)) and incubated on ice for 30 minutes with occasional 
vortexing. Suspension was spun down at 1780 xg at 4°C and the pellet was washed 
with no-salt buffer, centrifuged again and the pellet was then resuspended in 1x SDS 
loading buffer, heated for 3 minutes at 95°C and sonicated for 15 seconds (6 microns 
peak to peak) before loading on a gel. The protein content of cytoplasmic and nuclear 
fractions was determined by Bio-Rad protein assay for equal loading. Cytoplasmic, 
nuclear and chromatin fractions equally in protein concentrations were loaded on a 4-
15% SDS gel and ran at 130 volts for 1hour 30 minutes in 1x SDS running buffer. The 
gel was then transferred to a nitrocellulose membrane as described for Western 
Blotting. Proteins were visualized with the appropriate antibody, histone H3 antibody 
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was used as a control for correct fractionation of the chromatin fraction, tubulin to test 
for the cytoplasmic fraction.  
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CHAPTER 4  
4.1 STUDY OF THE INTERACTION BETWEEN BRCA2 AND THE MEIOTIC 
RECOMBINASE DMC1 
DMC1 is the meiotic counterpart of RAD51 as it forms nucleoprotein filaments for 
homology search and strand invasion (D-loop formation) in meiosis I in a similar 
fashion. As described in Chapter 1.10, the physical interaction between DMC1 and 
BRCA2 has been demonstrated before however, the functional significance of this 
interaction remained unclear. In humans, a motif conserved in mammalian species was 
reported to be responsible for the binding 70,101,181,183,184 . However, in mice a mutation 
predicted to disrupt the conserved motif had no impact on meiotic recombination 187. 
Because of the structural conservation of RAD51 and DMC1, especially at the interface 
where the BRC repeats bind to RAD51, 120,146 we set out to investigate if the BRC 
repeats can interact with DMC1 and if so, whether or not BRCA2 acts as a mediator on 
meiotic recombination, analogous to its function in mitotic recombination.  
First, we examined the binding affinities of DMC1 to the BRC repeats of BRCA2 using 
purified protein and peptides, respectively. Almost all BRC repeats bound DMC1 
although the affinities where, in some cases, much lower than for RAD51. The BRC 
repeat interact with RAD51 via 2 modules (4.2 Figure 1A) 146. Surprisingly, a BRC4 
repeat mutated in module I, necessary for the interaction with RAD51, could still bind 
DMC1 even at higher affinity than BRC4, indicating that the BRC repeats bind DMC1 
via a different motif than RAD51 (4.2, Figure 1 B, C).  
To find out the functional relevance of this interaction we next determined whether the 
BRC repeats could stimulate DMC1 recombination function. Juan Martinez (postdoc in 
the lab) performed a joint-molecule assay, and found that the individual BRC repeats 
promote joint molecule (D-loop) formation by DMC1 (4.2, Figure 2). 
In RAD51, two classes of BRC repeats, class I (BRC 1-4) and class II (BRC5-8), 
promote RAD51 filament formation and DNA strand exchange. On the one hand, class 
I limits RAD51 ATPase activity to stabilize the ssDNA-RAD51 filament and blocks 
dsDNA binding for the promotion of strand exchange activity. On the other, class II 
further supports the filament growth by facilitating binding and stabilizing already 
formed RAD51 filaments on ssDNA 124. Thus, to find out the mechanism behind the 
stimulation of D-loop formation observed we tested the ssDNA binding of DMC1 in the 
presence of each BRC repeats. All BRC repeats promoted the ssDNA binding except 
BRC4 that, inhibited D-loop formation, In addition, none of the BRC repeats except 
BRC4 inhibited assembly on dsDNA (4.2, Figure 5), discarding this as a mechanism for 
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the stimulation of D-loop formation. These results suggest that the stimulatory action 
on DMC1-ssDNA complex stabilization is the basis for the enhanced joint molecule 
formation observed. The BRC repeats only marginally affected the ssDNA-dependent 
ATP activity of DMC1 (4.2, Figure 4 & S3) distinguishing the mechanism of stimulation 
from that of RAD51.  
To confirm these results with the full-length protein we purified BRCA2 as described in 
chapter 2 and analyzed the effect on the ATPase, joint molecule formation and DNA 
strand exchange. BRCA2 did not affect the ssDNA dependent ATPase of DMC1 
confirming the results with the BRC repeats and in contrast to the effect on RAD51 70 . 
Juan Martinez performed the joint molecule assay with DMC1 and increasing 
concentrations of BRCA2 and found that, indeed, BRCA2 stimulates DMC1 D-loop 
formation. In addition, in collaboration with the group of Steve Kowalczykowski, we 
showed that BRCA2 was also able to alleviate the kinetic barrier posed by RPA on the 
ssDNA and allowed DMC1 DNA strand exchange in vitro, a feature that defines a 
mediator of recombination (4.2, Figure 6&7).  
We thus identified BRCA2 as a mediator of meiotic recombination. The detailed 
experimental setup, results and discussion can be found in the published version of 
this work in the following section. 
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4.2 RESULTS 
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4.3 DISCUSSION & OUTLOOK 
Evidence from studies in mice, plants and humans suggested a role of BRCA2 in 
meiotic recombination. Since BRCA2 and DMC1 were known to interact, it was 
proposed that BRCA2 has a similar role in mediating DMC1 recombination in meiosis I 
as for RAD51 in mitosis 92,101,156,180,181,184,187. The results of our study confirm these 
assumptions and show that indeed BRCA2 regulates DMC1 activity.  
In an earlier study, the interaction of human DMC1 and BRCA2 was mapped to a 
highly conserved region, a so-called PhePP motif between amino acids 2386 and 2411 
by using in vivo pull downs, yeast-two-hybrid assays and peptide arrays 92. Here, 
DMC1 did not interact with the BRC repeats as it was suggested previously and shown 
in other organisms 120,184. Thorslund et al. (2007) argued that the DMC1 interaction site 
in BRCA2 is different to RAD51 to allow the simultaneous action of the two proteins 92. 
In U. maydis that lacks a Dmc1 homolog, RAD51 does not only bind to the BRC 
repeats but also to this PhePP motif of Brh2, which could mean that the site serves as 
a secondary binding site for DMC1 besides the BRC repeats 245.  
In our in vitro study we proved the interaction between the BRC repeats and DMC1 
and established the binding affinities for each single BRC repeat. The binding affinities 
were overall lower compared to RAD51 and we could not make out a similar pattern of 
two classes of binding modules as for RAD51. Nevertheless, we established that the 
joint molecule formation of DMC1 was enhanced by the BRC repeats, meaning that the 
mechanism by which BRCA2 mediates recombination is different to the one observed 
for RAD51. Based on our study we suggest that DMC1 recombination is supported by 
BRCA2 by facilitating its association with ssDNA and stabilization of the nucleoprotein 
filaments. In turn, this activity facilitates joint molecule formation and DNA strand 
exchange.  
In contrast to what was shown for RAD51, BRC4 does not have the strongest affinity to 
DMC1. Instead, it reduces joint molecule formation and ssDNA/dsDNA binding. A 
mutant peptide of BRC4, Δ7BRC4, is unable to bind RAD51 because it lacks the 
oligomerization interface for RAD51 interaction. Since Δ7BRC4 readily stimulated 
DMC1 activity in contrast to BRC4, is possible that this oligomerization interface FxxA 
is not necessary for the interaction with DMC1. It is hence plausible that a second BRC 
binding module identified before 146, LFDE, constitutes the primary interaction site for 
DMC1 in the BRC repeats. To confirm this, further studies using mutant BRC peptides 
with DMC1 would be needed. 
In yeast, Rad51 and Dmc1 localize together to the DSB. Both proteins are required for 
proper meiotic recombination whereas Rad51 plays only an accessory role 93. Rad51 is 
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not needed for its catalytic activity but rather to form a nucleoprotein filament, probably 
in regulating DMC1 strand exchange activity together with Mei-Sae3. Also, in A. 
thaliana, Rad51 mutants without a catalytic domain could complement rad51 mutants 
in meiosis but where defective in mitosis, showing that Dmc1 is the primary 
recombinase in meiosis but needs the presence of Rad51 93,246. The hypothesis that 
DMC1 is the primary strand-invasion enzyme in meiosis but needs the supportive role 
of RAD51 also in human, probably by initiating a nucleoprotein filament at the DSB, is 
in line with our working model. Based on the results from this and my supervisor’s 
earlier work 124 we hypothesize that BRCA2 binds directly free RAD51 monomers via 
BRC1-5 and DMC1 via BRC6-8 that have a low affinity to free RAD51. The latter pre-
forms a nucleoprotein filament on the ssDNA with BRCA2 replacing RPA and blocking 
RAD51 ATPase and binding to dsDNA 123,124. DMC1 could then bind to the RAD51 
nucleus and start forming filaments that are stabilized by BRCA2 for homology search, 
strand invasion and exchange (2.2, Figure 8).  
This working model requires further investigation, for example, performing joint 
molecule formation in presence of the two proteins and one or more different BRC 
repeats. A single molecule approach as shown before for RAD51 and BRC4 123 but 
including DMC1 and ssDNA would allow us to address some of these questions. 
Based on our results in chapters 2 and here, BRCA2 NTD would be positioned at the 
ssDNA/dsDNA junction where BRC1-5 would load RAD51. DMC1 would bind to the 
nucleus of RAD51 downstream on the ssDNA.  
Given the intrinsic strand exchange activity of RAD51, it is of interest how this activity is 
inhibited to allow DMC1 to solely promote meiotic recombination. This regulation might 
depend on accessory factors described for DMC1 and RAD51 such as Hop2-Mnd1 
however, the regulation of the two recombinases and how they interplay remains to be 
investigated 189.  
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CHAPTER 5 
5.1 FUNCTIONAL EVALUATION OF INTERMEDIATE RISK VUS IN BRCA2 
The difficulty to assess the clinical relevance of rare missense variants in BRCA2 found 
in breast cancer families has been described in detail in Chapter 1.9. In contrast to the 
mutations that lead to truncated or inactive protein products for which the impact on 
BRCA2 function can be easily assessed, missense variants are more difficult to 
evaluate because it is not known whether any of these changes actually alter BRCA2 
function sufficiently to predispose carriers of these mutations to cancer 211.  
The majority of VUS are rare, they are only found in few families, making the 
application of multifactorial likelihood models to estimate their cancer risk difficult. 
Hence, for these variants, it is important to apply in vitro and in vivo functional assays 
to complement genetic data and assess breast cancer risk. The majority of BRCA2 
variants (~60 %) remain unclassified (BRCA2share database) 210. This represents a 
very important clinical challenge, as the carriers of those variants cannot follow cancer 
risk assessment 97. 
In collaboration with members of the Evidence-based Network Investigating Germline 
Mutant Alleles (ENIGMA) consortium and the Breast Cancer Association Consortium 
(BCAC) we contributed to the functional evaluation of 20 BRCA1 and 33 BRCA2 
missense variants genotyped on ~40,000 breast cancer cases and 40,000 matched 
controls using the illumina Collaborative Oncological Gene-Environment Study 
(iCOGS) custom genotyping array. The goal of the study was to assess the association 
between these rare VUS and breast cancer risk. Because they confer intermediate 
phenotype or partial impact on function, the question addressed was whether an 
intermediate effect in the function corresponds to an intermediate risk. This study 
shows for the first time that a moderate or intermediate risk can be assigned to VUS 
using functional as well as case-control approaches.  
Here I will present the work conducted in our lab that contributed to the evaluation of 
these intermediate risk VUS. 
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5.2 WORK FOR iCOGS STUDY 
Previous work from Fergus Couch laboratory found a number of variants from the C-
terminal region of BRCA2 that result in an intermediate phenotype in homologous 
recombination assay. Using a quantitative multifactorial likelihood model, our 
collaborators in this work estimated for the first time a moderate to high breast cancer 
risk for variant Y3035S, G2508S and K2729N. In addition, A2717S yielded mildly 
protective effect. Two class 5 variants (pathogenic variants) were also analyzed but 
they were not detected in enough cases and controls for estimation of breast cancer 
risk, D2723H, R3052W 211. Since the DNA binding activity of BRCA2 is integral to its 
recombination function, and these variants are located in the C-terminus DNA binding 
domain, a deleterious phenotype in HR could be due to impaired DNA binding. We 
contributed to this study by analyzing the DNA binding ability of these variants. 
We used a mammalian expression vector coding for EGFP-MBP-BRCA2 (see methods 
in chapter 2.5) to introduce the missense mutations present in six variants by site-
directed mutagenesis. The location of the variants in the context of human BRCA2 
scheme is shown in Figure 1A. We then transfected HEK293 cells with the respective 
construct for overexpression of the protein. The purification, based on a previous 
publication from my supervisor and colleagues 70 with some modifications, involved two 
steps:  
 
Figure 1: A) Structure of BRCA2 with the VUS indicated in the CTD.   
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First, the proteins were isolated from the cell lysate by amylose resin to which the MBP 
tag binds and the proteins were eluted with maltose. Second, the eluates were further 
subjected to a weak ion-exchange resin (BioRex 70) and eluted step-wise using NaCl 
(250 mM, 450 mM, 1M) (Figure 2A, B). We detected the purified proteins on SDS-
PAGE gels and verified their identity by western blot using an antibody against the 
central region of BRCA2 (OP95) (Figure 2C). Even though the yield of the proteins was 
Figure 2: Purification of BRCA2 and variants. A) Purification protocol B) 
Representative example of the fractions of a purification (K2729N) shown on a SDS-
PAGE: M) molecular weight marker 1) lysate loaded 2) unbound fraction 3) amylose 
beads 4) maltose elution 5) flow through BioRex70 6) 250 mM NaCl elution 7) 450 mM 
NaCl elution 8) 1M NaCl elution. C) Left: Purified proteins (0.25 μg) on 4-15% SDS-
PAGE M) molecular weight marker 1) wild type BRCA2 2) Y3035S 3) K2729N 4) 
G2508S 5) A2717S. Right: Western Blot of BRCA2 detected with anti-BRCA2 antibody 
OP95.  
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small (usually between ~5 and 7 µg) the proteins were stable, free of nucleases and 
the concentration was enough to test their DNA binding activity.  
Using a DNA binding assay (EMSA, see Chapter 2) we then tested the ability of the 
variants to associate with DNA.  
Increasing concentrations of each protein was incubated with 5’-radiolabeled ssDNA 
(167 nt polymer) at 37C for 1 hour before loading on a 6% PAGE, dried and exposed 
overnight. As shown in Figure 3, wild type BRCA2 could form up to 20% of DNA-
protein complexes at the maximum attainable concentration (20 nM). The variant 
protein G2508S, K2729N and A2717S showed a minor reduction of protein-DNA 
complex formation to 12%. Importantly, Y3035S, associated with moderately increased 
risk of breast cancer in this study, showed similar impairment of DNA binding as the 
Figure 3: DNA binding assays with wild type and variant BRCA2 proteins. A) 
Autoradiographs from EMSAs with radiolabeled ssDNA (167 nt polymer) and 
proteins in the indicated concentrations. B) Quantification of experiments from (A) 
(n=3). 
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pathogenic variant R3052W (~7%). This is consistent with their location close to the 
DNA binding site in the crystal structure (Figure 4). This phenotype was confirmed by 
four functional assays including cell-based homologous recombination assay 
performed by the groups of F. Couch and M. Vreeswijk (see 5.3, Figures 2 & 3).  
The combined results from genetic and functional data led us to conclude that 
hypomorphyic BRCA2 missense variant Y3035S can confer moderate clinically 
relevant risk of breast cancer.  
5.3 OUTLOOK  
In the work presented here, we evaluated the impact of BRCA2 Y3035S and G2508S 
intermediate risk variants on BRCA2 function using biochemical (DNA binding), cell-
based homologous recombination and in vivo embrionic stem cells cell-based assays. 
We demonstrated for the first time that hypomorphic BRCA2 mutation, like Y3035S, 
can confer an intermediate risk to develop breast cancer. In contrast, G2508S, that 
Figure 4: Position of BRCA2 DNA binding domain (DBD) variants on a ribbon 
diagram of the murine DBD crystal structure 127. 
Ribbon diagram of the crystal structure of the mouse BRCA2 DBD-DSS1-ssDNA 
(PDB ID: 1MJE) generated using MacPyMOL (Molecular Graphics version 1.3.) 
highlighting the location of the variants analyzed by EMSA. The location of the 
known deleterious variant p.D2723H is shown in yellow. The human variants 
displaying a neutral phenotype (G2058, K2729, A2717) are shown in blue. The 
position of the variant reducing the DNA binding activity (Y3035) is shown in red. 
The DNA is shown in orange and DSS1 in purple. Courtesy of A. Carreira 
175 
 
was also associated with a moderate breast cancer risk, when combined with 
functional assays, led us to conclude that it might be a neutral variant.  
BRCA2 is known to bind DNA via its C-terminal DNA binding domain where many 
missense mutations are located. A lot of pathogenic mutants have been found in this 
region probably because they affect the DNA binding and thus the HR proficiency of 
BRCA2. Until recently, the recombination function was tested using cell-based HDR 
assays in a BRCA2-/- background. Importantly, this is the first time purified full length 
BRCA2 and variants, and Electrophoretic mobility shift assay, EMSA, is used to 
evaluate VUS. With the help of the EMSA, we can now get more insight on the 
mechanism that is defective in the HR assay. This DNA binding assay could be 
eventually complemented with RAD51-mediated DNA strand exchange assay as 
described in chapter 2.  
In this study we observed that missense mutations with a decreased ssDNA binding 
activity also displayed a decreased efficiency in the HR assay in two cell-based 
systems.  The DNA binding results fit well with the prediction made on the basis of the 
crystal structure of the mouse DNA binding domain in complex with DSS1 and DNA 127.  
Because of its important functional relevance and, due to the lack of crystal structure 
available for the human CTD, we set out to do this in collaboration with the group of 
Xiaodong Zhang (Imperial College London, UK). With the help of the recombinant 
protein platform of I. Curie, we were able to obtain a soluble and active protein CTD-
DSS1 complex in sufficient amounts to use for crystallization (Chapter 2.2, Figure 7). 
The human CTD-DSS1-ssDNA crystal structure will give more insights into the 
functionality of this domain and help to predict more accurately the impact on the 
function of VUS located in this region.  
One consideration to keep in mind is that the partial HR and DNA binding proficiency 
we observe could also stem from the newly identified NTD (Chapter 2). It is plausible 
that the residual DNA binding activity of the variant Y3035S characterized in this work 
is due to the NTD, which might also be responsible for the intermediate phenotype in 
HR. To test this hypothesis we could use a combined mutant Y3035S with C315S and 
check the effect on DNA binding and HR.  
There is a large amount of rare VUS listed in the BRCA databases (ca. 1700 for 
BRCA2) that remain to be classified. Many of them lie in regions with a defined function 
such as the BRC repeats or the C-terminus, which helps to apply functional assays for 
evaluation of variants. Yet, many missense VUS are located in underexplored regions 
and moreover they are found rarely in families. With the functional characterization of 
the N-terminus of BRCA2 and the development of functional in vitro assays using 
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purified protein we will further contribute to the classification of VUS found in breast 
cancer families.  
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ABSTRACT 
 
Breast cancer risks conferred by many germline missense variants in the BRCA1 and 
BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not 
been established. In this study, associations between 19 BRCA1 and 33 BRCA2 
missense substitution variants and breast cancer risk were investigated through a 
breast cancer case-control study using genotyping data from 38 studies of 
predominantly European ancestry (41,890 cases and 41,607 controls) and nine studies 
of Asian ancestry (6,269 cases and 6,624 controls). The c.9104A>C, p.Tyr3035Ser 
(OR=2.52, p=0.04) and c.7522G>A, p.Gly2508Ser (OR=2.68, p=4.0x10-3) variants in 
BRCA2 and c.5096G>A, p.Arg1699Gln (OR=4.29, p=0.009) variant in BRCA1 
wereassociated with moderately increased risks of breast cancer. Detailed functional 
characterization of BRCA2 p.Tyr3035Ser using five quantitative functional assays 
showed reduced, intermediate BRCA2 activity. The consistent genetic and functional 
data establish that hypomorphic BRCA2 missense variants, such as p.Tyr3035Ser, can 
confer potentially clinically relevant moderately increased risks of breast cancer. 
 
SIGNIFICANCE 
 
The results suggest that calibrated functional assays or genotyping studies can be 
used to identify clinically relevant BRCA1 and BRCA2 missense variants. Because 
hypomorphic BRCA1 and BRCA2 variants are associated with moderately increased 
risks of breast cancer, guidelines for risk management of women with these specific 
variants will be needed. 
 
INTRODUCTION 
 
Mutation screening of the BRCA1 and BRCA2 genes has resulted in the discovery of 
thousands of unique germline BRCA1 and BRCA2 variants. Many pathogenic variants 
of BRCA1  or BRCA2 resulting in truncation of these proteins, along with a small 
number of pathogenic missense variants, have been associated with high risks of 
breast cancer with cumulative risks of 55% to 85% by age 70 (1). In contrast, the 
influence on cancer risk of many rare variants of uncertain significance (VUS), 
accounting for between 2% and 10% of results from genetic testing, is not known (2-4). 
As a result, carriers of VUS in these predisposition genes cannot benefit from cancer 
risk management strategies for women with pathogenic mutations. 
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Clinical classification of BRCA1 and BRCA2 VUS has been largely based on 
probability-based models which incorporate likelihood-ratios associated with family 
history of cancer, co- segregation of variants with breast and ovarian cancer within 
families, tumor histopathology,  and prior probabilities of pathogenicity associated with 
cross-species amino acid sequence conservation (5, 6). While over 200 BRCA1 and 
BRCA2 variants have been classified as pathogenic or neutral/non-pathogenic using a 
multifactorial likelihood model (7-10) , many VUS remain because of limited availability 
of families segregating the variants. Clinical classification of VUS in BRCA1 and 
BRCA2 has been further complicated by the potential for variants associated with 
moderate risks (odds ratio (OR) between 2.0 and 5.0) of disease (5, 11, 12), with 
BRCA1 c.5096G>A, p.Arg1699Gln (R1699Q) recently associated with a cumulative 
risk of breast or ovarian cancer by age 70 of 24% and reduced penetrance relative to 
the pathogenic c.5095C>T, p.Arg1699Trp (R1699W) variant (13). In this study, the 
influence of 52 missense variants in BRCA1 and BRCA2 on breast cancer risk was 
investigated using the iCOGS breast cancer case-control project (14). In addition, the 
impact of the BRCA2 c.9104A>C, p.Tyr3035Ser (Y3035S) and c.7522G>A, 
p.Gly2508Ser (G2508S) variants on BRCA2 function
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were evaluated relative to known pathogenic and neutral variants using biochemical, cell-
based homology directed repair (HDR), and in vivo embryonic stem (ES) cell-based 
assays. 
 
METHODS 
 
Participants 
 
Breast cancer cases and controls from 38 studies of predominantly European ancestry 
(41,890 cases with invasive disease and 41,607 controls) and nine studies of Asian 
ancestry (6,269 cases and 6,624 controls) from the Breast Cancer Association Consortium 
(BCAC) were used for genotyping (Supplementary Table S1). All studies were approved 
by local ethics committees and institutional review boards (Supplementary Table S1). 
 
 
 
Variant selection 
 
Missense substitution variants from BRCA1 (n=19) and BRCA2 (n=33) were selected by 
ENIGMA for inclusion on the iCOGS genotyping array based on frequency in the ENIGMA 
database (15) (Supplementary Tables S2). The BRCA1 c.4327C>T, p.Arg1443Ter, 
R1443X variant served as a positive control for known pathogenic alterations. Variants are 
defined by Human Genome Variant Society (HGVS) nomenclature and are based of 
Refseq transcripts (BRCA1: NM_007294.3 ; BRCA2: NM_000059.3). 
 
Genotyping 
 
Genotyping was conducted using the custom Illumina Infinium array (iCOGS) (14). DNA 
samples containing each of the variants were included in iCOGS genotyping as positive 
controls and were used to inform genotype calling. Genotypes were called with the 
GenCall algorithm. Descriptions of sample and genotype quality control have been 
published (14, 16). Cluster plots for rare variants for this study were manually evaluated 
relative to positive control samples.
Statistical Methods 
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The association of each variant with breast cancer risk was assessed using unconditional 
logistic regression, adjusting for study (categorical). Analyses were restricted to either 
Caucasian or Asian women. Cases selected for iCOGS based on personal or family 
history of breast cancer were excluded to obtain unbiased OR estimates for the general 
population. The significance of associations (P-values) was determined by the likelihood 
ratio test comparing models with and without carrier status as a covariate. Because this 
study was focused on estimating breast cancer risk associated with each variant analyses 
were not adjusted for multiple testing.  Additional statistical analyses are outlined in 
Supplementary Methods. 
 
Homology directed repair (HDR) assay 
 
The HDR assay for BRCA2 has been described previously (11). Full-length BRCA2 wild-
type and mutant cDNA expression constructs were co-expressed with an I-Sce1 
expressing plasmid in BRCA2 deficient V-C8 cells, stably expressing the DR-GFP reporter 
plasmid. HDR- dependent repair of I-Sce1 induced DNA double strand breaks were 
quantified by fluorescence- activated cell sorting (FACS) of GFP positive cells after 72 
hours. Two independent clones of each variant were evaluated in the HDR assay on three 
separate occasions. Equivalent expression of wild-type and mutant BRCA2 proteins was 
confirmed by western blot analysis of anti-Flag-M2 (Sigma F1804) antibody 
immunoprecipitates from V-C8 cell lysates. 
 
Purification of full-length wild-type and mutated BRCA2 protein 
 
Wild-type and mutant human BRCA2 cDNAs were cloned into the C-terminal MBP-GFP-
tagged phCMV1 expression plasmids and purified as described (17). Briefly, 10 x 15-cm 
plates of HEK293 cells were transiently transfected using TurboFect (Thermo Scientific) 
following the manufacturer specifications and harvested 30 hours post-transfection. Cell 
extracts were bound to Amylose resin (NEB), and the protein was eluted with 10 mM 
maltose. The eluate was further purified by ion exchange using BioRex 70 resin (BIO-
RAD) and step eluted at 250mM, 450 mM, and 1M NaCl (17). Each fraction was tested for 
nuclease contamination. The 1M NaCl fractions were used for the DNA binding assay 
because they were free of nuclease contamination. 
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Electrophoretic Mobility Shift Assay (EMSA) 
 
The ssDNA substrate used for DNA binding was obtained from Sigma (Supplementary 
Methods) and purified by polyacrylamide gel electrophoresis (PAGE). Purified wildtype or 
mutated BRCA2 at concentrations 0, 1, 5, 10, 20 nM was mixed with the ssDNA 
oligonucleotide oAC423 167-mer (0.2 µM nt), labeled with 32P at the 5’ end, in a buffer 
containing 25 mM TrisAcO (pH 7.5), 1 mM MgCl2, 2 mM CaCl2, 1mM DTT, 1 mM ATP, 
ucts were resolved by 
6% PAGE, imaged on a Typhoon PhosphorImager (Amersham Biosciences), and 
analyzed with Image J software. The relative amount of product was calculated as labeled 
complex divided by the total labeled input DNA in each lane. The protein-free lane defined 
the value of 0% complex. 
 
 
 
Embryonic Stem (ES) cell complementation 
 
Selected BRCA2 variants were functionally analyzed based on the ability of human 
BRCA2 to complement the lethality of mouse Brca2 deficiency (18, 19). BRCA2 exons 
containing VUS were generated by mutagenesis PCR and engineered into a human 
BRCA2 (hBRCA2) Bacterial Artificial Chromosome (BAC) by Red/ET BAC recombineering 
in DH10B E.coli. BAC DNA was transfected into mES cells containing a conditional mouse 
Brca2 allele and a disrupted Brca2 allele (Brca2-/loxP), and the DR-GFP construct 
integrated at the pim1 locus. hBRCA2 containing cells were selected by G418. Per variant, 
two independent BAC transfections were performed and G418-resistant clones from each 
BAC transfection were pooled. Cell pools were transfected with Cre-recombinase 
expression construct to remove the conditional mBrca2 gene. hBRCA2 RNA and protein 
expression was confirmed. 
 
ES cell functional assays 
 
After Cre-recombinase transfection, mBrca2 depleted cells were selected for restoration of 
the HPRT minigene using hypoxanthine-aminopterin-thymidine (HAT) containing medium. 
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HAT resistant clones were pooled and evaluated for BRCA2 activity using functional 
assays. In the mES cell HDR assay, cells were transfected with an I-Sce1 expression 
vector, pCMV-RED- ISce, and GFP positive cells were quantified by flow cytometry 48 hr 
after transfection. mES cells were also treated with varying doses of PARP inhibitor (KU-
0058948, Astra Zeneca) and viable cells were quantified after 48 hr. Cell survival was 
calculated as the fraction of treated surviving mES cells relative to the cell count of 
untreated surviving cells per cell line. 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Association of BRCA1 and BRCA2 variants with breast cancer risk 
 
A total of 19 BRCA1 and 33 BRCA2 variants encoding missense substitution mutations 
and the pathogenic BRCA1 c.4327C>T, p.Arg1443Ter (R1443X) mutation on the iCOGS 
array were genotyped for 48,159 breast cases and 48,231 controls from the Breast Cancer 
Association Consortium (BCAC) (Supplementary Table S1). Among the BRCA1 variants, 
11 have been classified as Class 1-neutral and one each as Class 3-uncertain and Class 
5-pathogenic, using the quantitative multifactorial likelihood model described above 
(Supplementary Table S2). In addition, BRCA1 c.5207T>C, p.Val1736Ala (V1736A) (20) 
and c.5363G>A, p.Gly1788Asp (G1788D) variants have been classified as pathogenic in 
the ClinVar database. Among the BRCA2 variants, 18 are located in the DNA binding 
domain (amino acids 2490-3098), 26 have been classified as Class 1-neutral or Class 2-
likely neutral and one has been classified as Class 5-pathogenic using the same 
multifactorial likelihood model (Supplementary Table S2). 
The BRCA1 R1443X recurrent truncating pathogenic mutation was associated with high 
risk of breast cancer (odds ratio (OR) = 8.3, p=0.045) in the Caucasian studies in iCOGS 
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(Table 1), consistent with what has been estimated for pathogenic BRCA1 mutations. 
Among the missense variants, c.5096G>A, p.Arg1699Gln (R1699Q) was associated with a 
moderate risk of breast cancer (OR=4.29, p=0.009) (Table 1). This result was lower than 
expected for pathogenic BRCA1 variants, but consistent with the moderate penetrance of 
this variant estimated from other family-based studies (13). Several BRCA1 variants 
including the known pathogenic c.5123C>A, p.Ala1708Glu (A1708E); c.5207T>C, 
p.Val1736Ala (V1736A); and c.5363G>A, p.Gly1788Asp (G1788D) variants were not 
observed in sufficient numbers of cases and controls to allow for estimation of breast 
cancer risks (Supplementary Table S3). Three BRCA2 variants were statistically 
significantly associated with breast cancer risk (p<0.05) for Caucasian or Asian women. 
BRCA2 c.9104A>C, p.Tyr3035Ser (Y3035S) was observed in 18 cases and 7 controls in 
the Caucasian studies (OR=2.52, p=0.038) (Table 1), c.7522G>A, p.Gly2508Ser (G2508S) 
was observed in 31 cases and 12 controls in the Asian studies (OR=2.68, p=0.004) but not 
in any Caucasians, and BRCA2 c.8187G>T, p.Lys2729Asn (K2729N) was observed in 164 
cases and 128 controls in the Asian studies (OR=1.41, p=0.004) (Table 1). In addition, the 
BRCA2 c.8149G>T, p.Ala2717Ser (A2717S) (OR=0.77, p=0.02) and c.4258G>T, 
p.Asp1420Tyr (D1420Y) (OR=0.86, p=0.005) were negatively associated with risk for 
Caucasian women (Table 1, Supplementary Table S3). None of the remaining BRCA2 
variants, including the Class 5-pathogenic BRCA2 variants, c.8167G>C, p.Asp2723His 
(D2723H) and c.9154C>T, p.Arg3052Trp (R3052W), were observed in enough cases and 
controls for estimation of breast cancer risk (Supplementary Table S3). Thus, for the first 
time BRCA2 variants encoding missense alterations (Y3035S, G2508S, and K2729N) 
have been associated with moderately increased risks of breast cancer. 
To assess further the association of the Y3035S moderate risk variant with breast cancer, 
19 pedigrees with Y3035S were collected through the ENIGMA consortium (Fig. 1, 
Supplementary Fig. S1, Supplementary Table S4). Segregation studies of Y3035S, 
assuming the relative risk was constant with age, indicated an association with breast 
cancer risk (Risk Ratio (RR)=14.8; 95%CI 2.4-20.0) (Supplementary Table S4). A second 
analysis, allowing for a similar pattern of age specific effects as for population-based 
pathogenic BRCA2 truncating mutations, estimated the optimal cumulative penetrance for 
Y3035S at 0.75 of known pathogenic truncating BRCA2 mutations, and yielded a similar 
risk ratio for breast cancer (Supplementary Table S4). In addition, Y3035S co-occurred 
with a pathogenic BRCA2 mutation (S1882X) in Pedigree G (Supplementary Fig. S1) and 
with another VUS in BRCA2 (S1298del) in Pedigree K (Fig. 1), suggesting hypomorphic 
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effects. Overall, the pedigree analysis suggests that Y3035S is associated with increased 
breast cancer risk. No segregation studies of G2508S were performed because only one 
pedigree was collected (not shown). 
 
Cell-based HDR analysis of BRCA2 variants 
 
Inactivation or depletion of BRCA2 has been associated with deficient homology directed 
repair (HDR) of DNA double strand breaks (21), which can be quantified with a cell-based 
HDR green fluorescent protein (GFP) reporter assay (22). This assay has shown 100% 
sensitivity and specificity for known pathogenic missense mutations in the BRCA2 DNA-
binding domain and has been used for characterization of BRCA2 VUS (8, 11, 23). In this 
study, the impact of the G2508S, K2729N, A2717S, and Y3035S missense variants on 
BRCA2 HDR activity was assessed relative to the D2723H and R3052W known 
pathogenic and the c.9292T>C p.Tyr3098His (Y3098H) known neutral BRCA2 variants 
(11),(24). All wildtype and mutant proteins displayed equal and reproducible levels of 
expression by western blot for full-length BRCA2 protein (Supplementary Fig. S2). The 
D2723H and R3052W Class 5 pathogenic variants (11) showed substantial loss of BRCA2 
HDR activity (Fig. 2A). In contrast, BRCA2 Y3035S showed intermediate levels (2.3-fold 
relative to D2723H) (Fig. 2A) of BRCA2 HDR activity that was outside the thresholds for 
known pathogenic missense variants (HDR fold- change<1.66)  and  neutral/low  clinical  
significance  (HDR  fold-change  >2.41)  variants, which equate to 99% probability of 
pathogenicity and neutrality/low clinical significance, respectively (11). This intermediate 
functional effect was consistent with the moderate risk of breast cancer (OR=2.52, 
p=0.038) observed in the iCOGS case-control study (Table 1) and the estimated 0.75-fold 
penetrance of pathogenic BRCA2 mutations from segregation studies (Supplementary 
Table S3), and to our knowledge, is the first evidence that partial loss of BRCA2 function is 
associated with an intermediate or moderate risk of breast cancer. In contrast, BRCA2 
G2508S exhibited 3.2-fold HDR activity relative to D2723H (Fig. 2A). While reduced 
relative to a wildtype activity of 5.0, this level of HDR activity was associated with >99% 
probability of neutrality/low clinical significance. Similarly, BRCA2 K2729N showed 
reduced HDR activity relative to the wildtype protein (Fig. 2A), which was consistent with a 
mild influence on breast cancer risk (OR=1.41, p=0.004) in the Asian population, and 
>99% probability of neutrality/low clinical significance (Fig. 2A). Together, these results 
suggest that the HDR assay is calibrated relative to cancer risk, with minor functional 
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effects for variants associated with low- or modest risks of breast cancer such as 
c.9976A>T, p.Lys3326Ter (K3326X) (OR=1.28) (25) and K2729N (OR=1.41), more 
substantial functional effects for the intermediate risk Y3035S (OR=2.52), and strong 
effects for known pathogenic variants such as D2723H and R3052W. On this basis, the 
HDR assay can readily distinguish variants associated with intermediate levels of breast 
cancer risk from those considered high-risk pathogenic or neutral/low clinical significance. 
 
Single strand DNA (ssDNA) binding activity of BRCA2 variants 
 
BRCA2 directly binds to ssDNA and recruits RAD51 to ssDNA at sites of DNA damage 
during homologous recombination DNA repair (17, 26). Hence, ssDNA binding is integral 
to the homologous recombination activity of BRCA2. On this basis, an in vitro biochemical 
assay was used to examine the influence of the BRCA2 variants on BRCA2 ssDNA 
binding activity. Full- length wildtype and mutant human BRCA2 proteins tagged with (N-
terminal) green fluorescence protein (GFP) and maltose binding protein (MBP) (GFP-
MBP-BRCA2) were expressed and
purified to near homogeneity (Supplementary Fig. S3) as described previously (17). Full-
length BRCA2 protein expression was confirmed by western blotting using an antibody 
against the C- terminus of BRCA2 (Supplementary Fig. S3). The ssDNA binding activity of 
full-length wildtype and mutant BRCA2 proteins was evaluated using an electrophoretic 
mobility shift assay (EMSA). The wildtype protein bound to ssDNA with a yield of ~18% at 
the maximum attainable concentration of BRCA2 protein (Fig. 2B, 2C), consistent with 
previous results (17). Similar to the R3052W pathogenic variant, the Y3035S variant 
exhibited 2-fold reduced protein-ssDNA complex formation compared to the wildtype 
protein (Fig. 2B, 2C). In contrast, G2508S,  A2717S, and K2729N showed only partially 
reduced protein-ssDNA complex formation (Fig. 2C). These results are consistent with 
predictions from the crystal structure of the BRCA2 DBD, where Y3035S is predicted to 
impair DNA binding, similarly to R3052W, because of proximity to DNA (Supplementary 
Fig. S4) (21). Thus, although this is the first time DNA binding has been used for 
evaluating BRCA2 VUS, the results suggest that the protein-ssDNA binding assay can 
discriminate between low-risk/neutral variants and high/moderate risk variants when 
investigating VUS located in the DBD of BRCA2. 
 
Mouse embryonic stem cell-based functional analysis of BRCA2 missense variants 
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Functional complementation of murine (m) Brca2-null ES cell lethality by human (h) 
BRCA2 variants (18, 19) has been used to characterize BRCA2 VUS. Wildtype human 
BRCA2 expression rescues Brca2 deficient ES cells from lethality, whereas ES cells 
expressing known pathogenic forms of BRCA2 fail to survive (18). In addition, several 
variants have shown partial or reduced ES cell survival relative to wildtype BRCA2. 
Surviving cells expressing these variants have shown moderate defects in HDR assays 
and sensitivity to cisplatin or a PARP inhibitor (27). In this study three independent pools of 
BAC clones for each of hBRCA2 W31C, G2508S, A2717S, D2723H, K2729N, Y3035S, 
and R3052W were tested for complementation of mBrca2 deficiency, HDR proficiency, 
and sensitivity to PARP inhibition. Cells expressing hBRCA2p.D2723H or p.R3052W 
pathogenic variants did not survive after disrupting endogenous mBrca2 expression and 
were not included in the downstream functional analysis. Instead, we included cells with 
the W31C variant that complements the lethality but shows a severe defect in HDR activity 
because of disruption of the BRCA2-PALB2 interaction. BRCA2 G2508S, A2717S, 
K2729N, and Y3035S BACs partially rescued the lethality of the mBrca2-deficient ES cells, 
suggesting at least partial functional complementation of BRCA2 deficiency. This result for 
W31C was unexpected, because this variant disrupts the interaction of PALB2 with 
BRCA2. HDR activity of surviving cells was assessed using the DR-GFP reporter assay. 
BRCA2 W31C showed only 14% (p<0.001) activity, BRCA2 Y3035S, G2508S and 
K2729N variants displayed 50% (P=0.002), 55% (P=0.007), and 70% (P=0.02) of wildtype 
HDR activity, respectively, whereas A2717S was not significantly different to wildtype 
protein (Fig. 3A). The sensitivity of wildtype and mutant BRCA2 expressing ES cells to 
PARP inhibitor (KU-0058948) was also evaluated by counting viable cells after 48 hours of 
exposure to different doses of drug. Wildtype BRCA2, G2508S, and A2717S rescued ES 
cells from sensitivity to PARP inhibitor, whereas W31C expressing cells showed significant 
sensitivity to PARP inhibitor (Fig. 3B). In contrast, K2729N and Y3035S resulted in partial 
rescue of ES cell sensitivity (Fig. 3B). Collectively, the results from complementation and 
HDR assays and to a lesser extent the PARP inhibitor sensitivity assay, in mBrca2 
deficient ES cells show that Y3035S is partially deficient in BRCA2 activity, whereas 
G2508S and K2729N have a substantially lesser effect, and A2717S has no discernable 
influence on BRCA2 function. 
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DISCUSSION 
 
In this study, associations between 52 BRCA1 and BRCA2 missense variants and breast 
cancer risk were evaluated using a large breast cancer case-control study. To our 
knowledge, this is the largest case-control study conducted to establish the clinical 
relevance and estimate the risks of individual rare BRCA1 and BRCA2 variants encoding 
missense substitutions. The
case-control analysis showed that BRCA1 c.5096G>A, R1699Q (OR=4.29) and BRCA2 
c.9104A>C, Y3035S (OR=2.52) were associated with moderately increased breast cancer 
risks for Caucasian women (Table 1), whereas BRCA2 c.7522G>A, G2508S (OR=2.68) 
and c.8187G>T, K2729N (OR=1.41, p=0.004) were associated with increased risks for 
Asian women. This is the first study to estimate low to moderate risks of breast cancer for 
specific BRCA1 and BRCA2 missense variants. 
The moderate risk of breast cancer associated with the BRCA1 R1699Q variant (OR=4.29) 
is consistent with previous findings from segregation analyses of breast cancer families, 
which estimated that the penetrance of R1699Q was 0.6-fold that of the corresponding 
R1699W known pathogenic variant in the same residue. Similarly, R1699Q was estimated 
to be associated with a cumulative risk of breast or ovarian cancer by age 70 years of 24% 
relative to the pathogenic R1699W variant and BRCA1 truncating variants (13). Consistent 
with these findings, BRCA1 R1699Q mutant protein exhibits only partial protein function in 
HDR and other in vitro experiments (12, 13). While, in silico sequence conservation-based 
prediction models predicted R1699Q as damaging (Supplementary Table S2), quantitative 
multifactorial likelihood prediction model based on family data and sequence conservation 
yielded a posterior  probability of pathogenicity (cancer risk similar to truncating BRCA1 
mutations) for R1699Q of 0.79 and identified R1699Q as Class 3-uncertain (13). 
Importantly, the probability model is based on the assumption that all pathogenic variants 
have the same penetrance as truncating BRCA1 variants, and is not intended to 
discriminate between high and moderate risk variants. Thus, the case-control study was 
effective in confirming that R1699Q is a moderate risk variant in BRCA1. Interestingly, 
previous data suggest that BRCA1 G1788D and V1736A may also be associated with 
moderate risks of breast cancer. The G1788D variant is predicted damaging by sequence-
based in silico models (Supplementary Table S2) and functional studies using a validated 
transcription activation assay have shown partially reduced activity (9, 28). Similarly,
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V1736A is predicted damaging by in silico models (Supplementary Table S2), but 
functional studies have shown only partially reduced transcription activation activity, a mild 
folding defect, and partially compromised binding specificity (9, 28, 29). The BRCA1 
V1736A variant was also found in-trans with a frameshift mutation in the first reported case 
of a biallelic BRCA1 pathogenic mutation carrier with Fanconi Anemia like symptoms and 
ovarian cancer (20). However, risks of breast cancer for these variants have not been 
defined risks and could not be established in the case-control study because of low 
numbers of carriers of these variants even among over 40,000 breast cancer cases. 
 
As noted above, BRCA2 Y3035S was associated with increased risk of disease (OR=2.52) 
for Caucasian women. While the numbers of cases and controls with the Y3035S variant 
were small, the moderate risk estimate is supported by family data showing partial co-
segregation  with breast cancer, and one pedigree in which BRCA2 Y3035S co-occurred 
with BRCA2 c.5645C>A p.Ser1882Ter (S1882X) (Supplementary Fig. S1). Several 
sequence-based in silico prediction models including MetaLR, MetaSVM, Vest3, and A-
GVGD (C55 - prior probability of pathogenicity of 0.66) (Supplemental Table S2) predicted 
Y3035S as deleterious. In addition, the missense substitution is predicted as likely 
deleterious by a protein likelihood ratio model based on sequence analysis (30). Analyses 
of splicing defects using Minigene-based assays have shown no influence on RNA splicing 
(31), suggesting that the increased risks are not due to abnormal splicing. Importantly, 
functional analysis of Y3035S using multiple independent assays consistently revealed 
hypomorphic activity. HDR analysis in VC8 cells showed intermediate BRCA2 function 
outside the range of known pathogenic or neutral variants based on 99% probability of 
pathogenicity and neutrality. Consistent with this finding, Y3035S failed to restore HR 
activity and partially rescued sensitivity to PARP inhibition in ES cells (Fig. 3A, 3B). 
Similarly, Y3035S showed significantly reduced ssDNA complex formation (Fig. 2B, 2C) 
consistent with the predicted effect on DNA binding based on the location of Y3035 
in the
crystal structure of the BRCA2 DBD (26), (Supplementary Fig. S4). These results suggest 
that the reduced HR activity associated with Y3035S is due to defective DNA binding 
activity. Together these results provide the first evidence that a hypomorphic BRCA2 
missense variant confers a moderate risk of breast cancer. However, Y3035S is 
consistently reported as “likely benign” and “benign” in the ClinVar public database. Since 
this database is widely used by researchers and clinicians, this under-appreciation of 
191 
 
moderate risks of breast cancer associated with this variant has the potential to impact 
patient care. Further prospective studies are required to estimate age-dependent risks of 
cancer and to inform management protocols for carriers of this variant. 
 
 
The BRCA2 G2508S (OR=2.68, p=0.004) variant was associated with a moderate risk of 
breast cancer in Asian women, but could not be evaluated in the Caucasian population 
(Table 1). The variant was predicted neutral by a protein likelihood prediction model (30), 
but was predicted deleterious by other in silico prediction models including MetaLR, 
MetaSVM, Vest3, and A- GVGD (C55 - prior probability of pathogenicity of 0.66) 
(Supplementary Table S2). However, the HDR V-C8 cell-based assay showed only mildly 
reduced activity similar to K2729N (OR=1.41) and p.K3326X (OR=1.28) (25), which are 
both classified as neutral/non-pathogenic (Fig. 2A). Likewise, the impact of G2508S on 
ssDNA binding was limited and most similar to K2729N (Fig. 2B, 2C). Although G2508S 
had a substantial influence on HDR activity in ES cells similar to Y3035S (Fig. 3A), no 
influence on ES cell sensitivity to PARP inhibitor was observed (Fig. 3B). Thus, the 
functional results suggest a lower risk of breast cancer for the G2508S variant, consistent 
with the wide confidence limits (95%CI 1.37-5.23) for the association. As the variant has 
only been detected in the East Asian population (32, 33), one possibility is that genetic and 
environmental modifiers in the Asian population account in part for the influence of the 
variant  on breast cancer risk and the discrepancy between the case-control and functional  
study results. The Asian specific risk association for G2508S was consistent with a 
recent study of
cases and controls from the Shanghai Breast Cancer Study (34), which suggested that 
G2508S was associated with development of breast cancer, although the effect estimate 
(OR=16.5, 95%CI:2.2-124.5, P=2.2×10-4) was unstable due to limited numbers of events 
(16 cases and 1 control). Further studies are needed to resolve this issue, but for now the 
breast cancer risks associated with this variant must be treated with caution. BRCA2 
K2729N (OR=1.41, p=0.004) is also common in Asians, but rare in Caucasians (33). This 
variant has previously been classified as neutral/little clinical significance by the 
multifactorial likelihood classification model (8). Consistent with these findings, functional 
analysis of K2729N showed only a minor influence on HDR function (8, 11) (Fig. 2A), 
ssDNA binding (Fig. 2B), and BRCA2 activity in the ES cell- based HR assay (Fig. 3B), 
and had no impact on ES cell drug sensitivity (Fig. 3A, 3B). The mild defect in HR function 
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correlated well with the low risk of breast cancer (OR=1.41, P=0.004) associated with the 
K2729N variant in the Asian case-control study. 
 
To date, 1,167 BRCA1 and 1,908 BRCA2 unique missense variants have been reported in 
the Clinvar database, with 1,006 and 1,779 variants, respectively, classified as VUS. This 
observation stresses the lack of validated high throughput methods for classification of 
missense variants in these genes. Current methods of classification rely heavily on family 
data. However, this study highlights the utility of functional assays for this purpose. In 
particular, evaluation of missense variants in the BRCA2 DBD is possible with the cell-
based HDR assay that has been validated using known pathogenic and non-pathogenic 
variants in the DBD to have 100% sensitivity (95% confidence interval (CI): 75.3%-100%) 
and 100% specificity (95% CI: 81.5%-100%) (11). Thresholds of 99.9% probability of 
pathogenicity and non- pathogenicity/low clinical significance/neutrality have been 
established for classification of variants (11), with variants showing HDR fold change 
between these thresholds remaining classified as Class 3 VUS. However, based on 
variants with moderate levels of risk [K3326X (OR=1.28) (25), K2729N (OR=1.41), 
Y3035S (OR=2.52)], the HDR assay is now calibrated to
differentiate between variants with high, moderate, or low breast cancer risks (Fig. 2A). 
Thus, the assay can be used to identify other hypomorphic BRCA2 DBD variants 
associated with moderate breast cancer risk. While not yet validated, ES cell 
complementation assays have also been effectively used to classify missense variants in 
the BRCA2 DBD (18, 27, 35, 36). Whether all variants that show reduced HDR activity in 
V-C8 or ES cells are hypomorphic and associated with moderate risks of breast cancer 
remains to be determined. 
This study also contains the first evidence that a biochemical assay using purified full-
length BRCA2 protein can be used to assess missense the DNA binding capacity of 
variants in the BRCA2 DBD. While purification of wildtype full-length BRCA2 protein to 
near homogeneity has previously been described (17), in this study the functional integrity 
of purified mutant BRCA2 proteins was assessed for the first time in a quantitative ssDNA 
binding assay. Full-length proteins were used to limit potentially inaccurate interpretation of 
effects from partial protein fragments. As noted in the Results section, defective ssDNA 
binding activity was observed for the pathogenic R3052W variant and for the moderate risk 
Y3035S variant, but not for wildtype protein, suggesting that the assay can be used to 
assess pathogenicity of missense variants in the BRCA2 DBD. 
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This study highlights the existence of functionally intermediate or hypomorphic missense 
variants that are associated with moderate risks of breast cancer. Using a combination of 
large case-control studies and functional assays, a BRCA2 missense variant (Y3035S) 
was classified as a moderate risk pathogenic variant for breast cancer (OR=2.52, p=0.038) 
for the first time. In addition, BRCA1 R1699Q was confirmed as a moderate risk (OR=4.29, 
p=0.009) breast cancer missense variant, consistent with previous penetrance studies. In 
addition, the consistency of results from the independent cell-based HDR, ssDNA binding, 
and ES-cell based assays for all of the missense BRCA2 variants in the study, and the 
close agreement with the results from the iCOGS case-control study, suggests that 
validated functional assays calibrated to defined levels of risk can be used to classify 
BRCA2 variants as pathogenic, moderate risk, or neutral. 
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FIGURE LEGENDS 
 
Figure 1. BRCA2 p.Y3035S segregates with breast cancer in high risk families. Five of the 
most informative pedigrees are shown. Upper black quadrants reflect breast cancer status. 
Type of cancer and age at diagnosis are displayed. Variant status is indicated by 
“Y3035S”. (+), mutation positive; (-), mutation negative reflects results of genetic testing. 
 
Figure 2. (A) HDR and ssDNA binding activity of BRCA2 p.Y3035S is reduced. (A) Activity 
of BRCA2 missense variants is shown as HDR fold change with standard error (SE) (of 
three independent measures of duplicates) on a scale of one to five. Solid lines represent 
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99.9% and 0.1% probability of pathogenicity. (B) Representative Electrophoretic Mobility 
Shift Assays (EMSA) of DNA-protein complexes formed by mixing increasing 
concentrations (0, 5, 10, 20 nM) of purified BRCA2 wildtype and mutant proteins with 
ssDNA. (C) Quantitation of the DNA- protein complex formation shown in Fig. 2B. Error 
bars represent SE derived from at least three independent experiments. Statistical 
difference between WT and mutant BRCA2 Protein-DNA complexes formation was 
determined by two-sample t-test.  **P < 0.001; *p < 0.05. WT, wildtype. 
 
Figure 3. HR efficiency and PARP inhibitor sensitivity of mES cells expressing hBRCA2 
variants. (A) GFP expression from the DR-GFP reporter was analyzed as a measure of 
HR activity. The percentage GFP positive cells for each variant was normalized to wildtype 
hBRCA2 expressing cells. Results represent the mean of three independent experiments 
with two independent pools of BAC clones tested per variant. Error bars represent 
standard error of three independent experiments. Statistical significance is indicated by “ * 
”. (B) Relative cell survival compared to untreated cells was determined by cell count after 
48hr exposure to PARP inhibitor KU-0058948. Data represent the mean of three 
experiments using three different pools of BAC clones. **P < 0.001; *p < 0.05. WT, 
wildtype. 
 
 
Supplementary Figure 1: BRCA2 p.Y3035S pedigrees. Upper black quadrants reflect 
breast cancer status. Type of cancer and age at diagnosis are displayed. Variant status is 
indicated by “Y3035S”. Genotyping results are indicated by (+), mutation positive; (-), 
mutation negative. The bilateral breast cancer patient in Pedigree H was a heterozygote 
for BRCA2 mutations p.R1882X and p.Y3035S. 
 
 
Supplementary Figure 2: Western blot of ectopically expressed full-length wildtype and 
mutant hBRCA2 protein in VC8 DR-GFP cells that were subjected to HDR assay. 
 
 
Supplementary Figure 3. Purification of wildtype and mutant BRCA2 from human cells. 
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(A) Scheme of the purification protocol of full-length BRCA2 proteins from human cells. (B) 
SDS-PAGE of purified wildtype and mutant BRCA2 proteins tagged with GFP-MBP at the 
N terminus. WT, wildtype. (C) Western blot (WB) of purified BRCA2 with an antibody 
specific for the C-terminal region of BRCA2 (CA1033, EMD). 
 
 
Supplementary Figure 4. Position of BRCA2 DNA binding domain (DBD) variants on a 
ribbon diagram of the murine DBD crystal structure. 
Ribbon diagram of the crystal structure of the mouse BRCA2 DBD-DSS1-ssDNA (PDB ID: 
1MJE) generated using MacPyMOL (Molecular Graphics version 1.3.) highlighting the 
location of the variants analyzed by EMSA. The location of the known deleterious variant 
p.D2723H is shown in yellow. The human variants displaying a neutral phenotype (G2058, 
K2729, A2717) are shown in blue. The position of the variant reducing the DNA binding 
activity (Y3035) is shown in red. The DNA is shown in orange and DSS1 in purple.
 
 
Table 1.  Variants in BRCA1 and BRCA2 significantly associated with breast cancer risk in 
a case-control analysis 
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6. FINAL CONCLUSIONS 
During my PhD thesis presented here, we were able to uncover new functional aspects of 
the tumor suppressor protein BRCA2 and evaluate the impact of several variants of 
unknown clinical significance (VUS) found in breast cancer patients which is illustrated in 
Figure 1 and 2. 
THE N-TERMINUS OF BRCA2 POSSESSES A DNA BINDING DOMAIN 
In the study presented in Chapter 2, we identified an N-terminal DNA binding domain 
(Figure 1 B). 
This region, containing a putative zinc finger PARP like domain (zf PARP) unraveled by in 
silico analysis showed DNA binding activity in vitro. As the fragment utilized comprises aa 
250-500, it remains to be established whether the DNA binding activity specifically requires 
the zf PARP domain (267-349), however, the prediction of DNA binding residues coincides 
with the zf-PARP domain suggesting that this is indeed the case. Moreover the cysteine 
residues that supposed to be important for the correct assembly of the zinc finger motif 
showed a reduced DNA binding activity when mutated further supporting this hypothesis.  
We observed that NTD and CTD share similar structure specificities but the NTD has a 
generally higher affinity for DNA. One unexpected result was the ability of the NTD to 
associate with dsDNA. This revealed a hitherto unknown feature of the DNA binding 
capacity of BRCA2 that showed only high affinity to ssDNA and tail substrates until this 
work 70,127. However, this dsDNA binding activity is most likely responsible for the weak 
dsDNA binding capacity observed with the full-length BRCA2 protein 70(ref Jensen et al., 
2010).  
We could show that the NTD can stimulate RAD51 strand exchange activity between RPA-
coated ssDNA and homologous dsDNA. We propose that the NTD has a mediator activity 
by facilitating the loading of RAD51 on substrates with a ssDNA/dsDNA junction due to its 
high affinity for dsDNA, although it can also stimulate the DNA strand exchange activity of 
RAD51 on ssDNA.  
In the model presented in Chapter 2 (2.3, Figure 18), the NTD and CTD could thus act 
consecutively at DSBs or daughter strand gaps to facilitate RAD51 loading at the 
ssDNA/dsDNA junctions. The NTD would be responsible for the binding at the 
ssDNA/dsDNA junction rendering RPA-coated ssDNA accessible for RAD51 loading by 
the BRC repeats 124. The CTD/DSS1 complex could then further promote RAD51 filament 
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growth by replacing RPA at multiple sites as proposed 69,158. It remains unclear whether 
the two DNA binding domains act together on the same substrate in the context of full-
length BRCA2 or if they have specialized functions depending on the nature of the DNA 
damage.  
It is also of great interest how the two binding modules coordinate BRCA2 activity in vivo. 
As a part of this study we wanted to investigate if NTD together with a BRC repeat can 
rescue the phenotype of BRCA2 deficient cells in response to DNA damage as it was 
shown for the CTD and proposed for the N-terminus 152,109,157. So far, despite several 
attempts, we have not been able to establish an in cellulo system with BRCA2-/- 
background to test the BRCA2BRC4-T2 construct. We are currently working on a human FLP-
IN system in HEK293 cells in which we can downregulate endogenous BRCA2 and 
simultaneously induce the expression of BRCA2T2-BRC4 from a gene locus.  
 
We will also make use of this system to evaluate the HR capacity of the VUS defective in 
DNA binding. In this way, we will know if the NTD is sufficient to perform BRCA2 
recombination function in cells and at the same time, evaluate the impact of VUS on 
BRCA2 function which was the focus of my second objective (1.14).  
 
Figure 1: BRCA2 structure with known functional domains and interaction partners. 
State of the art A) before and B) after this study showing the identified DNA binding 
domain in the N-terminus and the DMC1 interaction site at the BRC repeats. Note that 
not all interaction partners are illustrated. 
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VARIANTS OF UNKNOWN CLINICAL SIGNIFICANCE LOCATED IN THE NTD SHOW 
DEFECTS IN DNA REPAIR AND CYTOKINESIS 
We selected VUS located in the DNA binding domain that sufficiently met the criteria for a 
high probability to exhibit a deleterious phenotype. We subjected these variants to 
established functional assays 212,118,165,213,164 to evaluate their phenotype in DNA repair and 
cytokinesis (Figure 2). As described in Chapter 3.2, we found that some missense 
mutations in the NTD can affect the DNA repair capacity of BRCA2. Moreover, the variants 
showed cytokinetic delay or failure speaking for defects in the midbody formation and/or 
abscission as described before 118. In summary, we observed that one VUS selected in the 
NTD in Exon 10, G267E, has an impact on BRCA2’s functionality cytokinesis (see 3.3, 
Table 2). The cytokinetic defect observed might be due to a defective localization of 
BRCA2 to the midbody or interaction with players involved in abscission. By application of 
more functional assays as described in 3.4, we will be able to further evaluate the 
phenotype of the VUS in the NTD. Currently, we are testing the purified variants in 
BRCA2T2 in DNA binding assays as described for the cysteine mutants (2.2). Supported by 
our findings in Chapter 2 it would be interesting to know if C315S also exhibits a 
phenotype in cytokinesis. So far, we have been able to show that the DNA binding activity 
of the NTD contributes to the recombination function of BRCA2.  
In the future, both the identification of the NTD as well as established functional assays for 
VUS located in this region will be of advantage for the genetic counseling of VUS carriers. 
VUS LOCATED IN THE CTD SHOW AN INTERMEDIATE PHENOTYPE 
As described in my second objective, we collaborate with several groups from the 
ENIGMA network for the evaluation of BRCA2 VUS. In a side project, I contributed to a 
publication that focused on the evaluation of VUS that had been rated to confer a 
moderate or increased risk by using likelihood models. BRCA2 hypomorphic mutations 
can lead to the expression of proteins that retain partially their functions and thus have an 
intermediate phenotype. By testing purified variants in DNA binding assays in vitro, I could 
confirm the results observed in cellulo assays by our collaborators (Chapter 5.2, Figure 3 
and 5.4 Figure 2 & 3). This is the first study that showed the existence of intermediate risk 
variants and highlights the importance to combine functional assays with case-control 
studies to optimize the accurate predictions for the impact of VUS on BRCA2 function and 
on cancer risk. 
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In Figure 2 I illustrate the variants selected and evaluated in these two studies (Chapter 3 
and 5).  
 
BRCA2 REGULATES DMC1 – MEDIATED RECOMBINATION THROUGH THE BRC 
REPEATS 
In the third objective of my PhD I collaborated with JSM from the lab to investigate if 
BRCA2 mediates DMC1 recombination activity in meiosis as it was shown for RAD51 in 
mitosis 70. BRCA2 was shown to be implicated in meiosis and its absence causes infertility 
and chromosomal aberration 180,181. In addition, it was shown that BRCA2 and DMC1 
interact, however the mechanism and reason for this interaction remained enigmatic 
70,92,184.  
In our study we revealed that DMC1 interacts with BRCA2 via the BRC repeats (Figure 
1B) to stimulate its association with ssDNA and the formation of nucleoprotein filaments 
(4.2, Figure 8). Moreover, BRCA2 alleviates the kinetic barrier posed by RPA bound to the 
ssDNA, making it accessible for DMC1 loading. These findings established BRCA2 as a 
mediator protein of DMC1 recombination in meiosis. Our model is consistent with an 
accessory role of RAD51 in meiotic recombination as described before in yeast 93,95. In this 
model, BRCA2 would bind RAD51 monomers via BRC1-5 to provide a filament that serves 
as a starting nucleus for DMC1 to allow homofilament assembly on the ssDNA. The DMC1 
filament could then grow and start homology search and strand invasion.  
 
Figure 2: Variants of unknown clinical significance in the NTD and CTD of BRCA2 that 
were selected and evaluated in this thesis. 
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In summary, in my PhD I contributed to reveal new functions of BRCA2 in the N-terminus 
(NTD, cytokinetic defects associated with G267E) but also in the BRC repeats (DMC1 
binding) and the C-terminus (residues important for DNA binding, CTD future crystal 
structure). In addition, we have established new functional assays for the evaluation of 
BRCA2 variants. In turn, these findings will proof useful for the classification of BRCA2 
VUS. 
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APPENDIX 
 
MATERIALS 
PLASMIDS 
Name Insert Cloning Strategy Purpose 
pAC012 2x MBP BRCA2 Gift from S.C. 
Kowalczykowski 
Expression and 
purification of 2xMBP 
BRCA2 
pAC013 2x MBP BRCA2 NT 
(1-1000 aa)  
BbvCI/XhoI from 
pAC012 
Expression and 
purification of 2xMBP 
BRCA2 NT 
pAC022 GST-BRC4 BamH/XhoI Expression of BRC4 
pAC037 GFP-MBP-BRCA2 
siRNA res 
MBP-tag of a 
phCMV1 2x MBP-
BRCA2 substituted 
by eGFP and cloned 
by KpnI digest (gift 
S.Kowalczykowski) 
Expression of GFP 
MBP BRCA2 for 
purification and for in 
vivo assays 
pAC039 GFP-MBP-BRCA2 
siRNA res K268R 
Mutagenesis Expression of GFP 
MBP BRCA2 K268R 
mutant for purification 
and for in vivo assays  
pAC040 2x MBP 2 NLS 
BRCA 
Insertion of 2 NLS in 
pAC013 with 
NotI/BbvCI  
Expression and 
purification of 2xMBP 
BRCA2 NT 
pAC044 GFP-1MBP* Cut out BRCA2 Negative control for 
BRCA2 assays 
pAC045 2x MBP 2 NLS 
BRCA2 si resistant 
siRNA-resistance 
SDM 
cloning 
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pAC048 GFP-MBP-BRCA2 
siRNA res S273L 
Mutagenesis  Expression of GFP 
MBP BRCA2 S273L 
mutant for purification 
and for in vivo assays 
pAC055 GFP-MBP-BRCA2 
siRNA res G267E 
Mutagenesis Expression of GFP 
MBP BRCA2 G267E 
mutant for purification 
and for in vivo assays 
pAC086 pEGFP-MBP-
BRCA2-D2723H 
Mutagenesis Expression of GFP 
MBP BRCA2 G267E 
mutant for purification  
pAC097 2x MBP BRCA2-NT 
T1 (1-250 aa of 
BRCA2) 
Cloning with Xho/NotI 
in pAC045 
Expression and 
purification of 2xMBP 
BRCA2 1-250 aa 
pAC098 2x MBP BRCA2-NT 
T2 (250-500 aa of 
BRCA2) 
Cloning with Xho/NotI 
in pAC045 
Expression and 
purification of 2xMBP 
BRCA2 250-500 aa 
pAC101 2x MBP BRCA2-NT 
LT2 (1-500 aa of 
BRCA2) 
Cloning with 
BbvCI/XhoI in 
pAC045 
Expression and 
purification of 2xMBP 
BRCA2 1-500 aa 
pAC102 2x MBP BRCA2-NT 
LT3 (1-750 aa of 
BRCA2) 
Cloning with 
BbvCI/XhoI in 
pAC045 
Expression and 
purification of 2xMBP 
BRCA2 1-500 aa 
pAC122 pEGFP-MBP-
BRCA2-N277K 
Mutagenesis  Expression of GFP 
MBP BRCA2 N277K 
for purification and in 
vivo assays 
pAC138 GFP MBP 2NLS 
BRC4 
Gibson Assembly 
with pAC022 
For further cloning 
pAC150 pGEX-BRC1 Gift from S.C. 
Kowalczykowski 
Expression and 
purification GST-
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BRC1 
pAC151 pGEX-BRC2 Gift from S.C. 
Kowalczykowski 
Expression and 
purification GST-
BRC2 
pAC152 pGEX-BRC3 Gift from S.C. 
Kowalczykowski 
Expression and 
purification GST-
BRC3 
pAC153 pGEX-BRC5 Gift from S.C. 
Kowalczykowski 
Expression and 
purification GST-
BRC5 
pAC154 pGEX-BRC6 Gift from S.C. 
Kowalczykowski 
Expression and 
purification GST-
BRC6 
pAC155 pGEX-BRC7 Gift from S.C. 
Kowalczykowski 
Expression and 
purification GST-
BRC7 
pAC156 pGEX-BRC8 Gift from S.C. 
Kowalczykowski 
Expression and 
purification GST-
BRC8 
pAC162 Trex flag eGFP 
BRCA2 
Gift from Fumiko 
Esashi 
FLP-in system - to 
insert FLAG eGFP 
BRCA2 at FRT site 
pAC164 6His SUMO pET28 P. Duchambon Cloning  
pAC165 6His SUMO pET28 
BRCA2 2474-3190 
(CTD) 
Cloning of BRCA2 
2474-3190 (CTD) into 
6His SUMO pET28 
Expression and 
purification of CTD 
pAC173 2x MBP 2 NLS T2 
C279A 
Mutagenesis Expression and 
purification T2 C279A 
pAC174 2x MBP 2 NLS T2 
C341 
Mutagenesis Expression and 
purification T2 C341S 
pAC177 GFP-MBP-BRCA2 Gift from F. Couch Expression and 
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siRNA res Y3035S purification 
pAC178 GFP-MBP-BRCA2 
siRNA res R3052Q 
Gift from F. Couch Expression and 
purification 
pAC179 GFP-MBP-BRCA2 
siRNA res K2729N 
Gift from F. Couch Expression and 
purification 
pAC180 GFP-MBP-BRCA2 
siRNA res G2508S 
Gift from F. Couch Expression and 
purification 
pAC181 GFP-MBP-BRCA2 
siRNA res A2717S 
Gift from F. Couch Expression and 
purification 
pAC189 2xMBP-T2-C315S Mutagenesis  Expression and 
purification T2 C315S 
pAC192 pCDF DSS1 pCDF (A.el Marjou) 
Gibson Assembly 
with DSS1  
Coexpression DSS1 
with CTD for 
purification 
pAC194 2xMBP-T2-C279A 
C341S 
Mutagenesis Expression and 
purification T2 C279A 
C341S 
pAC197 2xMBP-T2-C315S 
C341S  
Mutagenesis Expression and 
purification T2 C315S 
C341S 
pAC201 2xMBP-T2-C279A 
C315S  
Mutagenesis Expression and 
purification T2 C279A 
C315S 
pAC232 2x MBP BRC4 T2 Gibson Assembly Expression and 
Purification 
pAC249 GFP-MBP-2NLS -T2 
C315S -BRC4 
Mutagenesis in vivo assays 
pET28 6His 
SUMO 
vector. 
- Gift A. el Marjou Expression and 
Purification 
pFASTBAC DSS1 Gift R.Jensen Expression and 
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Dual-DSS1 Purification 
pUC19   Gift from S. 
Kowalzcykowksi 
Joint molecule assay 
pCDF 6his 
SUMO 
RAD51   
 
PRIMER  
Name Purpose Sequence 
oAC014 RT PCR N-ter ATGACTGGTACCATGGTGAGCAAGGGCGAGG
AGC 
oAC033 RT PCR N-ter CCTGTTATAGCCTTTATCGCCG 
oAC041 RT PCR C-ter AGGAGTTGTGGCACCAAATACGAAACACCC 
oAC188 RT PCR C-ter CGGCCGCAATTGTTAGATATATTTTTTAGTTG 
oAC203 Joint molecule assay 
ATP assay 
EMSAs 
CGGGTGTCGGGGCTGGCTTAACTATGCG
GCATCAGAGCAGATTGTACTGAGAGTGC
ACCATATGCGGTGTGAAATACCGCACAG
ATGCGT 
oAC361 Mutagenesis BRCA2 N277K  CAGGGAATTCATTTAAAGTAAAGAGCTGCAAAG
ACC 
oAC362 Mutagenesis BRCA2 N277K TATTTTGGTACCCCCGAGGTTGTTGTTATTGTT
ATT 
oAC403 Oligo for DNA binding 42-mer 
5' to anneal to 167-mer 
(oAC423) 
CGGATATTTCTGATGAGTCGAAAAATTATCTTG
ATAAAGCAG 
oAC379 dT40 for EMSA TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTT 
oAC405 40mer for EMSA, anneal with 
oAC406 
TAATACAAAATAAGTAAATGAATAAACAGAGAA
AATAAAG 
oAC406 40mer for EMSA, anneal with 
oAC405 
CTTTATTTTCTCTGTTTATTCATTTACTTATTTTG
TATTA 
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oAC423 167mer for EMSA CTGCTTTATCAAGATAATTTTTCGACTCATCAGA
AATATCCGTTTCCTATATTTATTCCTATTATGTTT
TATTCATTTACTTATTCTTTATGTTCATTTTTTAT
ATCCTTTACTTTATTTTCTCTGTTTATTCATTTAC
TTATTTTGTATTATCCTTATCTTATTTA 
oAC490 42mer for 3’tail substrate with 
167mer (oAC423)  
TAAATAAGATAAGGATAATACAAAATAAGTAAAT
GAATAAAC 
oAC491 Mutagenesis C279A in T2 
BRCA2  
AAG TAA ATA GCG CCA AAG ACC ACA TTG 
GAA AGT CAA TGC CAA ATG 
oAC492 Mutagenesis C279A in T2 
BRCA2 
AAG TAA ATA GCG CCA AAG ACC ACA TTG 
GAA AGT CAA TGC CAA ATG 
oAC493 Mutagenesis C341S in T2 
BRCA2 
CTTGGTTTTTAGATTTTTCACTTTCATCAGCGTT
TGCTTCATGG 
oAC494 Mutagenesis C341S in T2 
BRCA2 
CCATGAAGCAAACGCTGATGAAAGTGAAAAAT
CTAAAAACCAAG 
oAC520 Mutagenesis C315S in T2 
BRCA2 
GTTTTTCATTATGTTTTTCTAAAAGTAGAACAAA
AAATCTACAAAAAG 
oAC596 PCR for Gibson Assembly on 
pAC138 to make NotI 2NLS 
BRC4 
TTCCAGGGGCCCGGCGGCCGCGATCCAAAAA
AGAAGAGAAAGG 
oAC597 PCR for Gibson Assembly on 
pAC138 to make NotI 2NLS 
BRC4 
GTGTTTTCACTTTGCTCTTTTTCATCAAAAAGG 
oAC598 PCR gibson assembly on 
pAC098 for overlap T2 BRC4 
AAAGAGCAAAGTGAAAACACAAATCAAAGAG 
oAC599 PCR gibson assembly on 
pAC098 for T2 stop 
GCTGATTATGATCTAGACTCGAGTTAACCCTGA
AATGAAGAAGC 
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PRIMARY AND SECONDARY ANTIBODIES  
Name Antigen Vendor 
BRCA2 OP95 BRC repeats BRCA2 EMD Millipore (OP95-100UG) 
BRCA2 E36 BRCA2 NT (188-563) Genetex (GTX70121) 
BRCA2 CA 1033 BRCA2 (C-ter) EMD Millipore (CA1033) 
Centrin-2(N-17) Centrin-2 N-terminus Santa Cruz Biotechnology (sc-
27793-R) 
DSS1 (FL-70) DSS1 full length Santa Cruz Biotechnology (sc-
28848) 
GFP  GFP  Life Technologies (A11122) 
GFP GFP SIGMA (Roche) (11814460) 
His (6x) 6-His peptide Eurogentec (PEP-156P) 
Histone H3  H3 Abcam (ab1791) 
HRP goat anti-mouse 2ndary AB anti-mouse 
antigen 
Santa Cruz Biotechnology (sc-
2055) 
HRP goat anti-rabbit 2ndary AB anti-rabbit 
antigen 
Santa Cruz Biotechnology (sc-
2055) 
MBP Maltose binding protein Invitrogen (33-5100) 
RAD51 (H-92) N-ter 1-92 of RAD51 Santa Cruz Biotechnology (sc-
8349) 
Tubulin (alpha) Alpha-tubulin Genetex (GTX102078) 
AlexaFluor555 goat anti-
mouse IgG 
Gamma Immunoglobins 
heavy and light chains 
Invitrogen A-31570 
AlexaFluor555 donkey 
anti-rabbit IgG 
Gamma Immunoglobins 
Heavy and Light chains 
Invitrogen A-21428 
 
CELL LINES 
Name Origin Grow in  
HEK293  Human embryonic kidney cells DMEM medium, FCS serum 
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VC8 BRCA2
-/- cell line from V79 
chinese hamster lung 
fibroblast 
HAM’s medium, FCS serum  
 
 
VC8 stable cell lines VC8, complemented with 
GFP-MBP BRCA2 WT or 
mutant DNA 
HAM’s medium, FCS serum  
 
G418 selection 10 ug/ml 
 
BACTERIAL STRAINS   
Designation Supplier 
E. coli BL21 DE3 pISO Dscb Gift from A. el Marjou 
DH5 alpha electrocompetent cells  Gift from C.Janke  
XL-10 gold supercompetent cells Agilent (XL kit) 
BL21(DE3)pLysS chemo-competent 
cells 
Made by the lab 
E. Coli BL21 BRL Recombinant platform I. Curie 
EQUIPMENT, KITS, INVENTORY 
Designation Supplier 
1kb DNA Ladder  Invitrogen 
3D deconvolution microscope  Nikon 
4-5 D video microscope deconvolution Nikon 
AKTA prime plus chromatograph GE Life Sciences 
Amersham ECL Prime Western Blotting 
Detection Reagent 
VWR 
Amylose Magnetic Beads NEB 
Amylose resin NEB 
ATP [γ-32P]- 3000Ci/mmol 10mCi/ml EasyTide Perkin Elmer 
BioRexin resin BioRAD 
Cell culture material TPP 
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Cell culture media (HAM’s, DMEM) Eurobio 
Centrifuge Refrigerated Model 5810 R Eppendorf 
ChemiDoc camera  Bio-Rad 
Coomassie Brilliant Blue  Bio-Rad 
Disintegrator CellD Constant System  
Disposable columns Pierce 
Dynabeads MyOne Streptavidin Thermo Scientific 
FACSCalibur BD Biosciences 
FCS Sigma 
UV Transilluminator  Vilber 
Gel casting system Hoefer  Dutscher 
Gibson Assembly Cloning kit HiFi  NEB 
Glutathione sepharose 4B beads Dutscher 
Graph Pad Prism Software 
HiSpeed Plasmid Maxi kit QIAGEN 
HiTrap Heparin HP column 5 ml  GE Healthcare 
Hoefer Protein vertical electrophoresis system 
Mighty Small II SE 250 
Dutscher 
Hybond ECL Membrane VWR 
illustra MicroSpin G-25 columns GE Healthcare 
Illustra Minispin Kit GE healthcare 
Image Quant (GE) Software  
Image Quant Software  GE Healthcare 
Microcentrifuge 5424 Eppendorf 
Mini Transblot Cell Bio-Rad 
Mini-PROTAN Tetra cell Bio-Rad 
Mini-PROTEAN TGX SDS gels (4-15%, 7.5%, 
10%, 12%) 
Bio-Rad 
Mini-PROTEAN TGX stain-free SDS gels (4-
15%, 7.5%, 10%, 12%) 
Bio-Rad 
Nanodrop 2000  Thermo Scientific 
NanoOrange Protein Quantitation Kit Thermo Fisher 
NucleoBond Xtra Midi kit Macherey Nagel 
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Plate reader Victor 3  perkin elmer 
Polyethyleneimine (PEI) thin layer 
chromatography (TLC) plate  
EMD chemicals 
Precision plus SDS-PAGE Standards dual 
colors 
Bio-Rad 
Precision plus SDS-PAGE Unstained  Bio-Rad 
ProLong® Gold antifade reagent with DAPI Thermo Fisher 
PROTEIN CONCENTRATORS, 9K MWCO Thermo Scientific 
Protein-Assay Bio-Rad 
Protino® Ni-NTA agarose  Macherey Nagel 
PVDF Hybond Membrane Dutscher  
QuikChange II site-directed mutagenesis kit  Agilent 
QuikChange XL site-directed mutagenesis kit  Agilent 
Refrigerated Microcentrifuge 5424 R Eppendorf 
SPECTRA/POR Dialysis Tubing Thermo Scientific 
Storage phosphor screen GE healthcare 
SYPRO Orange staining solution  Sigma-Aldrich 
T100 Thermal Cycler Bio-Rad 
TITANIUM One-Step RT-PCR kit Clontech 
TurboFect Transfection Reagent Thermo Scientific 
Typhoon PhosphorImager FLA7000 Amersham Biosciences 
Watman paper GE Healthcare 
Wizard SV Gel and PCR clean-up system  Promega 
 
ENZYMES 
Designation Suppplier 
Proteinase K recombinant Roche 
Restriction Enzymes NEB 
SUMO Protease Thermo Scientific 
T4 DNA ligase and Ligase Buffer 10x NEB 
T4 Polynucleotide Kinase and Buffer 10x NEB 
Taq DNA Polymerase and ThermoPol Buffer NEB 
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10x 
CHEMICALS 
Designation Supplier 
100 mM dNTP set Invitrogen 
1x PBS Laverie Curie 
20% SDS Euromedex 
ABT-888 Veliparib Selleck Chemicals 
Acetic acid,ReagentPlus(R) Sigma-Aldrich 
Adenosine 5’ triphosphate (ATP) Sigma-Aldrich 
Agarose 100% Euromedex 
Ammoniumpersulfate (APS) Bio-Rad 
Ampicillin sodium salt Sigma-Aldrich 
Bromophenol blue Bio-Rad 
BSA Sigma-Aldrich 
Calcium Chloride Sigma-Aldrich 
Crystal Violet  Bio-Rad 
DMSO - Dimethyl Sulfoxide Sigma-Aldrich 
DNase I recombinant RNAse free Roche 
DTT Sigma-Aldrich 
EDTA  Magasin Curie 
EDTA-free Protease Inhibitor Cocktail  Roche 
EGTA Sigma-Aldrich 
Ethanol absolute 99.9 % Magasin Curie 
Ethidium Bromide Sigma-Aldrich 
Formic Acid Sigma-Aldrich 
G418 Disulfate salt Sigma-Aldrich 
Glutaraldehyde Sigma-Aldrich 
Glutaraldehyde Sigma Aldrich 
Glycerol 99% Laverie Curie 
Glycine Magasin Curie 
HEPES  Euromedex 
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HEPES Euromedex 
Imidazole Sigma-Aldrich 
IPTG - Isopropyl beta-D-1-thiogalactopyranoside Sigma-Aldrich 
Kanamycin monosulfate Sigma-Aldrich 
L-(+)-Arabinose  Sigma-Aldrich 
LB plates & media for bacterial growth Laverie Curie 
L-Glutamin  Eurobio 
Lithium Chloride VWR 
Lysozyme Sigma-Aldrich 
Magnesium Chloride Sigma-Aldrich 
Maltose Magasin Curie 
Methanol 99.9 % Magasin Curie 
Mitomycin C  Sigma-Aldrich 
MTT - Thiazolyl Blue Tetrazolium Bromide Sigma-Aldrich 
Nonidet P40 Magasin Curie 
Paraformaldehyde 16% Euromedex 
PIPES Euromedex 
PMSF Sigma-Aldrich 
Potassium Chloride Sigma-Aldrich 
Potassium phosphate monobasic Sigma-Aldrich 
Sodium Chloride (NaCl) Magasin Curie 
Sodium hydrogen carbonate Sigma-Aldrich 
Sucrose Sigma-Aldrich 
TEMED Bio-Rad 
TRIS acetate salt Sigma-Aldrich 
Triton X-100 Euromedex 
Trizma(R) base, Sigma Aldrich 
TRIzol Reagent  life technologies 
Trypsine/EDTA Gibco 
Zinc Chloride Sigma-Aldrich 
Β-Mercaptoethanol Bio-Rad 
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BUFFERS 
Designation Composition  
6x DNA loading buffer 
 
0.25% xylene cyanol solution (1%), 0.25% 
bromophenol blue 1% solution (0.25%), 
30% glycerol  
6x Laemmli Buffer for SDS PAGE 6% SDS, 0.003% Bromophenol blue, 48% 
glycerol, 375 mM Tris pH6.8,  9% β-
Mercaptoethanol 
Agarose gel electrophoresis buffer 1x Tris-Acetate EDTA 
SDS PAGE running buffer  1x TrisGlycine, 0.1% SDS 
Transfer buffer 1x TrisGlycine, 10% Methanol, 0.025% 
SDS 
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RESUMÉE EN FRANÇAIS 
 
 
Titre : Caractérisation d’un nouveau domaine de fixation à l’ADN dans le N-terminus de 
BRCA2 et évaluation des variantes BRCA2 non-classifiées identifiées dans les patients de 
cancer du sein dans la même région 
Mots clés : Réparation d’ADN, Recombinaison Homologue (RH), BRCA2, cancer du sein 
Résumée 
Les mutations héréditaires dans le gène BRCA2 sont associées à une forte susceptibilité 
au développement du cancer du sein et de l’ovaire. La protéine suppresseur de tumeur 
BRCA2 est essentielle pour préserver l’intégrité des chromosomes après 
endommagement de l’ADN. BRCA2 est impliquée dans la recombinaison homologue 
(RH), une voie fiable de réparation des cassures de l’ADN. BRCA2 exerce aussi un rôle 
pendant la mitose afin d’assurer un point de contrôle et une division cellulaire correcte. 
Bien que le rôle de BRCA2 dans la RH soit bien établi, la littérature décrive une 
restauration partielle de la fonction de RH dans des cellules ne possédant pas le site de 
liaison à l’ADN en C-terminal (CT-DBD), ce que nous a encouragé à voir s’il existait un 
domaine secondaire de liaison à l'ADN. L'analyse in silico a révélé un domaine zf-PARP 
putatif dans la région N-terminale. Normalement, ce type de domaine s’associe à l’ADN, 
ce que nous a porté à l’examiner. En utilisant des fragments purifiés de la partie N-
terminale comprenant le site putatif dans des analyses de changements de mobilité 
électrophorétique, nous avons montré une activité de liaison à l’ADN. En comparaison 
avec le CT-DBD canonique, le site de liaison à l’ADN en N-terminal (NT-DBD) 
manifeste une affinité plus forte pour divers substrats et contrairement du CT-DBD il est 
capable de s’associer à l’ADN à double brin. En utilisant des tests d’échange de brin, 
nous avons également montré que le NT-DBD peut stimuler la fonction de 
recombinaison de RAD51. De plus, des variantes faux-sens dans le NT-DBD trouvé chez 
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les patients atteints de cancer du sein ont montré une activité réduite d’association à 
l’ADN et une stimulation diminuée de l’activité de RAD51 ce qui implique que ces 
amino-acides sont importants pour les deux fonctions. Ce travail révèle un nouveau site  
de liaison à l’ADN, ce qui contrairement au CT-DBD est capable de s’associer à l’ADN 
double-bras(db) et stimuler l’activité de recombinaison de RAD51. Nous proposons que 
le NT-DBD positionne RAD51 à la jonction entre ADNdb et ADNsb, ce qui facilite le 
chargement de RAD51 sur l’ADN recouvert de RPA. Cette activité pourrait promouvoir 
la RH pendant la réparation des cassures de l’ADN (von Nicolai, C et al., 2016, under 
revision).  
Afin de définir la prévalence des mutations de NT-DBD pour la prédisposition au cancer, 
nous avons sélectionné des variants faux-sens non-classifiés (variants of unknown 
clinical significance), identifiés dans des familles à risque élevé de développer un cancer 
du sein. Nous avons effectué des tests afin d’étudier l’impact de ces variants sur la 
fonction de BRCA2 dans la RH et la mitose. Certains de ces variants ont conduit à une 
hypersensibilité aux agents endommageant l’ADN et aux inhibiteurs de PARP, 
caractéristique d’une RH défectueuse alors qu’un de ces variants était compétent pour la 
réparation. Tous les variants ont induit une duplication normale des centrosomes, mais la 
cytokinèse était défectueuse. Ce phénotype suggère un défaut dans la formation du 
midbody et de l’abscission. Cette étude aidera à classifier les VUS dans le NT-DBD et 
facilitera la consultation génétique pour des individus. BRCA2 est un médiateur de la RH 
dépendante de RAD51. Son homologue méiotique, DMC1, partage structure et fonction 
similaire et s’associe à BRCA2. Néanmoins, la pertinence fonctionnelle de cette 
interaction reste élusive. Nous avons montré que BRCA2 interagit avec DMC1 au travers 
des répétitions BRC et promeut la formation de molécules d'adhérence. Cet effet 
stimulant est dû au renforcement de la liaison de DMC1 à l’ADN. BRCA2 complet et 
fonctionnel était surtout capable de stimuler l’activité d’échange de brin de DMC1, ce 
qui confirme les résultats obtenus avec les répétitions BRC. Nos résultats identifient 
BRCA2 comme une protéine de médiation de la recombinaison méiotique et renforcent 
le rôle des répetitions BRC dans cette fonction (Martinez, von Nicolai, et al., PNAS, 
2016). 
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ABSTRACT  
 
Title : Characterization of a novel DNA binding domain in the N-terminus of BRCA2 and 
evaluation of BRCA2 variants identified in breast cancer patients in the same region 
Keywords : DNA repair, Homologous Recombination (HR), BRCA2, breast cancer  
Abstract :  
Germline mutations in the BRCA2 gene lead to high susceptibility to the development of 
breast and ovarian cancer. The tumor suppressor protein BRCA2 is essential for 
preserving chromosome integrity after DNA damage emerging from endogenous or 
exogenous sources. BRCA2 functions in Homologous Recombination (HR), the most 
reliable pathway to repair DNA double strand breaks. BRCA2 exerts its tumor suppressor 
role also at several stages during mitosis where it ensures checkpoint control and proper 
cell division.  
Although the function of BRCA2 in HR is well established, evidence from the literature 
describing a partial restoration of HR function in cells lacking the C-terminal DNA 
binding domain (CT-DBD) brought us to test the hypothesis of a secondary DNA binding 
domain in BRCA2.  
In silico analysis of the protein revealed a putative zinc finger-PARP domain in exon 10 
of the N-terminal region. This type of domain usually binds DNA which prompted us to 
examine this activity in vitro. Using purified N-terminal fragments comprising the 
putative DNA binding domain in electrophoresis mobility shift assay we demonstrated 
the DNA binding activity of the N-terminus of BRCA2. When compared to the canonical 
CT-DBD, the N-terminal DNA binding domain (NT-DBD) exhibits stronger affinity for 
various DNA substrates and unlike the CT-DBD, it can also associate with dsDNA. 
Using a DNA strand exchange assay we also showed that the NT-DBD stimulates the 
recombination function of RAD51. In addition, BRCA2 missense variants in the NT-
DBD found in breast cancer patients showed reduced dsDNA binding and decreased 
stimulation of RAD51 recombination activity on dsDNA/ssDNA containing substrates, 
implying that these residues are important for both functions. This work revealed a novel 
DNA binding domain in the N-terminus of BRCA2 that, in contrast to the CT-DBD, can 
248 
 
associate with dsDNA and promote RAD51 recombination activity. We propose that the 
NT-DBD positions RAD51 at the ssDNA/dsDNA junction facilitating RAD51 loading  
onto the RPA-coated ssDNA. This activity may promote HR in DSB repair and in 
daughter strand gap repair (von Nicolai, C et al., 2016, under revision). 
To define the relevance of NT DBD on cancer predisposition, we selected several 
missense variants of unknown clinical significance (VUS) found in families at high risk 
to develop breast cancer located in this region. We used in vitro and in vivo functional 
assays to study the impact of the mutations on BRCA2 function in HR and mitosis. Some 
of the variants exhibited hypersensitivity to DNA damaging agents and PARP inhibitors, 
a hallmark of defective HR while one variant was proficient in repair. All variants 
showed normal centrosome duplication, but exhibited delayed or failed cytokinesis. This 
phenotype suggests a defect of the variants in midbody formation and abscission as a 
consequence of impaired BRCA2 function. It remains to be established if the defects in 
HR and cytokinesis are related. In the future, this study will help to classify VUS in the 
NT-DBD and facilitate genetic counselling of individuals carrying these mutations.  
BRCA2 is a mediator protein in RAD51-dependent HR. Its meiotic counterpart, DMC1, 
shares similar structure and function and binds BRCA2. However, the functional 
relevance of this interaction remained elusive. In this work, we showed that through the 
BRC repeats, BRCA2 interacts with DMC1 and promotes joint molecule formation. This 
stimulatory effect is due to the enhancement of DMC1 assembly on ssDNA. Importantly, 
full-length BRCA2 also stimulated the DNA strand exchange activity of DMC1, 
confirming the results with the isolated BRC repeats. Our results identify BRCA2 as a 
mediator of meiotic recombination and underline the role of the BRC repeats on this 
function (Martinez, von Nicolai, et al., 2016, PNAS).  
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ANNEXE 
SYNTHESE DU MANUSCRIPT EN FRANCAIS  
HYPOTHESES ET OBJECTIFS DE CE TRAVAIL 
Les mutations héréditaires dans le gène BRCA2 sont associées à une forte susceptibilité 
au développement du cancer du sein et de l’ovaire. La protéine suppresseur de tumeur 
BRCA2 est essentielle pour préserver l’intégrité des chromosomes après 
endommagement de l’ADN. BRCA2 est impliquée dans la recombinaison homologue 
(RH), une voie fiable de réparation des cassures de l’ADN. Ici, BRCA2 servit pour le 
recrutement de la recombinase RAD51 à l’ADN et favorise sa fonction dans la RH afin de 
réparer les cassures d’ADN. Ainsi, le mauvais fonctionnement de BRCA2 peut conduire à 
l’instabilité génomique, une marque de la formation des tumeurs. L’absence de BRCA2 
peut également conduire à l’amplification du centrosome et l’échec dans les derniers pas 
dans la cytokinèse, suggérant une fonction de BRCA2 dans ce processus, ce qui pourrait 
expliquer l’aneuploïdie dans les cancers qui sont liés à l’absence de BRCA2. Plusieurs 
domaines fonctionnels de BRCA2 ont été décrits, néanmoins, le rôle d’autres domaines 
comme le domaine N-terminale restent énigmatiques. Les fonctions, modifications et 
partenaire d’interaction de BRCA2 sont sous l’examen minutieux. 
 
OBJECTIF 1: INVESTIGATION ET CARACTERISATION D’UN DOMAINE DE 
FIXATION A L’ADN PUTATIVE DANS LE N-TERMINUS DE BRCA2 
Les premiers 40 acides aminés de BRCA2 sont bien conservés et contiennent un domaine 
d’interaction avec PALB2. Cependant, on sait peu des choses sur la région N-terminale 
laquelle constitue un tiers de la protéine. Des études avec des cellules humaines 
résistantes aux inhibiteurs de PARP ainsi qu’avec l’orthologue de BRCA2, Brh2 dans U. 
maydis ont été montré que des mutants manquant du domaine de fixation à l’ADN C--
terminale ont été capables de restaurer la compétence la recombinaison en réponse aux 
dommages d’ADN. Ces indications nous ont conduits à émettre l’hypothèse que la 
compétence en RH et la résistance aux dommages d’ADN observés dans les cellules 
exprimant une version tronqué de BRCA2 ce qui manquent le domaine de fixation à l’ADN 
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C—terminale, proviennent d’un deuxième domaine de fixation à l’ADN dans le N-terminus. 
En utilisant la séquence primaire de BRCA2 avec l’outil in silico SMART, nous avons 
révélé un domaine zf-PARP putatif dans la région N-terminale. Normalement, ce type de 
domaine s’associe à l’ADN, ce que nous a porté à l’examiner. 
Mon premier objectif de ce travail était donc l’investigation de ce domaine de fixation à 
l’ADN putatif dans le N-terminus de BRCA2 humaine (NTD) 
 
OBJECTIF 2: CARACTERISATION DES VARIANTS FAUX-SENS NON-
CLASSIFIES (VARIANTS OF UNKNOWN CLINICAL SIGNIFICANCE) 
DANS LE DOMAINE DE FIXATION A L’ADN N-TERMINALE DE 
BRCA2 (NTD) 
Afin de caractériser la pertinence fonctionnelle du N-terminus et le domaine de fixation de 
l’ADN en particulier, nous avons décidé d’étudier des variants faux-sens identifiés (VUS) 
dans des familles à risque élevé de développer un cancer du sein situés dans cette région. 
Nous avons voulu étudier la pertinence du nouveau domaine en examinant l’impact de ces 
variants dans leur fonction et au même temps ça nous permettra d’évaluer des variants 
faux-sens non-classifiés qui sont très rares et leur causalité pour le développement du 
cancer du sein est difficile à évaluer.  
Nous avons sélectionné des VUS situés dans le NTD qui sont probablement nuisibles 
pour les individus portant la mutation. Tous les VUS sont bien conservés dans les 
mammifères et prévues de se lier à l’ADN. Dans ce travail, j’ai effectué des tests afin 
d’étudier l’impact de ces variants sur la fonction de BRCA2 dans la RH et la mitose. 
 
OBJECTIF 3: ETUDE DU ROLE DE BRCA2 DANS LA RECOMBINAISON 
MEIOTIQUE 
Dans les cellules somatiques BRCA2 catalyse le rôle du médiateur de RAD51 dans le RH. 
Son homologue méiotique, DMC1, partage structure et fonction similaire et s’associe à 
BRCA2 afin de stimuler l’activité d’échange de brin de DMC1. Une interaction physique a 
été établie pour BRCA2 pleine longueur et DMC1. Dans les plantes, cette interaction était 
trouvé d’être réalisée via les répétitions BRC alors que chez les humains, un motif 
conservé PhePP était suggéré d’être responsable pour la liaison avec DMC1. Cependant, 
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le domaine PhePP parait négligeable dans les souris ce qu’il indique qu’il existe 
probablement un autre site pour l’interaction de DMC1 dans BRCA2. De plus, l’alignement 
des séquences avec les paralogues de RAD51 a montré que le motif pour interagir avec 
les répétitions BRC est très bien conservé dans DMC1. Nous avons donc examiné si les 
répétitions BRC pourraient également se lier à DMC1 et la pertinence fonctionnelle de 
cette interaction.  
 
RESULTATS 
Objectif 1: Investigation et caractérisation d’un domaine de fixation à l’ADN putative 
dans le N-terminus de BRCA2 
Afin d’effectuer des analyses biochimiques du N-terminus de BRCA2, nous avons 
construit la région N-terminale comprenant les premiers 750 acides aminés de BRCA2 
humaines. Nous avons purifié le fragment des cellules humaines HEK293s et nous avons 
réussi en obtenant la protéine pure et non-dégradée (Figure 1).  
Après avoir obtenu la protéine, nous l’avons utilisé dans des analyses de changements de 
mobilité électrophorétique (EMSA). Nous avons incubé la protéine avec une ADN à simple 
brin radio marqué avec 32γ ATP (ssDNA*). La séparation des complexes protéine-ADN et 
l’ADN seule a été effectuer sur un gel natif de polyacrylamide (Figure 2A). Comme indiqué 
dans la figure 2B, BRCA2LT3 s’est lié à l’ADN et a formé des complexes protéine-ADN, 
contrairement au contrôle négatif, le tag de 2xMBP seul.  
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Figure 1: Purification du domaine N-terminale de BRCA2. A) structure de BRCA2 et le fragment 
BRCA2LT3 utilisé pour la transfection des cellules et purification B) protocole pour la purification C) 
SDS PAGE montrant la procédure de la purification et la protéine obtenue dans la voie 8.  
 
A 
B 
C 
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Figure 2: EMSA avec BRCA2LT3  et une ADN à simple brin radio marqué avec 
32
γ ATP ssDNA * (A) 
mécanisme d’EMSA B) résultat d’EMSA en montrant des complexes de la protéine et l’ADN et la 
quantification.  
Pour trouver le domaine spécifique qui se lie à l’ADN, on a construit des fragments de 
BRCA2LT3 plus petits : BRCA2 T1 (1-250 aa), BRCA2 T2 (250-500 aa) et BRCA2 LT2 (100-500 
aa) (Figure 3A). Nous avons purifiés les fragments comme démontré pour BRCA2LT3 et les 
utilisé pour EMSA. Comme indiqué dans 3B, BRCA T1 n’a pas été capable de se lier avec 
l’ADN, contrairement au BRCA2 T2 et BRCA2 LT2 qui s’est liés avec l’ADN, indiquant que le 
domaine de fixation à l’ADN du N-terminus se trouve dans BRCA2 T2 (250-500 aa) comme 
prévu dans les analyses in silico.  
 
A B 
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Figure 3 A) fragments pour la purification et SDS PAGE montrant les fragments purifiés et confirmé 
avec Western Blot B) EMSA avec les fragments et ssDNA* et sa quantification. 
Après avoir montré la localisation du domaine de fixation à l’ADN dans le NTD, nous 
avons conçu de comparer l’activité NTD avec le domaine C-terminale canonique 
(CTD). Pour cela, nous avons construit un fragment du CTD en complexes avec DSS1 
et nous les avons exprimés dans les cellules E.coli (Fig 4A). Nous avons purifié le 
complexe en utilisant Ni NTA resin et puis une colonne d’hépar ine. Le complexe était 
purifié sans dégradation en complexe avec DSS1 (Fig 4B).  
Ensuite, nous avons utilisé les deux protéines (NTD et CTD) afin de les comparer en 
utilisant EMSA. J’ai préparé des substrats d’ADN radio marqué avec 32γ ATP imitant la 
jonction entre ADNdb et ADNsb après les cassures double-bras d’ADN : ssDNA, dsDNA, 
3’tails, 5’tails et gapped substrats. J’ai pu montrer que le NTD ainsi le CTD est capable de 
se lier avec tous les substrats ssDNA, 3’tails, 5’tails et gapped substrats. Contrairement au 
CTD, le NTD a montré une association forte avec le dsDNA, indiquant que cette fonction 
est particulière pour le NTD. De plus, j’ai observé que l’affinité pour l’ADN en général est 
plus forte pour le NTD car j’ai vu la formation de complexes avec l’ADN déjà en faibles 
concentrations contrairement au CTD (Figure 5).  
A 
B 
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Figure 4: Purification du CTD. A) construction du CTD en complexe avec DSS1 pour la purification 
B) Purification du CTD avec Ni-NTA resin et colonne d’heparine (gauche). Droite : SDS PAGE et 
Western Blot de la protéine purifié en complexe avec DSS1. 
A 
B 
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Comme le domaine de fixation à l’ADN était décrit comme zinc-finger PARP-like 
domaine, nous étions intéressés si de résidus de Cystéines et Histidine, normalement 
responsables pour la fixation à l’ADN dans des zinc-fingers, jouent un rôle important 
pour le NTD. J’ai effectué une mutagenèse de cystéines différentes dans BRCA2T2 et 
également des combinaisons des mutations. Comme indiqué dans Figure 6, j’ai purifié 
les fragments (variants) pour des EMSAs en utilisant ssDNA et dsDNA.  
Figure 5: EMSAs et quantifications pour la comparaison du NTD et CTD en utilisant des 
substrats différents d’ADN. Explications dans le texte.  
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Figure 6: Cystéines sélectionnés pour la mutagenèse dans BRCA2T2. En bas, le SDS PAGE des 
variants purifiés est montré. À gauche, la quantification des EMSAs avec ssDNA et dsDNA. 
Pour les réactions avec ssDNA, je n’ai pas pu observer un impact négatif des 
mutations sur la capacité de BRCA2T2 de former des complexes avec l’ADN. Au 
contraire, en utilisant dsDNA, j’ai remarqué une réduction de formation des complexes 
protéine-dsDNA pour la mutante C315S et les double-mutants portant la même 
mutation. Ça pourrait indiquer que ce résidu est important pour le fonctionnement du 
NTD dans la réparation d’ADN par RH.  
BRCA2 joue un rôle principal comme médiator de la recombinaison de RAD51 en RH. Ici, 
son fonction est d’interagir avec RAD51 via les répétitions BRC afin de la localiser au site 
du dommage d’ADN et de l’aider à se lier avec ssDNA. BRCA2 est capable d’enlever la 
barrière cinétique de RPA pour que RAD51 puisse former des filaments nucléoprotéiques 
et accomplir son rôle en RH. Il a été prouvé ultérieurement que le domaine de fixation 
d’ADN CTD de BRCA2 et une seule répétition BRC sont suffisants de stimuler l’activité 
d’échange de brin de RAD51. Nous avons demandé si l’activité du NTD avec une 
répétition BRC étaient aussi assez pour assumer cette fonction. J’ai donc construit un 
fragment se composant de BRC4 et BRCA2T2, puis j’ai exprimé et purifié BRCA2BRC4T2 
comme décrit avant. On utilise des tests in vitro pour mesurer l’activité d’échange de brin 
de RAD51. Ici, quand on incube un substrat 3’tail d’ADN avec RPA, RAD51 n’est pas 
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capable de se lier avec l’ADN. BRCA2 ou un fragment composé d’une répétition BRC et 
un domaine de fixation à l’ADN peuvent atténuer l’inhibition de RPA est RAD51 forme des 
produits d’échange de brin comme indiqué dans la Figure 7. Quand nous testaient le 
fragment BRCA2BRC4T2 dans cette manipulation, on a pu observer que la protéine était 
capable d’enlever RPA et aider à RAD51 d’échanger les brins. Curieusement, en utilisant 
BRCA2T2 seul dans les mêmes conditions, il était aussi capable de stimuler RAD51 et la 
quantification montre que les deux fragments avec ou sans BRC4, ont eu un effet dans les 
mêmes proportions. Par contre, le CTD n’a pas eu le même effet que BRCA T2 seul, ce qui 
nous a conduit à spéculer que l’effet est dû à la capacité du NTD de se lier avec dsDNA. 
De cette façon, le NTD pourrait s’attacher particulièrement à la jonction ssDNA/dsDNA en 
remplaçant RPA et permettant l’assemblement de RAD51 au ssDNA.  
 
Figure 7: DNA strand exchange assays avec BRCA2T2, BRCA2BRC4T2 et CTD et ses quantifications. 
Explications dans le texte. 
Afin de tester cette hypothèse, nous avons effectué les mêmes tests en utilisant la 
mutante C315S montrant un défaut de se lier à dsDNA (Figure 8). En effet, C315S a 
montré d’être moins capable de stimuler l’activité de RAD51. En plus, le double mutant 
C279A/C315S a eu une réduction plus forte que C315S. Comme contrôle négative, nous 
avons effectué le même test avec un substrat ssDNA au lieu du 3’tail et nous avons 
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observé que l’activité était rétablie, indiquant que le mutant peut se lier avec ssDNA pour 
stimuler l’activité de RAD51. 
 
Figure 8: Strand exchange assays et quantifications avec BRCA2T2 et les mutants C315S ainsi que 
C279AC315S avec 3’tail substrat (panneau supérieur) ou ssDNA (panneau inférieur). 
Dans notre modèle (Fig 9), on propose que soit aux cassures d’ADN double-bras soit aux 
fourches de réplication bloquées, le NTD de BRCA2 est capable de s’associer aux 
jonctions ssDNA/dsDNA comme premier contact avec l’ADN en replaçant RPA. Ici, les 
répétitions BRC délivrent des monomères de RAD51 au site, et permettent RAD51 de 
s’associer à ssDNA en bloquant l’association avec dsDNA. Le domaine C-terminale (CTD) 
est ensuite capable d’enlever RPA par interaction avec DSS1 et RAD51 peut former les 
filaments nucléoprotéiques pour réaliser son rôle d’échange des brins d’ADN avec le 
modèle homologue pour la réparation du dommage. Ce modèle expliquerait pourquoi les 
fragments de BRCA2 en manque du CTD sont encore capables de servir comme 
médiateur dans le RH et permettent aux cellules de survivre des dommages d’ADN. 
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Figure 9: Modèle pour l’interaction du NTD et CTD pour la réparation d’ADN. 
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OBJECTIF 2: CARACTERISATION DES VARIANTS FAUX-SENS NON-
CLASSIFIES (VARIANTS OF UNKNOWN CLINICAL SIGNIFICANCE) DANS LE 
DOMAINE DE FIXATION A L’ADN N-TERMINALE DE BRCA2 (NTD) 
Pour mon deuxième objectif, j’ai sélectionné des variants faux-sens non-classifiés 
(variants of unknown clinical significance VUS) dans le domaine de fixation à l’ADN (NTD) 
que nous avons identifié. Ces mutations faux-sens étaient identifiées dans des patients du 
cancer du sein mais leur impact sur le fonctionnement de la protéine et donc le risque de 
développer un cancer pour les individus avec un de ces mutations restent inconnu. Les 
VUS sont enregistrés dans les bases des données BRCAshare et BIC et sont aussi 
prévus d’être délétères (Fig 1). 
 
 
Figure 1: variants faux-sens (VUS) situé dans la NTD de BRCA2 sélectionnés pour cette étude.  
 
RESULTATS ET CONCLUSIONS 
Nous avons appliqué plusieurs tests fonctionnels sur ces variants qui sont résumés dans 
le tableau récapitulatif 1. Afin d’étudier les VUS in vivo, nous avons complémentés des 
cellules BRCA2-/- (VC8) avec cDNA du wild type ou variant et établi des lignées cellulaires 
stables. De plus, nous avons introduit les mutations dans le fragment BRCA2T2 pour la 
purification des mutants pour tester leur capacité de s’associer avec l’ADN. Les cellules du 
VUS G267E n’ont pas été sensitives aux dommages ADN (MMC et inhibiteurs de PARP) 
ce qu’exclus un défaut du RH. Toutefois nous avons observé un défait du cytokinèse car 
les cellules, même en absence des agents nuisibles, ont montré une croissance diminuée. 
En utilisant time-lapse microscopy on a pu observer que l’abscission des cellules dans la 
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cytokinèse est retardé ou même absent ce que corresponde à un niveau élevé des 
cellules multinuclées. Les deux phénomènes indiquent un défait probable dans les 
dernières étapes de la cytokinèse, mais ils ne sont ni dus à une interaction interrompu 
avec les protéines du midbody testés ni à l’amplification du centrosome.  
Les autres variants testé ont eu un phénotype délétère dans les tests du RH. Comme 
nous n’avons pas pu détecter leur expression en qualité égal comme pour BRCA2 et 
G267E, nous ne pouvons pas conclure que l’effet provient d’un fonctionnement perturbé 
ou de l’absence d’expression des protéines variants. Jusqu’à présent, nous pouvons 
seulement être certains que les variants localisent jusqu’au nucleus et interagissent avec 
les protéines du midbody testés quand on les surexprime dans les cellules HEK293.  
Le variant K268R est une mutation artificielle non-enregistrée dans les bases données 
pour les VUS de BRCA2. Dans les survival assays avec MMC et après le traitement avec 
les inhibiteurs de PARP, les cellules ont eu un phénotype qui est sensitif aux dommages 
d’ADN. Elles ont aussi montrés un défait en cytokinèse mais nous n’avons pas encore pu 
analyser leur statut en multinucleation et amplification des centrosomes. La protéine a été 
capable d’interagir avec les components du midbody. Nous allons tester si le défait en RH 
est connecté avec le défait de croissance observé.  
Nous avons observé le même phénotype pour le VUS S273L qui est enregistré deux fois 
dans les bases données. Les analyses fonctionnelles identiques seront donc appliquer à 
S273L. 
Nous avons sélectionné le mutant N277K car il a été déjà analysé dans les tests 
fonctionnels qui ont relevé un phénotype défectueux pour la formation du midbody et dans 
l’abscission. Nous avons été intéressés à son comportement dans les tests pour analyser 
la RH. Les traitements avec MMC et les inhibiteurs de PARP ont relevé un défait dans la 
réparation d’ADN. Maintenant nous sommes curieux de savoir s’il y a une connexion entre 
les défaits en RH et la mitose car BRCA2 est également impliquée sur des postes de 
contrôle dans le cycle cellulaire.   
Car les VUS sont localisés dans le NTD, nous sommes intéressés si les mutants montrent 
des défaits dans la liaison avec l’ADN comme nous avons montré pour C315S dans 
l’objectif 1. En utilisant EMSAs, nous pouvons tester l’association des VUS avec ssDNA 
ou dsDNA. Les quatres variants ont pu se lier à ssDNA par contre C273L a montré une 
capacité baisse de se lier à dsDNA ce qu’il pourrait expliquer un phénotype délétère en 
RH.  
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D’autre part, nous sommes en train de caractériser les VUS que nous avons testé dans 
l’objectif 1 pour leur capacité de l’association à l’ADN (C279A, C315S et C341) en 
appliquant clonogenic survival assay et tests pour la compétence de RH. 
 
À l’avenir, nous avons planifié d’établir ces lignes cellulaires humaines BRCA2-/ -qui 
expriment les VUS d’un locus endogène (HEK293 FLP in system ou DLD1 cells) afin de 
reproduire les résultats obtenu avec les VC8 et tester les phénotypes d’autres variant pas 
encore testé en cytokinèse comme pour G267E. De plus nous allons mettre en place un 
test de RH (GFP reporter assay et RAD51 foci). Pour mieux comprendre le défait du 
mutant G267E dans la formation du midbody et l’abscission nous avons planifié de tester 
l’interaction avec autres component du midbody, la localisation et le profil du cycle 
cellulaire. 
 
 
 
 
Variant 
MMC/ 
PARPi 
sensitive 
Cyto-
kinetic 
defect 
Multi-
nucleation 
Centrosome 
amplification 
Interaction 
with 
midbody 
proteins 
DNA 
binding 
proficient 
G267E No yes yes no Yes yes 
K268R Yes yes TBT TBT Yes yes 
S273L Yes yes TBT TBT Yes Yes 
N277K Yes yes TBT TBT Yes yes 
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OBJECTIF 3: ETUDE DU ROLE DE BRCA2 DANS LA RECOMBINAISON 
MEIOTIQUE 
DMC1 est la contrepartie méiotique de RAD51 car elle forme des filaments 
nucléoprotéique pour la recherche d’homologie et l’invasion du brin homologue (D-loop 
formation) dans la méiose I de manière similaire. Comme décrit, l’interaction physique 
entre DMC1 et BRCA2 a été démontré déjà avant, néanmoins, la signifiance fonctionnelle 
de cette interaction est restée incertain. Dans les humaines, un motif conservé a été 
rapporté d’être responsable pour l’association. Dans les souris, une mutation prévue de 
perturber le motif conservé n’a eu aucun impact sur la recombinaison méiotique. Ici, nous 
avons étudié si les répétions BRC peuvent interagir avec DMC1 et si, BRCA2 ou non agit 
comme une protéine médiateur pour la recombinaison méiotique, dans la même manière 
comme dans la recombinaison mitotique. Les résultats de cette étude ainsi la discussion 
sont présentés ci-après dans la publication qui se retrouve dans le chapitre 4.2. 
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CONCLUSIONS FINALES   
Dans cette étude de thèse, nous avons réussi à découvrir des nouveaux aspectes du 
suppresseur de tumeur BRCA2 et évaluer l’impact des VUS identifiés dans les patients du 
cancer du sein comme illustré dans Figure 1.  
LE DOMAINE N-TERMINALE DE BRCA2 POSSEDE UN DOMAINE DE FIXATION A 
L’ADN 
Nous avons identifié un domaine de fixation à l’ADN dans la région N-terminale de BRCA2 
(Figure 1 A). 
Cette région contenant un zinc finger PARP like domaine (zf PARP) putatif a montré in 
vitro une activité de liaison à l’ADN dans la région de BRCA2T2. Il reste à établir si vraiment 
le domaine zf PARP est requis pour cette activité. De plus, quelques résidus de cystéine 
mutés qui sont censés d’être importants pour assembler le motif du zinc finger ont montré 
une activité réduits de se lier à l’ADN.  
Nous avons observé que le NTD et le CTD partagent des affinités ressemblants pour des 
substrats d’ADN mais le NTD possède une affinité plus élevée pour l’ADN que l CTD. Un 
résultat inattendu a été la capacité du NTD de se lier à dsDNA. Nous assumons que cette 
activité avec dsDNA est probablement responsable pour l’activité de se lier à dsDNA 
montré dans la BRCA2 full-length. 
Nous avons pu montrer que le NTD stimule l’activité d’échange des brins de RAD51 dans 
la présence de RPA. On propose que le NTD possède une activité de médiateur en 
facilitant l’association de RAD51 à l’ADN en remplaçant RPA grâce à son affinité élevé 
pour les jonctions de dsDNA/ssDNA. Nous proposons que le NTD et le CTD puissent agir 
consécutivement aux DSB ou daughter strand gaps pour faciliter l’association de RAD51. 
Le NTD représenterait le site primaire pour l’interaction avec l’ADN en rendant l’ADN plus 
accessible pour RAD51 qui est délivré par les répétitions BRC. Le complexe entre 
CTD/DSS1 pourrait ainsi promouvoir la formation des filaments de RAD51 en remplaçant 
RPA comme proposé avant. C’est un grand intérêt d’examiner comment BRCA2 
coordonne les deux modules in vivo. Nous allons investir si le NTD avec BRC4 pourrait 
sauver le phénotype en surexprimant le construct dans les cellules BRCA2-/- comme décrit 
dans l’objectif 2.  
 
266 
 
 
 
VARIANTS FAUX-SENS NON-CLASSIFIES (VARIANTS OF UNKNOWN CLINICAL 
SIGNIFICANCE) DANS LE DOMAINE DE FIXATION A L’ADN N-TERMINALE DE 
BRCA2 MONTRENT DES DEFAITS EN RH ET CYTOKINESE 
Nous avons selectionné des VUS dans le NTD et appliqué des tests fonctionnels in vivo et 
in vitro pour l’évaluation de leur phénotype dans la réparation d’ADN et la cytokinèse 
(Figure 1 B) Comme décrit dans le chapitre 3.2, nous avons trouvé des mutants faux-sens 
dans le NTD qui peuvent affecter la capacité de la fixation à l’ADN de BRCA2. De plus, 
des variants ont montré des délais ou bien l’échec dans la cytokinèse ce qui parle pour 
des défauts dans la formation du midbody et/ou abscission comme décrit avant. En 
résumé, nous avons observé que un VUS sélectionné dans le NTD, G267E a un impacte 
A C
B
Figure 1: Résumé des résultats de ces travaux. 
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sur la fonctionnalité de BRCA2 en cytokinèse. Ce défaut pourrait être lié à une localisation 
défectueuse de BRCA2 vers le midbody ou l’interaction abrogé avec les protéines 
requises pour l’abscission.  
Les VUS ne montrent pas une diminution évidente dans leur capacité de se lier à ssDNA 
en comparaison avec BRCA2T2, par contre le variant S273L n’est pas capable d’interagir 
avec dsDNA ce qu’il pourrait expliquer le phénotype délétère en RH. 
En appliquant des tests fonctionnels supplémentaires, nous serons capables d’évaluer 
plus profondément  le phénotype des VUS dans la RH ainsi dans la mitose. 
Dans l’avenir, l’identification du NTD ainsi que les tests fonctionnels établi pour l’évaluation 
de VUS dans ce région seront très avantageux pour le service de conseil des porteurs de 
VUS dans BRCA2.  
BRCA2 EST LE MEDIATEUR DE LA RECOMBINASE DMC1 DANS LA MEIOSE  
Pour mon troisième objectif j’ai collaboré avec JSM du laboratoire pour enquêter si BRCA2 
fait la médiation de l’activité de recombinaison de DMC1 dans la méiose comme montré 
pour RAD51 dans la mitose. BRCA2 a été montré d’être impliqué dans méiose et son 
absence cause infertilité et des aberrations chromosomiques. De plus, il est connu que 
BRCA2 et DMC1 interagissent, bien que le mécanisme et la raison pour cette interaction 
restent énigmatiques. Dans notre étude, nous avons relevé que DMC1 interagit avec 
BRCA2 via les répétitions BRC pour stimuler son association avec ssDNA et la formation 
des filaments nucléoprotéiques. BRCA2 soulage la barrière cinétique posée par RPA lié à 
ssDNA, ce qui le rend accessible pour DMC1. Ces découvertes établissent BRCA2 
comme protéine médiateur pour la recombinaison méiotique de DMC1. Notre modèle est 
cohérent avec un rôle accessoire de RAD51 dans la recombinaison dans la méiose 
comme décrit dans la levure. Dans ce modèle, BRCA2 se lierait aux monomères de 
RAD51 via BRC1-5 pour assurer un filament qui sert comme une base de nucléation pour 
DMC1 permettant l’assemblement des homofilaments. Le filament de DMC1 pourrait ainsi 
grandit et commence la recherche d’homologie (Figure 1C) 
 
En résumé, pendant cette thèse, j’ai contribué de relever des nouvelles fonctions du N-
terminus de BRCA2 (NTD, défauts cytokinétique) mais aussi l’association des répétitions 
BRC avec DMC1. De plus, nous avons établi des tests fonctionnels pour l’évaluation des 
VUS de BRCA2.  
